

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
8 July 2004 (08.07.2004)

PCT

(10) International Publication Number
WO 2004/056874 A2

(51) International Patent Classification⁷: **C07K 16/28**

(21) International Application Number:
PCT/EP2003/014756

(22) International Filing Date:
22 December 2003 (22.12.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/435,893 20 December 2002 (20.12.2002) US
03000615.9 15 January 2003 (15.01.2003) EP

(71) Applicant (for all designated States except US): **XERION PHARMACEUTICALS AG** [DE/DE]; Sauerbruchstr. 50, 81377 München (DE).

(71) Applicant (for US only): **TUFTS UNIVERSITY** [US/US]; 136 Harrison Avenue, Boston, MA 02111 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **UNGER, Christine, Margarete** [DE/DE]; Arndt Strasse 11, 80469 München (DE). **BESTE, Gerald** [DE/DE]; Helmpertstr. 2, 80687


München (DE). **ZEHEMEIER, Carolin** [DE/DE]; St. Martin Strasse 3, 81541 München (DE). **LAIN, Blanca** [ES/US]; 100 Washington St. Apt. 7, Brighton, MA 02135 (US). **TORELLA, Claudia** [IT/DE]; Brodstr. 6A, 81829 München (DE). **NIEWÖHNER, Jens** [DE/DE]; Wengleinstrasse 3, 81477 München (DE). **JAY, Daniel, G.** [US/US]; 45 Bigelow Street, Brighton, MA 02135 (US). **EUSTACE, Brenda, K.** [US/US]; 95 Coolidge Street #2, Brookline, MA 02446 (US). **KNAUER, Roland** [DE/DE]; Gabelsberger Strasse 63, 80333 München (DE). **JENSEN, Kristian, Hobold** [DK/DE]; Daiserstrasse 50, 81371 München (DE).

(74) Agents: **FLEUCHAUS, Andrea** et al.; Melchiorstr.42, 81479 München (DE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

[Continued on next page]

(54) Title: **NEUROPILIN-1 INHIBITORS**



(57) Abstract: The present invention relates to molecules interfering with the function of neuropilin-1 in the context of angiogenesis and the treatment of cancer. Molecules, polypeptides, antibodies, compositions and methods are provided that are useful for reducing, inhibiting or treating angiogenesis, the invasion of blood vessels into tumors, and/or the invasion or the metastatic potential of specific tumor cells. Additionally, a method is provided that allows identifying molecules, which interfere with the functionality of neuropilin-1. Furthermore, a method is provided that allows determining whether a naturally occurring tumor cell depends on functional neuropilin-1 for its invasiveness and/or metastatic potential.

BEST AVAILABLE COPY



(84) **Designated States (regional):** ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv)) for US only

Neuropilin-1 Inhibitors

The present invention relates to molecules interfering with the function of neuropilin-1 in the context of angiogenesis and the treatment of cancer. Molecules, polypeptides, antibodies, compositions and methods are provided that are useful for reducing, inhibiting or treating angiogenesis, the invasion of blood vessels into tumors, and/or the invasion or the metastatic potential of specific tumor cells. Additionally, a method is provided that allows identifying molecules, which interfere with the functionality of neuropilin-1. Furthermore, a method is provided that allows determining whether a naturally occurring tumor cell depends on functional neuropilin-1 for its invasiveness and/or metastatic potential.

BACKGROUND OF THE INVENTION

Malignant tumors shed cells, which migrate to new tissues and create secondary tumors. The process of generating secondary tumors is called metastasis and is a complex process in which tumor cells colonize sites distant from the primary tumor. Recently, research has been focused on identifying specific proteins involved in metastasis, which can be used as a basis for better diagnostic or improved therapeutic strategies. Cell adhesion molecules (CAM's), which mediate cell-cell or cell-matrix interactions, have been proposed to be involved in the process of metastasis. Cell adhesion in normal cells involves interactions between numerous cell surface proteins. Adhesive interactions are known to involve interactions between substances surrounding the cell (e.g., extracellular matrix molecules, for example fibronectin, vitronectin and laminin) and extracellular adhesion receptors. It has also become apparent that cell adhesion molecules fulfill much more complex functions, which may result in cells acquiring the ability to proliferate and invade host tissues.

- 2 -

Liotta (1986) Cancer Res. 46, 1-7 has proposed a three-step hypothesis for the process of metastasis: The first step is tumor cell attachment via cell surface receptors. The anchored tumor cell next secretes hydrolytic enzymes or induces host cells to secrete enzymes, which can degrade the matrix locally. Matrix lysis most likely takes place in a highly localized region close to the tumor cell surface. The third step is tumor cell locomotion into the region of the matrix modified by proteolysis. Thus, invasion of the matrix is not merely due to passive growth pressure but requires active biochemical mechanisms. Degradation of the surrounding normal tissue is a central feature of invasiveness of malignant tumors.

The growth of a tumor or metastasis can also be described as the growth of undifferentiated cells that divide rapidly, and expand three-dimensionally to create a new mass of tissue. The cells within this mass require oxygen and nutrients. As the tumor grows, many cells within it are too far from the nearest blood vessel to maintain adequate concentrations of oxygen. When oxygen levels are decreased (a condition known as hypoxia), certain genes are activated. One of these genes, hypoxia-inducible factor 1 (HIF-1) in turn binds to the vascular endothelial growth factor (VEGF) gene and helps to activate VEGF gene expression. In addition to hypoxia, other factors can activate VEGF expression in tumor cells. For example, certain hormones or growth factors have been shown to activate VEGF expression, and some studies suggest that the activation of certain oncogenes or the inactivation of certain tumor suppressor genes may also lead to VEGF gene expression.

The VEGF protein is secreted by tumor cells and activates VEGF receptors on vascular endothelial cells. These cells begin to form new blood vessels into the tumor, providing a supply of oxygen and nutrients that support tumor growth.

This process of the growth of new vessels from pre-existing vasculature is called angiogenesis and generally occurs during the development of all tissues.

Angiogenesis is understood herein, furthermore, as the sprouting of new blood vessels, which is dependent on endothelial cell proliferation and migration. It occurs at specific times in development and growth, e.g. during development of the

- 3 -

embryo or wound healing. (Folkman et al. (1987) Science 235, 442-447, Folkman (1991) J. Natl. Cancer Inst. 82, 4-6).

Moreover, it has been shown that angiogenesis is involved in the pathogenesis of disorders dependent on the growth of new blood vessels, the most relevant of which are tumor growth and growth of metastases (Hanahan et al. (1996) Cell 86, 353-364).

Vascular endothelial growth factor (VEGF) is considered to be the prime regulator for both physiological and pathological angiogenesis, acting through VEGF receptors on endothelial cells and mediating angiogenic signals (Dvorak et al. (1999) Curr. Top. Microbiol. Immunol. 237, 97-132, Neufeld et al. (1999) FASEB J. 13, 9-22).

Angiogenesis depends essentially on the expression of vascular endothelial growth factors to stimulate endothelial cell growth and formation of new blood vessels. This family of proteins consists of six members (VEGF A-E and PlGF) of which VEGF-A is the most important for angiogenesis. There are seven known splice variants of VEGF-A of which six are pro-angiogenic. The VEGF isoforms that are produced by alternative splicing from a single gene containing nine exons (Ferrara, et al., Endocr. Rev., 13:18-32 (1992); Tischer, et al., J. Biol. Chem., 806:11947-11954 (1991); Ferrara, et al., Trends Cardio Med., 3:244-250 (1993); Polterak, et al., J. Biol. Chem., 272:7151-7158 (1997)). Human VEGF isoforms consists of monomers of 121, 145, 165, 189, and 206 amino acids, each capable of making an active homodimer (Polterak et al., J Biol. Chem, 272:7151-7158 (1997); Houck, et al., Mol. Endocrinol., 8:1806-1814 (1991)). The VEGF121 and VEGF165 isoforms are the most abundant.

As said before, VEGF stimulates specifically VEGF receptors and thereby induces VEGF receptor tyrosine kinases, KDR/Flk-1 and/or Flt-1, which are mostly expressed by endothelial cells (EC) (Terman, et al., Biochem. Biophys. Res. Commun., 187:1579-1586 (1992); Shibuya, et al., Oncogene, 5:519-524 (1990); De Vries, et al., Science, 265:989-991 (1992); Gitay-Goran, et al., J. Biol.

Chem., 2 87:6003-6096 (1992); Jakernan, et al., J Clin. Invest., 89:244-253 (1992)).

It appears that VEGF activities such as mitogenicity, chemotaxis, and induction of morphological changes are mediated by KDR/Flk- I but not Flt- 1, even though
5 both receptors undergo phosphorylation upon binding of VEGF (Millauer, et al., Cell, 72:835-846 (1993); Waltenberger, et al., J Biol. Chem., 269:26988-26995 (1994); Seetharam, et al., Oncogene, 10: 135-147 (1995); Yoshida, et al., Growth Factors, 7:131-138 (1996)). Recently, Soker et al., identified a new VEGF receptor which is expressed on EC and various tumor-derived cell lines such as breast
10 cancer-derived MDA-MB-231 (23 1) cells (Soker, et al., J. Biol. Chem., 271:5761-5767 (1996)).

This receptor requires the VEGF isoform to contain the portion encoded by exon 7. For example, although both VEGF121 and VEGF 165 bind to KDR/Flk- I and Flt- 1, only VEGF 165 binds to the new receptor.

15 Thus, this it seems that the new receptor is an isoform-specific receptor. It has been named the VEGF165 receptor (VEGF165R). It will also bind the 189 and 206 isoforms. VEGF165R has a molecular mass of approximately 130 kDa, and it binds VEGF165 with a Kd of about 2×10^{-10} M, compared with approximately 5×10^{-12} M for KDR/Flk- 1. In structure-function analysis, it was shown directly
20 that VEGF 165 binds to VEGF165R via its exon 7 encoded domain, which is absent in VEGF121 (Soker, et al., J Biol. Chem., 271:5761-5767 (1996)).

By isolating the VEGF165R related DNA it was discovered that this novel VEGF receptor is structurally unrelated to Flt- I or KDR/Flk- I and is expressed not only by endothelial cells but also by non-endothelial cells, including tumor cells.

25 Furthermore, in ascertaining the function of the VEGF165R it has been discovered that this receptor has been identified as a cell surface mediator of neuronal cell guidance and called neuropilin (Kolodkin et al., Cell 90:753-762 (1997)).

Neuropilin-1 is a transmembrane glycoprotein with a mass of approximately 130kDa. Neuropilin-1 is a multifunctional protein. Fujisawa et al. (1998) Cur.

- 5 -

Opin. Neurobiol. 8, 587-592 describe that neuropilin-1 acts as a receptor for the semaphorin/collapsin family of neural guidance mediators. Furthermore, the expression of neuropilin-1 in endothelial cells enhances the binding of VEGF₁₆₅ to VEGFR-2 and VEGF₁₆₅-induced chemotaxis. According to Gagnon et al. and
5 WO 99/29729, neuropilin-1 acts as a co-receptor that enhances VEGFR-2 activity (Gagnon et al. (2000) PNAS 97, 2573-2578).

Neuropilin-1 is also expressed on certain tumor cells of ectodermal origin, like cells derived from prostate and breast carcinoma as well as from melanoma. In experiments with breast cancer cells VEGF₁₆₅ stimulated breast cancer cell motility in a dose-dependent manner (WO 99/29729). A comparison between two types
10 of rat prostate carcinoma cells, AT2.1 cells and AT3.1 cells showed that the highly motile AT3.1 cells expressed more neuropilin-1 than the less motile AT2.1 cells. Collapsin-1, a ligand of neuropilin-1, inhibited the basal migration of PAE cells (porcine aortic endothelial cells) when cells were transfected with the neuropilin-1 cDNA to overexpress neuropilin-1. All this was interpreted by the
15 authors of WO 99/29729 to suggest that neuropilin-1 expression was associated with a motile phenotype of tumor cells. However, it is dangerous and speculative to assign a physiological role for a protein based on a study in which it has been overexpressed, and it is an accepted standard in science to interpret results of
20 overexpression studies with great care.

As discussed in WO99/29729 as well as in Soker et al., Cell (1998) 92, 735-745, neuropilin-1 can act as a co-receptor of VEGFR-2 for VEGF₁₆₅ to mediate the effects of this regulator for both physiological and pathological angiogenesis. VEGFR-2 is expressed in endothelial and haematopoietic precursors, endothelial
25 cells, nascent haematopoietic stem cells and the umbilical cord stroma only (for review see Robinson and Stringer J. Cell Sci. (2001) 114, 853-865). If the cancer-related function of neuropilin-1 was dependent on its role in VEGF-signaling - as suggested by, e.g., WO 99/29729 - then this cancer-related function of neuropilin-1 should only be relevant for tissues which express neuropilin-1 and VEGFR-2
30 together in the presence of VEGF. The expression of VEGFR-2 is, however, lim-

- 6 -

ited to certain tissues. It is therefore unclear whether neuropilin-1 plays any cancer-related role in those tissues, which do not express VEGFR-2. The authors of WO 99/29729 showed that VEGF₁₆₅ stimulated 231 breast cancer cell motility in a dose dependent-manner. They postulated that tumor cells, which do not express
5 the VEGF receptors KDR or Flt-1, are responsive to VEGF₁₆₅ via the neuropilin-1.

The determination of the physiological role of a protein is a prerequisite for deciding whether interference with this protein's function might be a possible avenue for the treatment of disease or not. It must be kept in mind that in a physiological setting, that is to say for example in a naturally occurring tumor cell of a patient,
10 neuropilin-1 is overexpressed together with other proteins which can modulate and change the function of neuropilin-1. It is the functional interplay between neuropilin-1 and interacting proteins that determines its physiological role.

Accordingly, it was an object of the present invention to identify and provide further molecules that bind to neuropilin-1 and modulate the neuropilin-1 function
15 and can thus be used to further characterise neuropilin-1 function, but also can be used to actively interfere and modulate the neuropilin-1 function e.g. in medical treatment or therapeutic set ups.

SUMMARY OF THE INVENTION

20 In an unbiased screen for molecules that can inhibit angiogenesis of endothelial cells as well as the invasion and/or adhesion of tumor cells surprisingly a polypeptide, particularly an antibody fragment binding to the extracellular domain of neuropilin-1 has been identified as such an inhibitor.

The present invention relates to neuropilin binders, e.g. polypeptides, antibodies,
25 antibody fragments, single chain antibodies (scFv) or bioconjugates, which can specifically bind to the extracellular domain of neuropilin-1 and inhibit neuropilin-1 function.

- 7 -

In a further embodiment the neuropilin binders (NPBs) are characterised by the additional feature, that they are capable of modulating or inhibiting neuropilin related functions, but can not interfere or inhibit VEGF/neuropilin-1 interaction.

The NPBs of the invention can be selected from the group comprising the sequences SEQ ID No: 1, 2, 5 to 38.

Furthermore, the NPB of the invention can be labeled with detectable groups, if desired.

The invention further relates to pharmaceutical compositions comprising the NPB or a bioconjugate comprising the NPB of the invention.

In a further embodiment the invention relates to nucleic acid molecules encoding the NPB of the invention, as well as to vectors comprising such a nucleic acid and to host cells comprising such a vector.

In a further embodiment the invention relates to the use of NPB as molecules inhibiting neuropilin-1 function for the manufacture of a medicament for the treatment or prevention of invasion and/or metastasis of naturally occurring cancer cells; e.g. of mesodermal origin, wherein invasiveness and/or metastatic potential of said cancer cells depends on neuropilin-1 function.

In a further embodiment the invention relates to a method of treating or preventing invasion and/or metastasis in a patient, wherein the invasiveness and/or metastatic potential of said cancer cells depends on neuropilin-1 function.

In still a further embodiment the invention relates to the NPBs of the invention as medicament or the use of the NPB of the invention in the manufacture of a medicament for the treatment or prevention of neuropilin-1-dependent angiogenesis and non-physiological blood vessel growth, particularly correlated with a tumor, wherein said NPBs do not interfere or inhibit the interaction between neuropilin-1 and VEGF₁₆₅.

In a further embodiment the invention relates to a method to determine the dependency of the invasiveness and/or adhesiveness of a naturally occurring cancer cell on the functionality of neuropilin-1.

- 8 -

In a further embodiment the invention relates to a method for the identification of a ligand useful for inhibiting the invasiveness and/or adhesiveness of a naturally occurring cancer cell, particularly the identification of such ligands that bind to the extracellular domain of neuropilin-1.

- 5 In still a further embodiment the invention relates to a method for the identification of a ligand useful for inhibiting the angiogenesis of endothelial cell, particularly the identification of such ligands that bind to the extracellular domain of neuropilin-1.

10 DETAILED DESCRIPTION OF THE INVENTION

The present invention now shows that neuropilin-1-dependent angiogenesis, invasion and/or adhesion can be inhibited by using the molecules of this invention. Surprisingly, it has surprisingly found that stimulation of HT1080 cells, a human sarcoma cell line, with VEGF₁₆₅ has no influence on the invasiveness of cells.

- 15 Invasiveness of tumor cells (e.g HT1080 cells) could only be stimulated in the presence of FCS, whereas the migration ability of HUVEC cells, primary human umbilical vein endothelial cells, could indeed be stimulated with VEGF₁₆₅.

Furthermore, it has been found that several molecules of this invention inhibit the tube formation of HUVEC cells, an assay used to study angiogenesis. The present
20 inventions shows for the first time that some of the neuropilin binders (NPBs) that inhibit angiogenesis do not to interfere or inhibit the NP-1/VEGF₁₆₅ interaction. Results show further that these NPBs bind to a different epitope of NP-1 than VEGF₁₆₅.

- The result show that neuropilin-1 acts as an active mediator of the invasion and/or
25 adhesion of metastatic tumor cells and furthermore has a functional role angiogenesis, whereby the NPBs do not interfere or inhibit the NP-1/VEGF₁₆₅ interaction. This opens, for the first time, the possibility to develop drugs, which inhibit metastasis of tumor cells - and especially of metastatic sarcomas, which are hardly

curable with current cancer treatments - wherein the metastatic potential depends on neuropilin-1-dependent influence on angiogenesis, invasion and/or adhesion.

In order that the invention described herein may be more fully understood, the following detailed description and definitions are provided. As used herein, the following definitions shall apply unless otherwise indicated.

A "polypeptide" as used herein is a molecule comprising more than 10, preferably more than 20, most preferably more than 30, and less than 10000, more preferably less than 2500, most preferably less than 1000 amino acids. Also polypeptides with substantial amino acid sequence identity and polypeptides, which contain a low percentage of modified or non-natural amino acids, are encompassed.

In the wording of the present invention the term polypeptide generally covers also the terms antibodies, antibody fragments or single chain antibodies (scFv).

The terms "antibody" and "immunoglobulin", as used herein refer to any immunological binding agent, including polyclonal and monoclonal antibodies. Depending on the type of constant domain in the heavy chains, antibodies are assigned to one of five major classes: IgA, IgD, IgE, IgG, and IgM. Several of these are further divided into subclasses or isotypes, such as IgG1, IgG2, IgG3, IgG4, and the like. The heavy-chain constant domains that correspond to the different classes of immunoglobulin are termed alpha, delta, epsilon, gamma and mu, respectively. The subunit structures and three-dimensional configurations of different classes of immunoglobulin are well known. -

Antibodies may be also selected from modified immunoglobulin, for example chemically or recombinantly produced antibodies, CDR (complementary determining region) grafted antibodies or humanized antibodies, site directed mutagenized antibodies that exhibit substantial amino acid sequence identity in their CDR regions, particularly in their CDR3 region, to the corresponding antibody fragments of the invention and retain substantially the same affinity for neuropilin-1 binding as the corresponding antibody fragments.

- 10 -

The CDRs (complementary determining region) of an antibody are the parts of these molecules that determine their specificity and make contact with specific ligands. The CDRs are the most variable parts of the molecule and contribute to the diversity of these molecules. They are structurally defined in a human IgG as amino acids 24 to 41 (CDR-L1), 50 to 57 (CDR-L2) and 90 to 101 (CDR-L3) of the light chain and amino acids 26 to 38 (CDR-H1), 51 to 70 (CDR-L2) and 100 to 125 (CDR-H3) of the heavy chain (see Kabat et al. (1987) 4th edn US Department of Health and Human Services, Public Health Service, NIH, Bethesda). The CDR regions of an antibody fragment can easily be determined by somebody skilled in the art by aligning the antibody fragment with said human IgG, e.g. using a program of the NCBI that allows to "Blast", and thereby align, two sequences with one another, and identifying the amino acids of the antibody fragment corresponding to the CDRs of a human IgG.

Substantial amino acid sequence identity as used herein means that at least 70%, preferably at least 75%, 80%, 85%, 90%, more preferably all but 5, still more preferably all but 3 and even more preferably all but 1 of the amino acids of two aligned amino acid sequences, particularly of aligned CDRs, are identical.

The term "antibody fragment" is used to refer to any fragment of an antibody-like molecule that has an antigen binding region, and this term includes antibody fragments such as scFv, dsFv, Fab', Fab, F(ab')₂, Fv, single domain antibodies (DABs), diabodies, and the like. The techniques for preparing and using various antibody-based constructs and fragments are well known in the art (see Kabat et al. (1991) J. Immunol. 147, 1709-19), specifically incorporated herein by reference.

"scFv" antibody fragments comprise the VH and VL domains of an antibody, wherein these domains are present in a single polypeptide chain. Generally, the scFv polypeptide further comprises a polypeptide linker between the VH and VL domains that enables the scFv to form the desired structure for antigen binding.

A "Fv" fragment is the smallest antibody fragment that retains an intact antigen binding site.

A "dsFv" is a disulfide stabilized Fv.

A "Fab" fragment, is an antigen binding fragment, containing complete light chains paired with the VH and CH1 domains of the heavy chain.

A "Fab'" fragment, is a reduced F(ab')₂ fragment.

- 5 A "F(ab')₂" fragment, is a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region.

A "single domain antibody (DAB)" is an antibody with only one (instead of two) protein chain derived from only one of the domains of the antibody structure. Dabs exploit the finding that, for some antibodies, half of the antibody molecule
10 binds to its target antigen almost as well as the whole molecule (Davies et al. (1996) Protein Eng. 9: 531-537).

"Diabodies" are bivalent or bispecific antibodies in which VH and VL domains are expressed on a single polypeptide chain, but using a linker that is too short to allow for pairing between the two domains on the same chain, thereby forcing the
15 domains to pair with complementary domains of another chain and creating two antigen binding sites (Holliger et al. (1993) Proc. Natl. Acad. Sci. USA, 90, 6444-6448).

The terms "label" or "labeled" refers to a detectable marker or the incorporation of such, respectively, e.g., by incorporation of a fluorophore-, chromophore- or
20 radio-labeled amino acid or attachment of a fluorophore-, chromophore- or radio-label to a polypeptide or attachment of moieties that can be detected by a labeled second molecule containing a fluorescent marker or enzymatic activity that can be detected by an optical or a colorimetric method. An example for such a two-step
25 detection system is the well-known biotin-avidin system. Various methods of labeling polypeptides and glycoproteins are known in the art and may be used (for example see Lobl et al. (1988) Anal. Biochem., 170, 502-511).

An "epitope" includes any protein determinant capable of specific binding to an immunoglobulin or an antibody fragment. Epitopic determinants usually consist of chemically active surface groupings of molecules such as exposed amino acids,

- 12 -

aminosugars, or other carbohydrate side chains and usually have specific three-dimensional structural characteristics, as well as specific charge characteristics.

A "naturally occurring cancer cell" as used herein is a cell that has not been transfected, transduced or otherwise genetically engineered in the laboratory. Such a cell does not comprise artificial DNA sequences, e.g. of vectors, or DNA sequences being found only in other species, but not usually in the species from which the naturally occurring cancer cell was derived. However, a naturally occurring cancer cell may comprise sequences that are not usually found in the species from which it was derived, if those sequences have arisen due to the processes of mutation and selection that took place within the individual from which the naturally occurring cancer cell was derived, and/or during continued culture of the naturally occurring cancer cell.

Selected cancer cell-types as used herein consist of tumor cells derived from, e.g. the mesoderm, preferably derived from the group of neoplasms consisting of soft tissue tumors and sarcomas, fibromatous neoplasms, myxomatous neoplasms, lipomatous neoplasms, myomatous neoplasms, complex mixed and stromal neoplasms, synovial-like neoplasms, mesothelial neoplasms, lymphatic vessel tumors, osseous and chondromatous neoplasms, giant cell tumors, miscellaneous bone tumors, odontogenic tumors, hodgkin's and non-Hodgkins's lymphoma, plasma cell tumors, mast cell tumors, immunoproliferative diseases and leukemias, in particular tumor cells derived from the group of neoplasms consisting of soft tissue tumors and sarcomas, fibromatous neoplasms, myxomatous neoplasms, lipomatous neoplasms, myomatous neoplasms, complex mixed and stromal neoplasms, synovial-like neoplasms, mesothelial neoplasms, lymphatic vessel tumors, osseous and chondromatous neoplasms, giant cell tumors, miscellaneous bone tumors, odontogenic tumors, in particular tumor cells derived from sarcomas, in particular derived from sarcomas of the bone or sarcomas of soft tissue. Neoplasms can also be derived from brain, central nervous system, lungs, stomach, lower intestine, colon, liver, kidneys, prostate and the pancreas.

In one embodiment sarcomas can be all sarcomas with the exception of angiomas and haemangiomas.

“Treating metastatic tumors” or “treating micro-metastases”, as used herein means that the metastasis of the tumor is stabilized, prevented, delayed, or inhibited by the molecule of the invention, either as a single medicament or in combination with other medicaments. Stable disease or “No Change” (NC) is a description for the course of the disease with either no change of the metastases or a reduction of less than 50% or an increase of less than 25 % over at least 4 weeks. Prevention can be, for example, that no new metastases are detected after the treatment is initiated. This can lead to a two- to three-fold median and/or a %-year survival rate of treated patients compared with untreated patients. A delay can signify a period of at least 8 weeks, 3 months, 6 months or even one year in which no new metastases are detected after the treatment is initiated. Inhibition can mean that the average size or the total number of new metastases is at least 30%, 40%, 50%, 60%, 70%, 80% or even 90% lower in a group treated with the molecule of the invention in comparison with an untreated group. Number, size and prevalence of metastases can be detected by a skilled practitioner in the field of oncology following generally accepted practice and diagnostic procedures for the detection of metastases, for example as outlined in *Harrisons Principles of Internal Medicine* 15th ed 2001 Mc Graw Hill.

“Metastatic tumors” as used herein includes both tumors at the primary site capable of metastasizing and metastasized tumors at a secondary site. Such metastatic tumors can be of any organ or tissue origin, like brain, central nervous system, lungs, stomach, lower intestine, liver, kidneys or the pancreas, etc., in particular tissue of mesodermal origin such as bone, spleen, thyroid, endometrial, ovarian, or lymphoid tissue.

A micro-metastase is an accumulation of tumor cells with a size smaller than 2 mm, which can usually only be detected by histological methods.

“Angiogenesis” as used herein refers to the ability of endothelial cells to form tubes and eventually, elaborate blood vessels. The angiogenic potential of cells or

in other words the inhibition of angiogenesis can be assayed in a so-called tube formation assay as described in Example 16. Inhibition of angiogenesis is seen and measured in correlation to the capacity of cells to form or not to form closed polygons as well as the status of aggregation of cells. As demonstrated in Example 16 and Figure 14 a significant aggregation of cells and the lack of closed polygon formation strongly correlates with the tube formation of endothelial cells.

“Invasiveness” as used herein is the ability of a cell to migrate through a layer of other cells or to migrate through the extracellular matrix. Invasiveness can be assessed by the Matrigel assay described in Example 8 or Example 9. Invasion is measured as cells that reach the lower surface of the filter during a certain incubation period. When more than 40% of cells within 6h to 12h reach the other side of the filter and form colonies in an invasion assay like in Example 8 or Example 9, the naturally occurring cancer cell is defined as invasive. The control cells instead form only up to 5% colonies in the same time frame and are defined as non-invasive.

“Adhesiveness” as used herein is the ability of a cell to reattach after they have been removed from the matrix on which it had been grown, resuspended as a solution of single cells (not in direct contact with other cells of the solution), and replated on a matrix to which adhesion is possible. A cell is defined as adhesive if in an assay as described in Example 11 or Example 12, more than 40% of the cells adhere within a time of 30-120 min. Instead, only up to 5% of the control cells adhere within the same time frame.

Metastatic potential as used herein is the ability of a tumor cell to form a new tumor at a site distant from the primary tumor of which the tumor cell was derived (a metastase). Metastatic potential can be measured by injecting, e.g. 1×10^6 , cells into the lateral tail vein of athymic nude mice and determining the number of tumor nodules in the lung, e.g. 2 months post injection, e.g. as described in the section “Tumor cell injections” on page 2346 of Huang et al (1996) Oncogene 13, 2339-2347, or the sections “Animals and production of tumors” and “Histochemical analysis for calcified matrix” on page 1882 of Radinsky et al. (1994) Onco-

- 15 -

gene 9: 1877-1883. A cell line to produce more than 3, preferably more than 8, more preferably more than 20 tumor nodules in the lung in this assay is considered metastatic.

Therapeutically effective amounts are amounts which eliminate or reduce the patient's tumor burden, or which prevent, delay or inhibit metastasis. The dosage will depend on many parameters, including the nature of the tumor, patient history, patient condition, the possible co-use of cytotoxic agents, and methods of administration. Methods of administration include injection (e.g., parenteral, subcutaneous, intravenous, intraperitoneal, etc), for which the molecule inhibiting neuropilin-1 function is provided in a nontoxic pharmaceutically acceptable carrier. In general, suitable carriers and diluents are selected so as not to significantly impair biological activity of the binding agent (e.g., binding specificity, affinity or stability), such as water, saline, Ringer's solution, dextrose solution, 5% human serum albumin, fixed oils, ethylolate, or liposomes.). Acceptable carriers can include biocompatible, inert or bio-absorbable salts, buffering agents, oligo- or polysaccharides, polymers, viscoelastic compound such as hyaluronic acid, viscosity-improving agents, preservatives, and the like. In addition, the pharmaceutical composition or formulation may also include other carriers, adjuvants, or nontoxic, non-therapeutic, non-immunogenic stabilizers and the like. Typical dosages may range from about 0.01 to about 20 mg/kg, or more particularly from about 1 to about 10 mg/kg.

Therapeutic methods employing molecules inhibiting neuropilin-1 function may be combined with chemotherapy, surgery, and radiation therapy, depending on type of the tumor, patient condition, other health issues, and a variety of factors. The molecules inhibiting neuropilin-1 function may also be used as the single effective medicament of a therapeutic composition.

A "molecule inhibiting neuropilin-1 function", is a molecule resulting in inhibition of the biological activity of neuropilin-1. This inhibition of the biological activity of neuropilin-1 can be assessed by measuring one or more indicators of neuropilin-1's biological activity, such as neuropilin-1 dependent angiogenesis,

- 16 -

neuropilin-1 dependent invasiveness or neuropilin-1 dependent adhesion. These indicators of neuropilin-1's biological activity can be assessed by one or more of several *in vitro* or *in vivo* assays (see, Examples 8 or 9 and Examples 11 or 12, or Example 16). Preferably, the ability of a molecule to inhibit neuropilin-1 activity is assessed by inhibition of neuropilin-1-induced invasiveness or adhesion of invasive human sarcoma cells, particularly the cells used in Examples 8 and 9 or Examples 11 and 12 or 19. Preferably, the ability of a molecule to inhibit neuropilin-1 activity is assessed by inhibition of neuropilin-1-induced angiogenesis of HUVEC cells, particularly as described in Example 16.

10 A "molecule inhibiting neuropilin-1 function" of the invention is not a molecule which is a general inhibitor of protein function, like a protease, like a denaturing agent, e.g. urea or guanidinium hydrochloride, like heavy metal atoms or like small molecules (e.g. aldehydes or isocyanates) reacting covalently and non-specifically with biomolecules (lipids, proteins, sugars). A molecule inhibiting neuropilin-1 function is characterized by its ability to inhibit neuropilin-1 function at a concentration at which it does not inhibit the function of the insulin receptor (e.g. as determined in an anti-Phosphotyrosine Western Blot Assay, see e.g. B. Cariou et al. (2002) J Biol Chem., 277, 4845-52) and the Acetylcholin receptor (e.g. as determined by measuring the Ca influx, see M. Montiel et al. (2001) Biochem Pharmacol. 63, 337-42.) and the B-CAM cell surface glycoprotein (e.g. by determining binding of hemoglobin A red blood cells (AA RBCs) to immobilized laminin as described in the section "Flow chamber assays" on page 2551 of Udani et al. (1998) J. Clin. Invest. 101, 2550-2558). Only a molecule inhibiting neuropilin-1 function but at the same concentration not significantly affecting the function of the other three receptors mentioned is a molecule inhibiting neuropilin-1 function as used in this patent. Inhibition is understood to be at least a 15%, preferably a 20%, more preferably a 25%, 30%, 40%, 50% or even a 60% decrease in function, as defined by neuropilin-1 function in an invasion and/or adhesion assay as mentioned above, when compared to a negative control with the same experimental conditions, but without the molecule of the invention. A molecule is defined as not significantly affecting the function of the other three recep-

tors if the decrease in function affected by the molecule of the invention is less than 10%, more preferably less than 5%.

Additionally, in the case of a molecule of the invention which inhibits gene expression of neuropilin-1, such a molecule decreases neuropilin-1 expression by
5 more than 50%, preferably by more than 80%, still more preferably by more than 90%, most preferably by more than 95% when measured in a quantitative western blot normalized to the level of beta tubulin present, when present in an experiment at a concentration of 10 nM to 100 μ M, preferably at around 1 μ M, in which the amount of neuropilin-1 is compared between two otherwise identical samples,
10 wherein in one sample the molecule of the invention was allowed to inhibit neuropilin-1 expression. In the same experiment the molecule of the invention does not decrease the amount of the beta tubulin present per cell by more than 20%, and said molecule does not decrease the relative level of the insulin receptor and the B-CAM cell surface glycoprotein by more than 20%.

15 Additionally, in the case of a polypeptide of the invention, particularly an antibody or antibody fragment of the invention, the polypeptide of the invention is considered to inhibit the biological function of neuropilin-1 if it reduces the invasiveness and/or adhesiveness of naturally invasive cancer cells in an experiment as in Example 8 or 9 or Example 11 or 12 by more than 15%, preferably more
20 than 20%, more preferably a 25%, 30%, 40%, 50% or even a 60% decrease in neuropilin-1 function as defined above, when said antibody fragment is present at a concentration of 1 nM to 50 μ M, preferably around 20 μ M.

Additionally, in the case of a small chemical compound of the invention, said compound is considered to inhibit the biological function of neuropilin-1 if it
25 reduces the invasiveness and/or adhesiveness of naturally invasive cancer cells in an experiment as in Example 8 or 9 and Example 11 or 12 by more than 15%, preferably more than 20%, more preferably a 25%, 30%, 40%, 50% or even a 60% decrease in neuropilin-1 function as defined above, when present at a concentration of 10 nM to 100 μ M, preferably at around 1 μ M, while not affecting cell
30 morphology, cell cycle progression (determined by analyzing the DNA content of

- 18 -

a cell population by propidium iodide staining and FACS analysis), and not increasing the percentage of the cells of the culture that show signs of apoptosis (determined by measuring the percentage of cells showing DNA fragmentation, e.g. by a so called tunnel-assay). A small chemical compound as used in this invention is a molecule with a molecular weight between 50 Da and 10000 Da, preferably between 100 Da and 4000 Da, more preferably between 150 Da and 2000 Da, or a physiologically acceptable salt thereof.

“Identifying” as used herein means the identification of a biomolecule having desired properties from a mixture of biomolecules comprising related but non-identical biomolecules with slightly different properties.

A “ligand” as used herein is a molecule displayable by an amplifiable ligand-displaying unit. A ligand is that part of an ALDU through which the ALDU can bind to a target. Preferably it is a polypeptide as defined above, an RNA-oligonucleotide or a DNA-oligonucleotide an oligonucleotide comprising more than 20 base units but less than 10,000, preferably less than 1,000 base units. A ligand can bind to an extracellular region of an antigen. This binding may have specificity in the sense that the ligand binds to one antigen with high affinity but to a moderately related antigen with lower, for example 10- or 50- or 200-fold lower affinity. Moderately related antigens are antigens with up to 30 % amino acid identity in the extracellular regions.

A ligand “binding specifically to a neuropilin-1” as mentioned herein can be a ligand which binds to neuropilin-1 under the buffer conditions given in Examples 2 and 3. The dissociation constant between the ligand and neuropilin-1 can be measured, e.g. by use of the so-called BIACORE System (see, for example, Fivash et al. Curr Opin Biotechnol. (1998) 9, 97-101) and “binding specifically” can then be understood to mean that the dissociation constant between the ligand and neuropilin-1 is lower than 10 μ M, preferably lower than 1 μ M, more preferably lower than 500, 400, 300, 200, 100, 50, 20 nM, most preferably from 0,1 nM to 20 nM if measured under standard conditions, for example at 20°C, ambient pressure and in a suitable buffer, e.g. 20 mM Tris, 100 mM NaCl, 0,1 mM EDTA

- 19 -

at an overall pH of 7.0. Further, this molecule does not bind to neuropilin-2, which is another member of the neuropilin family and shares a 47% homology to neuropilin-1. Thus, the dissociation constant between the ligand and neuropilin-2 is higher than 100 μ M, preferably higher than 1 mM, or is alternatively at least 50-fold, preferably at least 200-fold, 1000-fold or 5000-fold worse (higher) than the dissociation constant between ligand and neuropilin-1.

The term "at least one" as used here means "one and more than one", particularly one, two, three, four and five.

The present invention relates to polypeptides, antibodies, antibody fragments or single chain antibodies, which can specifically bind to the extracellular region of neuropilin-1 and can inhibit neuropilin-1 function in angiogenesis, invasion and/or metastasis. Such polypeptides, antibodies, antibody fragments or single chain antibodies are in the context of the present invention generally understood or summarized under the term "neuropilin binder (NPB)". Those NPBs comprise a sequence selected from the group consisting of SEQ ID NO. 1 and SEQ ID NO. 2 or SEQ ID No. 5 to SEQ ID No. 38.

In a preferred embodiment the polypeptide of the invention is an antibody fragment, in particular a scFv, dsFv, Fab', Fab, F(ab')₂, Fv, single domain antibody or diabody, more particularly a scFv, dsFv, Fv, single domain antibody or diabody, still more particularly a scFv, single domain antibody or diabody and even more preferably a scFv.

In another preferred embodiment the polypeptide of the invention is an antibody, in one preferred embodiment an antibody derived from a scFv antibody fragment, in another preferred embodiment a polyclonal or monoclonal antibody, particularly a human monoclonal antibody.

Anti-human neuropilin-1 binding antibodies may be selected from modified immunoglobulin, for example chemically or recombinantly produced antibodies or humanized antibodies, site directed mutagenized antibodies, that exhibit substantial amino acid sequence identity in their CDR regions, particularly in their CDR3

- 20 -

region, to the corresponding antibody fragments of the invention and retain substantially the same affinity for neuropilin-1 binding as the corresponding antibody fragments.

In another preferred embodiment the polypeptide of the invention is a human antibody selected from the group consisting of IgA, IgD, IgE, IgG, and IgM, in particular IgG and IgM, more particularly IgG1, IgG2a, IgG2b, IgG3, IgG4.

In another preferred embodiment the CRD3 region of the antibody or the antibody fragment is identical to one of the CDR3 regions shown in Figure 10.

In another preferred embodiment of the invention a polypeptide of the invention, particularly an antibody fragment or an antibody of the invention is labeled with a detectable label. Particularly, examples for detectable labels are radioisotopes, chromophores, fluorophores, enzymes or radioisotopes. The detectable label can, for example, be selected from this group.

In another embodiment, the polypeptide of the invention can be covalently or non-covalently conjugated and/or coupled to or with, respectively, another protein, a solid matrix (e.g. like a bead), with itself to form multimers, a cytotoxic agent further enhancing the toxicity to targeted cells, a cytostatic agent, a prodrug, or an effector molecule, which is able to modify the cell expressing neuropilin-1 or to recruit immune cells. All these conjugates are "bioconjugates" of the invention.

A list of cytotoxic agents include, but is not limited to, daunorubicin, taxol, adriamycin, methotrexate, 5 FU, vinblastin, actinomycin D, etoposide, cisplatin, doxorubicin, genistein, andribose inhibitors (e.g., trichosantin), or various bacterial toxins (e.g., Pseudomonas exotoxin; Staphylococcus aureus protein A).

Bioconjugates comprising the polypeptides of the invention, particularly the antibody fragment or antibody of the invention together with said cytotoxic moieties are made using a variety of bifunctional protein coupling agents. Some examples of such reagents are N-succinimidyl 3-(2-pyridyldithio)-propionate (SPDP), bifunctional derivatives of imidoesters such as dimethyl adipimidate HCl, active esters such as disuccinimidyl suberate, aldehydes such as glutaraldehyde, bisazido

compounds such as bis-(R-azidobenzoyl)hexanediamine, bisdiazonium derivatives such as bis-(R-diazoniumbenzoyl)ethylenediamine, diisocyanates such as tolylene 2,6-diisocyanate, and bis-activated fluorine compounds such as 1,5-difluoro-2,4-dinitrobenzene. Methods useful for the production of bioconjugates are described in detail in March's Advanced Organic Chemistry: Reactions, Mechanisms and Structure, 5th Edition, Wiley-Interscience; or Bioconjugate Techniques, Ed. Greg Hermanson, Academic Press.

The expression of a metastasis-associated neuropilin-1 antigen can be detected by using a bioconjugate or a polypeptide of the invention, particularly an antibody or an antibody fragment of the invention. A sample is taken from the subject, e.g., a biopsy specimen taken from tissue suspected of having a metastatic tumor. Generally, the sample is treated before an assay is performed. Assays, which can be employed include ELISA, RIA, EIA, Western Blot analysis, immunohistological staining and the like. Depending upon the assay used, the antigens or the antibodies can be labeled by an enzyme, a fluorophore or a radioisotope. (See, e.g., Coligan et al. (1994) Current Protocols in Immunology, John Wiley & Sons Inc., New York, New York; and Frye et al. (1987) Oncogene 4, 1153-1157.)

Therefore, one embodiment of the invention relates to the use of at least one polypeptide of the invention and/or at least one labeled polypeptide of the invention and/or at least one bioconjugate of the invention for the detection of neuropilin-1. For example one polypeptide of the invention or one labeled polypeptide of the invention or one bioconjugate of the invention can be used for the detection of neuropilin-1, or one labeled polypeptide together with one bioconjugate or two or three polypeptides or two labeled polypeptides can be used.

In another embodiment, the present invention encompasses a diagnostic kit. Such a kit comprises at least one bioconjugate and/or at least one labeled polypeptide of the invention and/or at least one polypeptide of the invention, particularly an antibody fragment or an antibody of the invention, or a labeled version of these, and consists additionally of the reagents and materials necessary to carry out a standard competition or sandwich assay. Said diagnostic kit may be used for the de-

- 22 -

termination of the invasive potential of biological samples, in particular of certain cancer cell types. A kit will further typically comprise a container.

By using the polypeptide of the invention, particularly the antibody fragment or antibody of the invention, it is further possible to produce anti-idiotypic antibodies, which can be used to screen antibodies to identify whether the antibody has the same binding specificity as a human monoclonal antibody of the invention and can also be used for active immunization (Herlyn et al. (1986) Science, 232, 100). Such anti-idiotypic antibodies can be produced using well-known hybridoma techniques (Kohler et al. (1975) Nature, 256:495). An anti-idiotypic antibody is an antibody, which recognizes unique determinants present on the antibody of interest. These determinants are located in the hypervariable region of the antibody. It is this region, which binds to a given epitope and, thus, is responsible for the specificity of the antibody. An anti-idiotypic antibody can be prepared by immunizing an animal with the polypeptide, particularly the antibody fragment or antibody, of interest. The immunized animal will recognize and respond to the idiotypic determinants of the immunizing antibody and produce an antibody to these idiotypic determinants. By using anti-idiotypic antibodies, it is possible to identify other hybridomas expressing monoclonal antibodies having the same epitopic specificity.

It is also possible to use the anti-idiotypic technology to produce monoclonal antibodies, which mimic an epitope. For example, an anti-idiotypic monoclonal antibody made to a first monoclonal antibody will have a binding domain in the hypervariable region, which is the "image" of the epitope bound by the first antibody. Thus, the anti-idiotypic monoclonal antibody can be used for immunization, since the anti-idiotypic monoclonal antibody binding domain effectively acts as an antigen.

In another embodiment the modified polypeptide or the bioconjugate of the invention, binds to human neuropilin-1 and reduces the invasiveness and/or adhesiveness of invasive human sarcoma cells by 15-70%, or preferably by 15-30%,

20-40% or even at least 50%, when tested in an invasion/or adhesion assay (see Example 8 or 9 and Example 11 or 12).

In another embodiment, the antibody fragment of the invention specifically recognizes one or more epitopes of neuropilin-1, or epitopes of conserved variants of neuropilin-1, or peptide fragments of the neuropilin-1.

In another embodiment, the invention relates to the use of a molecule of the invention, particularly selected from the group consisting of a small chemical compound of the invention, a molecule inhibiting gene expression of neuropilin-1, a bioconjugate or a polypeptide of the invention, more particularly an antibody fragment or an antibody of the invention as a medicament.

In another embodiment, the present invention relates to a pharmaceutical composition comprising effective amounts of at least one, particularly one, molecule of the invention, particularly at least a bioconjugate of the invention or at least one of a molecule inhibiting gene expression of neuropilin-1, more particularly wherein the molecule is an antibody fragment or antibody of the invention, in combination with a pharmaceutically acceptable carrier and/or a diluent.

The pharmaceutical composition can be used for the treatment of conditions related to the over-expression or ectopic expression of human neuropilin-1, especially the treatment of metastatic tumors, especially of metastatic tumors derived from the group selected of cancer cell-types of page 12.

The pharmaceutical composition of the invention can further be used for the treatment tumors or metastases whereby the comprised NPBs inhibit angiogenesis and the outgrowing of blood vessels, which provide the tumor with nutrition's, and thereby famish the tumor.

In another embodiment of the invention, pharmaceutical compositions are provided comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one molecule inhibiting neuropilin-1 function can particularly be a molecule which can bind to the extracellular region of neuropilin-1, more particularly wherein the molecule is a small chemical compound or a modi-

fied polypeptide or the bioconjugate of the invention, still more preferably wherein the molecule is a modified scFv of the invention or a modified antibody derived from such a scFv of the invention.

In another embodiment, the invention relates to a method of treating or preventing
5 tumors or metastasis in a patient comprising the administration of a molecule inhibiting neuropilin-1 function, in a pharmaceutical acceptable composition in an amount effective to treat, i.e. inhibit, delay or prevent, metastasis of neuropilin-1 mediated invasion and/or adhesion. The molecule inhibiting neuropilin-1 function can particularly be a molecule which can bind to the extracellular region of neu-
10 ropilin-1, which can be identified by the method of identifying a ligand binding specifically to the extracellular region of neuropilin-1 described below, more particularly wherein the molecule is a small chemical compound or an antibody or an antibody fragment or a modified polypeptide of the invention or a bioconjugate of the invention, still more preferably wherein the molecule is a modified scFv of the
15 invention or a modified antibody derived from such a scFv of the invention. This method of treating or preventing metastasis can be effective to reduce or inhibit the invasion and/or adhesion of cancer cells derived from mesodermal cells, in particular cancer cells derived from sarcomas, in particular cancer cells derived from sarcomas of the bone and/or soft tissue. The cancer cells can be selected
20 from the group of cancer cells described on page 12.

The present invention further relates to a method to produce the polypeptide of the invention by recombinant techniques. These techniques are well known in the art (Skerra et al. (1993), Curr. Opin. Immunol. 5, 256-62; Chadd et al. (2001), Curr. Opin. Biotechnol. 12, 188-94).

25 For example, nucleic acid sequences encoding a polypeptide of the invention, particularly an antibody fragment or an antibody (e.g., a gene encoding an antibody fragment of Figure 10 or an antibody thereof) can be isolated and cloned into one or more polynucleotide expression vectors, and the vector can be transformed into a suitable host cell line for expression of a recombinant polypeptide
30 of the invention. Expression of the gene encoding the polypeptide of the invention

provides for increased yield of the polypeptide, and also allows for routine modification of the polypeptide by introducing amino acid substitutions, deletions, additions and other modifications, for example humanizing modifications (Rapley (1995) Mol. Biotechnol. 3: 139-154) in both the variable and constant regions of the antibody fragment or of the antibody of the invention without critical loss of binding specificity or neuropilin-1 blocking function (Skerra et al. (1993) Curr. Opin. Immunol. 5, 256-262).

The present invention therefore relates to an above mentioned isolated nucleic acid molecule encoding any one of the polypeptides of the invention, particularly an antibody fragment of the invention, more particularly a scFv, dsFv, Fv, single domain antibody or diabody of the invention, still more particularly a scFv, single domain antibody, diabody of the invention or an antibody derived from such a scFv of the invention, and even more preferably a scFv of the invention or an antibody derived from such a scFv of the invention.

In a preferred embodiment the present invention relates to a nucleic acid molecule encoding a NBP comprising a sequence selected from the group consisting of SEQ ID NO. 1 and SEQ ID NO. 2, or SEQ ID No. 5 to SEQ ID No. 38.

The present invention further relates to a vector comprising a nucleic acid of the invention. Particularly the vector is a plasmid, a phagemid, or a cosmid.

For example, the nucleic acid molecule of the invention can be cloned in a suitable fashion into procaryotic or eucaryotic expression vectors (Sambrook et al., "Molecular cloning: a laboratory manual" Second edition, Cold Spring Harbor Laboratory Press (1989)). Such expression vectors comprise at least one promoter, at least one signal for translation initiation, at least one nucleic acid sequence of the invention and - in the case of procaryotic expression vectors - a signal for translation termination, while in the case of eucaryotic expression vectors preferably additional signals for transcriptional termination and for polyadenylation.

Examples for prokaryotic expression vectors are, for expression in *Escherichia coli*, e.g. expression vectors based on promoters recognized by T7 RNA polym-

- 26 -

erase, as described in US 4,952,496, for eucaryotic expression vectors for expression in *Saccharomuces serevisiae*, e.g., the vectors p426Met25 or 526GAL1 (Mummborg et al. (1994) Nucl. Acids Res., 22, 5767-5768), for the expression in insect cells, e.g., Baculovirus-vectors as e.g. described in EP-B1-0 127 839 or EP-
5 B1-0 549 721, and for the expression in mammalian cells, e.g., the vectors Rc/CMV and Rc/RSV or SV40-vectors, which are commonly known and commercially available.

The molecular biological methods for the production of these expression vectors, as well as the methods of transfecting host cells and culturing such transfected
10 host cells as well as the conditions for producing and obtaining the polypeptides of the invention from said transformed host cells are well known to the skilled person.

The present invention further relates to a host cell comprising a nucleic acid of the invention and/or a vector of the invention, particularly wherein the host cell is a
15 microorganism like yeast or other fungi, like *Escherichia coli*, *Bacillus subtilis* or other bacteria. The host cell can also be a cell of higher eucaryotic origin, like an insect cell, preferably a virus infected insect cell, more preferably a baculovirus infected insect cell, or like a mammalian cell like HeLa, COS, MDCK 293-EBNA1, NS0 or a hybridoma cell.

20 The present invention relates further to a method for the production of a polypeptide of the invention, particularly an antibody fragment of the invention, comprising culturing a microorganism transformed with a recombinant vector comprising DNA encoding a polypeptide of the invention, particularly an antibody fragment of the invention, and recovering said polypeptide of the invention, particularly an antibody fragment of the invention or a fusion protein containing it,
25 from the medium.

The present invention shows that blocking neuropilin-1 function may inhibit invasiveness and/or adhesiveness of certain cancer cells derived from group selected of cancer cell-types of page 12, and particularly inhibits invasiveness and or adhe-

- 27 -

siveness of cancer cells, e.g., derived from human sarcoma cells, lymphoma cells and mesothelial neoplasms, more particularly human sarcoma cells.

One embodiment of the invention is therefore the use of at least one, particularly one, molecule inhibiting neuropilin-1 function in the manufacture of a medication for the treatment or prevention of invasion and/or metastasis of naturally occurring cancer cells, wherein invasiveness and/or metastatic potential of said cancer cells depends on neuropilin-1 function, particularly of such tumor cells which are derived from mesodermal cells or cancer cells derived from the group selected of the cancer cell-types of page 12.

- 10 In another preferred embodiment the molecule inhibiting neuropilin-1 inhibits the function of expressed neuropilin-1. Expressed neuropilin-1 is to be understood in this context as neuropilin-1 protein already present on naturally occurring cancer cells before any kind of treatment is initiated.

These molecules are particularly molecules, which bind to the extracellular region of neuropilin-1.

The extracellular segment of neuropilin-1 is defined as that part of the neuropilin-1 protein outside of the cellular membrane, consisting of five domains a1, a2, b1, b2 and c. Domains, which are specifically involved in cell adhesion are b1 and b2. It should be appreciated that neuropilin-1 is a glycoprotein, so not only the mentioned amino acids, but also the sugar modifications on them are considered as being part of the extracellular segment of neuropilin-1.

More particularly this molecule is selected from the group consisting of a small chemical compound, an antibody against neuropilin-1, an antibody fragment against neuropilin-1, a polypeptide of the invention, an anti-idiotypic antibody of the invention and/or a bioconjugate of the invention, especially wherein the molecule is a polypeptide and/or a bioconjugate of the invention.

In another preferred embodiment the naturally occurring cancer, which depend on neuropilin-1 function for angiogenesis, invasiveness, adhesiveness and/or metastatic potential can be any cancer wherein the cancer cells are cells derived from

the group of neoplasms consisting of adenocarcinomas, sarcomas, morbus hodgkin, non-hodgkin lymphoma of high and low malignancy, multiple myeloma, malignant tumors of the brain, head and neck tumors, carcinoma of the thyroid, mesothelioma, leukemia, carcinoma of the esophagus, stomach and pancreas carcinoma, primary carcinomas of the liver, carcinoma of biliary duct and bladder, colorectal carcinoma, basal cell carcinoma, malignant melanoma, osteosarcoma, malignant gliomas, Ewing carcinoma, soft tissue sarcoma, Kaposi sarcoma, neuroblastoma, carcinoma of the kidney, testicular carcinoma, prostate carcinoma, carcinoma of the urinary bladder, malignant tumors of the ovaries, carcinoma of the endometrium of the cervix, tumors of the adrenal gland, particularly from the group of neoplasms consisting of malignant fibrous histiocytoma, liposarcoma, fibrosarcoma, synovial sarcoma, osteosarcoma (parosteal osteosarcoma, periosteal osteosarcoma, small-cell osteosarcoma), chondrosarcoma, Ewing's sarcoma, giant-cell tumor of bone, osteogenic sarcoma, leiomyosarcoma, rhabdomyosarcoma, mesothelioma, lymphangiosarcoma, myxosarcoma, endotheliosarcoma, chordoma, Kaposi's sarcoma and lymphangioendotheliosarcoma.

The invention further pertains to the neuropilin-1 antigen as a druggable target. Another aspect of the present invention pertains to antibody fragments that bind to human neuropilin-1 with high neutralizing capacity.

In another embodiment of the invention, at least one polypeptide of the invention and/or a bioconjugate of the invention are used for identifying additional molecules that specifically bind human neuropilin-1, particularly in screening assays. These methods entail contacting a reference anti-neuropilin-1 antibody fragment with a target species comprising the neuropilin-1 domain in the presence of a putative competitor test-binding agent. This step of contacting is conducted under conditions suitable for complex formation between the reference antibody fragment and the target species in the absence of the test-binding agent. Complex formation between the reference antibody fragment and the target species in the presence of the test-binding agent is detected as an indicator of specific binding activity of the test-binding agent to neuropilin-1. This screening method is useful

for high throughput screening of, e.g., other antibody libraries or antibody fragment libraries, antisense oligonucleotide libraries or peptide and small molecule libraries to identify and characterize additional "molecules binding specifically to neuropilin-1". Competition is determined by an assay in which the antibody fragment, or other binding agent under test substantially inhibits specific binding of the reference antibody fragment to the target species containing the neuropilin-1 domain. This can be determined for example by measuring binding of the reference antibody fragment to a target species comprising neuropilin-1 domain in the presence and absence of a putative competitor, i.e. a "molecule binding specifically to neuropilin-1" under conditions suitable for complex formation. Numerous types of competitive binding assays are known and routinely practicable within the invention, as described for example in U.S. Pat. No. 4,376,110. Typically, such assays involve the use of a target species containing the neuropilin-1 domain (e.g., purified neuropilin-1 or a cell line expressing the neuropilin-1 antigen), an unlabeled "molecule binding specifically to neuropilin-1", and a labeled reference antibody fragment or other binding agent. Competitive inhibition is measured by determining the amount of label bound to the target species in the presence of the "molecule binding specifically to neuropilin-1". Usually the "molecule binding specifically to neuropilin-1" is present in excess. "Molecules binding specifically to neuropilin-1" identified by these competition assays ("competitive binding agents") include antibodies, antibody fragments, peptides, antisense oligonucleotides, small molecules and other binding agents that bind to an epitope or binding site bound by the reference antibody fragment, as well as a "molecule binding specifically to neuropilin-1" that bind to an epitope or binding site sufficiently proximal to an epitope bound by the reference antibody fragment. Preferably, competitive binding agents of the invention will, when present in excess, inhibit specific binding of a reference antibody fragment to a selected target species by at least 10%, preferably by at least 25%, more preferably by at least 50%, and even more preferably by at least 75%-90% or greater.

In addition to a polypeptide of the invention, particularly a modified antibody fragment or a modified antibody of the invention, natural or artificial ligands,

peptides, anti-sense, or other small molecules capable of specifically targeting human neuropilin-1 may be employed. Drugs can be designed to bind or otherwise interact and inhibit human neuropilin-1 based upon the present invention. In this regard, rational drug design techniques such as X-ray crystallography, computer-aided (or assisted) molecular modeling (CAMM), quantitative or qualitative structure-activity relationship (QSAR), and similar technologies can be utilized to focus drug discovery efforts. Rational design allows prediction of molecules, which can interact with proteins or specific parts thereof. Such molecule structures can be synthesized chemically and/or expressed in biological systems. Small molecules may be produced by synthesizing organic compounds according to methods that are well known in the art. A plurality of peptides, semi-peptidic compounds or non-peptidic, and organic compounds may be synthesized and then screened in order to find compounds, which bind to neuropilin-1 with high neutralizing capacity. Particularly compounds that inhibit neuropilin-1 related invasion. See generally Scott and Smith, "Searching for Peptide Ligands with an Epitope Library", Science (1990), 249, 386-90 and Devlin et al., "Random Peptide Libraries: A Source of Specific Protein Binding Molecules", Science, (1990), 249, 40407.

The present invention also provides methods of using the modified antibody or modified antibody fragments to inhibit human neuropilin-1 activity or to detect human neuropilin-1 in cancer cells, preferably sarcoma cells, either in vitro or in vivo. In a preferred embodiment, treating cells expressing the antigen with one or more modified antibody fragments causes or leads to a reduction or inhibition of the invasive or adhesive abilities of human cancer cells, particularly of human sarcoma cells.

The migration of tumor cells into tissue is an important step in metastasis. The processes of adhesion and invasion can be studied in the transendothelial model (See, Woodward et al. (2002) Invest Ophthalmol Vis Sci 43, 1708-14 and Vachula et al. (1992) Invasion Metastasis 12, 66-81). The transendothelial model

provides a useful ex vivo, e.g. an *in vitro*, system for the investigations of cellular interactions during the invasion process.

The present invention therefore further provides an ex vivo, e.g. an *in vitro* method to determine the dependency of the invasiveness of a naturally occurring
5 invasive cancer cell on the functionality of neuropilin-1. This method comprises the steps of:

- a. contacting the cells with a molecule inhibiting neuropilin-1 function;
- b. contacting the cancer cell with a gel-like matrix, under conditions suitable for the growth of said cancer cells; and
- 10 c. determining the migration of said cancer cells through the gel-forming matrix.

The term "gel-like matrix" as used herein is understood to be a semi-solid substance with a water content of at least 90%, which allows cultivation of cancer cells in contact with the matrix and allows migration of invasive cancer cells
15 through a slab of said "gel-like matrix" of 0,1 mm to 1 mm, preferably 0,3 mm thickness, but not migration of non-invasive cells. Examples for such a "gel-like matrix" are substances resembling the extracellular matrix in protein and carbohydrate composition, particularly the commercially available "Matrigel". Particularly the "gel-like matrix" comprises one of the proteins selected from the
20 group consisting of the proteins collagen type IV, fibronectin and laminin. More particularly the gel-like matrix comprises the proteins collagen type IV, fibronectin and laminin. More preferably the gel-like matrix comprises the proteins collagen type IV, laminin, entactin, nidogen and heparan sulfate proteoglycans or collagen type IV, fibronectin, laminin, nidogen, entactin, and vitronectin.

25 In a preferred embodiment the interfering molecule of step a) is a polypeptide that specifically binds to an extracellular epitope of neuropilin-1, particularly a modified polypeptide of the invention, more particularly a modified antibody or a modified antibody fragment of the invention, still more particularly a modified antibody fragment, even more particularly a modified scFv, dsFv, Fv, single do-

main antibody or diabody, especially a modified scFv, single domain antibody or diabody and even more preferably a modified scFv.

The present invention therefore further provides an *ex vivo*, e.g. an *in vitro* method to determine the dependency of the adhesiveness of a naturally occurring
5 invasive cancer cell on the functionality of neuropilin-1. This method comprises the steps of:

- a. contacting the cells with a molecule inhibiting neuropilin-1 function;
- b. contacting the cancer cell with a layer of ECM proteins, under conditions suitable for the growth of said cancer cells; and
- 10 c. determining the adhesion of said cancer cells to the layer of ECM proteins.

The term "layer of ECM proteins" as used herein is understood to be a semi-dry layer of a protein solution, which allows cultivation of cancer cells in contact with the layer and allows attachment of invasive cancer cells to said layer. The thickness of said "layer of ECM proteins" is between 0,1 mm to 1 mm, preferably
15 0,3mm thick. Examples for "ECM proteins are substances of the extracellular matrix. Particularly "ECM proteins are selected from the group consisting of the proteins collagens, entactin, nidogen, vitronectin, fibronectin and laminins. More particularly ECM proteins are selected from collagen S type I, collagen type IV, fibronectin and laminin.

- 20 In a preferred embodiment the interfering molecule of step a) is a polypeptide that specifically binds to an extracellular epitope of neuropilin-1, particularly a modified polypeptide of the invention, more particularly a modified antibody or a modified antibody fragment of the invention, still more particularly a modified antibody fragment, even more particularly a modified scFv, dsFv, Fv, single domain antibody or diabody, especially a modified scFv, single domain antibody or
25 diabody and even more preferably a modified scFv.

The present invention further provides a method of identifying a ligand, binding specifically to the extracellular region of NP-1, by screening a naïve or immune library, preferably a phage display library, wherein said ligand is capable of inter-

- 33 -

fering with the functionality of neuropilin-1, specifically wherein said ligand is capable of inhibiting angiogenesis, tube formation of endothelial cells, and/or invasion or adhesion of tumor cells. Said method comprises the steps of:

- 5 a) contacting a phage library of ligands with cancer cells or endothelial cells;
- b) isolating said cells;
- c) removing phages bound unspecifically to said cells, e.g. by washing said cells with a buffered detergent solution, under conditions where said cells do not lyse;
- 10 d) eluting phages bound to said cells; and
- e) determining the identity of the ligand represented by said eluted phages
- f) testing the ligand in biochemical or biological assays on its capability to interfere with NP-1 function.

- 15 The identity of phages representing the ligand obtained with step e) can be determined by, e.g., sequencing the DNA encoding the ligand in case the ligand is an antibody or antibody fragment, or, in the case of a commercial ligand library with gridded or numbered phages, by determining the grid position or the number of the phage. The grid position or the number then can reveal the identity of the
- 20 ligand represented by the phage.

After step d) the pool of phages is enriched in phages binding to NP-1. Those phages binding to NP-1 can finally be identified by numerous methods known in the art. Phages can be separated to form individual clones and the clones of the phages can be probed with labeled NP-1 protein, or a labeled part of the NP-1

25 protein, e.g. an at least seven amino acid long peptide of the extracellular region of NP-1. Clones binding to such a probe are identified as NP-1-binders. Phages can also be affinity purified on purified NP-1 protein or on recombinant NP-1.

- 34 -

Alternatively, in case the ligand is e.g. an antibody or antibody fragment, the open reading frame encoding the antibody or antibody fragment can be recloned from the whole enriched pool into an expression vector, the antibody or antibody fragment can then be expressed in clones of another host cell, and the clone of the host cell carrying the expression vector comprising a nucleic acid encoding for the antibody or antibody fragment binding specifically to NP-1 can be identified, e.g. by the method described above for the identification of relevant phage clones, by the method of Examples 2 and 3, or by affinity purification on recombinant NP-1.

A particular advantage of this method is that the ligand specific for the accessible part of the extracellular region of NP-1 is obtained, since the initial selection step is performed on intact cells, which present the accessible part of the extracellular region of NP-1 for binding of the phages.

In another preferred embodiment of the invention the method comprises an additional step of screening on recombinant NP-1 protein. This method is described more specifically in Example 3.2.

The method comprises instead of step e) the further steps of:

- e) contacting isolated phages with recombinant NP-1;
- f) washing said NP-1 with a buffered detergent and/or high salt solution; and
- g) eluting phages bound to NP-1; and
- h) determining the identity of the ligand represented by said eluted phages.

In certain embodiments, the ligand expressed on the phages comprise an antibody or an antibody fragment selected from the group consisting of scFv, dsFv, Fab', Fab, F(ab')₂, Fv, single domain antibodies (DABs) and diabodies, more particularly selected from the group consisting of scFv, dsFv, Fv, single domain antibody or diabody, still more particularly selected from the group consisting of scFv, single domain antibody or diabody and even more preferably a scFv.

- 35 -

The "detergent" used in steps c) and f) is a detergent solution, preferably buffered, and can be Tween in a concentration of 0.001- 0.5%, particularly 0.01-0.1 %. "High salt" in step f) is a high salt solution, preferably buffered, and has an ionic strength of 10mM-1M, particularly 20-500mM, more particularly 50-350mM, even more preferably 80-250mM. Typical useful anions are, for example, chloride, citrate, phosphate, hydrogen phosphate or borate. Typical useful cations are, for example, sodium, potassium, lithium, calcium or magnesium.

The buffered solution in the above paragraph typically has a pH of 7-8. For example, DMEM or PBS, particularly with 1-20%, more particularly 5-15%, even more preferably about 10% FCS, can be used as buffers.

Isolation of cells with phages bound to them is effected by gentle centrifugation at g values from 200 to 300 for 3 to 20 minutes, particularly 5 to 10 minutes. Elution of bound phages, both to cells and to immobilized NP-1, is effected by a wash with 2-100mM, particularly 4-50mM, more particularly 5-20mM, even more preferably around 10mM glycine at a pH of from 0 to 2.5, particularly from 1 to 2.5, more particularly from 1.5 to 2.5.

The NP-1 interfering or inhibiting functionality of these ligands, particularly of these antibodies or antibody fragments may be assayed as described above, in vivo or in a cell culture experiment. Cell culture assays include assays that determine the inhibitory effect of the ligands of this invention in an invasion or adhesion assay as described in Examples 8 and 9 or 19 or Examples 11 and 12, or in a tube formation assay with endothelial cells as described in Example 16. Results of the different assays are provided in the Figures.

The method advantageously combines a screening step based on binding to the surface of a cell with a screening step based on a functional assay, which identifies ligands having the capability to interfere or inhibit NP-1 function.

In a preferred embodiment the ligand is capable of inhibiting a biological function of neuropilin-1. For example, the biological function of a neuropilin-1 can be in-

vasion, adhesion, or angiogenesis. Adhesion and invasion have been explained as adhesiveness and invasiveness before.

An invasion assay measures the invasiveness of a cell. An invasion assay is, e.g., the assay performed in Example 8 and 9 of this application.

- 5 An adhesion assay measures the adhesiveness of a target, e.g. a cell, to something else, e.g. another cell, a virus, or a complex biological mixture like, e.g., a population of vehicles derived from a cell or, e.g., the basal lamina. An example of an adhesion assay is given in Example 11 and 12 of the present application.

- “Angiogenesis” is the process where cells induce blood vessel formation in their proximity. Angiogenesis can accompany the growth of malignant tissue and can therefore be a property of malignant cells. That is to say that malignant cells can have the property of inducing angiogenesis. An angiogenesis assay measures the ability of a cell to induce blood vessel formation, a process, which usually accompanies the growth of malignant tissue. An angiogenesis assay is disclosed in
- 10
- 15 Kanda et al (2002) J. Natl. Cancer Inst. 94, 1311-9. An example of an angiogenesis assay, a so-called tube formation assay is given in Example 16 of the present application.

- In another preferred embodiment the method of identifying a ligand binding specifically to the extracellular region of neuropilin-1 also comprises the step of incorporating the ligand identified into a therapeutic, prophylactic or diagnostic composition. This can, e.g., be done by mixing the identified ligand with a pharmaceutically acceptable carrier known in the art, wherein the ligand is present in an amount, which is therapeutically effective.
- 20

- In another preferred embodiment the invention relates to a method for the production of a pharmaceutical composition, comprising the method of identifying a ligand binding specifically to neuropilin-1 and further the step of mixing the identified ligand, or a modified or a labeled version thereof, with a pharmaceutical acceptable carrier known in the art. A modified ligand is a ligand with a covalent modification. Examples of modified ligands are labeled ligands.
- 25

- 37 -

The invention further provides an advantageous combination of methods, which allow a functional increase of activity of the previously identified ligand. For this the method for identifying a ligand, which interferes with NP-1 functionality, is combined with the method of CALI (Chromophore-Assisted Laser Inactivation).

- 5 The principle of CALI is based on the local initiation of a photochemical reaction that leads to the generation of short-lived reactive species, which in turn selectively modify the target molecule and cause its functional inactivation. Highly specific but non-inhibitory ligands (e.g. antibodies, antibody fragments, small molecules) are labeled with a suitable chromophore (e.g. malachite green, fluorescein, methylene blue, eosin). After complex formation between the target
- 10 molecule (e.g. proteins) and the ligand, the complex is irradiated with laser light of an appropriate wavelength to excite the chromophore. The excitation triggers a photochemical reaction that initiates the generation of short-lived reactive species (e.g. hydroxyl radicals or highly reactive oxygen species). These reactive species
- 15 modify the protein within a small radius around their site of generation. The distance that a reactive species can travel is very short due to its short lifetime. Therefore, the modifications of amino acid residues within the protein occur in close proximity to the binding site of the ligand. The damaging effect is restricted to a radius of 15-40Å, which is well below the average distance of two proteins
- 20 within a cell, which is at about 80Å, (assuming an average cytosolic protein concentration of 300mg/ml and an average protein size of 50kDa) ensuring a high spatial resolution of the process. This principle is shown in Figure 13. As an example, a modified antibody against a given protein often can selectively inhibit the function of that particular protein after CALI, even if this antibody did not
- 25 show an inhibiting function without CALI. In cases where the binding site of the ligand is close or within an important functional domain of the protein, these induced modifications lead to permanent inactivation of the protein. The functional inactivation of the protein is measured in an appropriate readout assay and evaluated in the context of disease relevant physiological functions like cell invasion,
- 30 cell adhesion, cell signaling or apoptosis.

Inactivation of proteins with CALI was shown to be very specific to the respective protein. Linden et al showed that β -galactosidase could be efficiently inactivated with a malachite-green labeled anti- β -galactosidase antibody even in the presence of alkaline phosphatase in the same solution. β -galactosidase was inactivated by
5 95 % after 10 min of laser irradiation whereas alkaline was not effected at all (Linden et al. (1992) Biophys. J. 61, 956-962). Jay also demonstrated that a dye-labeled antibody bound to a single epitope of a protein was sufficient to inactivate acetylcholinesterase (Jay (1988) Proc. Natl. Acad. Sci. USA, 85, 5454-58).

Henning et al. described that CALI was successfully used against a diverse array
10 of proteins (Henning et al. Innovations in Pharmaceutical Technology (2002) 62-72). These protein include membrane proteins (eg. α -, β -, ϵ -chains of T cell receptor, β 1 integrins, ephrin A5 or FAS receptor), signal transduction molecules (eg. calcineurin, cyclophillin A or PKC), cytoskeletal proteins (eg. actin, ezrin or kinesin) or transcription factors. Henning et al. further described that CALI can be
15 used for identification of novel proteins as drug targets and at the same time the elucidation of their function in the biological context of interest (Henning et al. (2002) Current Drug Discovery May, 17-19).

Several application examples of CALI show that CALI is able to convert specific but non-inhibitory ligands into blocking reagents. Therefore, these ligands can be
20 used to modulate the action of inhibitory ligands. CALI can also be used to further enhance the inhibitory effect of a ligand that has already an inhibitory effect by itself. Example 9 and Example 12 are examples where CALI is integrated in an invasion and an adhesion assay, respectively.

In another embodiment of the invention the ligand can be modified.

25 The chemical modification of the ligand can be the addition of chromophores. A chromophore is that part of a molecule that possesses high optical activity due to mobile electrons that interact with light. Some examples of chromophores are, e.g., fluorescein derivatives, rhodamine derivatives, coumarin derivatives, porphyrin derivatives, phthalocyanine derivatives, naphthalocyanines derivatives eosin

derivatives, triphenylmethane derivatives or acridine derivatives. A list of chromophores useful for chemically modifying biomolecules is disclosed in The Sigma Aldrich Handbooks of Stains and Dyes, Ed., F.J. Green (1990) ISBN No. 0-941633-22-5.

- 5 The method of identifying a ligand according to the invention may further comprise at least one additional step of testing the ligand, e.g. wherein the testing is based on biochemical or biological properties of the ligand. Such an additional testing step may comprise a method selected from the group consisting of flow cytometry, ELISA, immunoprecipitation, binding assays, immunohistochemical
10 experiments, affinity studies, immunoblots and protein arrays. Biochemical properties can be determined by the size, the shape, the density, the charge density, the hydrophobicity, or the binding specificity of the ligand. The biochemical properties of the ligand form the basis of the applicability of the above-mentioned methods.
- 15 In another preferred embodiment of the invention, the method of identifying a ligand of the invention can further comprise a subtractive selection step. A subtractive selection step is a step, which removes ligands with an undesired property. For example a subtractive selection step can be affected by removing the ligands capable of binding to a control cell, if the property of binding to a control
20 cell is undesired. By way of example, if one wants to select for ligands specific for cancer cells one could first select those ligands which bind to cancer cells, elute the bound ligands, e.g. phages, and then remove those ligands which are capable of binding to non-cancer-cells, by for example contacting the pool of eluted ligands with non-cancer-cells and removing those ligands bound to the
25 non-cancer-cells. The ligands remaining in the supernatant are then ligands specific for cancer cells and can then be used in functional screening assays according to the method of identifying a ligand of the invention.

The neuropilin-1 inhibitory activity of the identified NP-1 binding ligands or antibody fragments, particularly of scFvs may be assayed as described above, in vivo
30 or in a cell culture experiment.

Cell culture assays include assays that determine the inhibitory effect of the antibody fragments of this invention in an angiogenesis, invasion or adhesion assay as described in Examples 16, 8 or 9 and Examples 11 or 12. Results of the angiogenesis assay are provided in Fig 14. Results of the invasion assay are provided in
5 Fig 2. Results of the adhesion assay are provided in Fig. 3 and 4.

In this part of the invention particularly neuropilin-1-binders (NPB) are described, which modulate neuropilin-1 (NP-1) functions particularly, but not limited to the context of angiogenesis. As described above neuropilin-1 (NP-1) is known as a coactivator of VEGF, an essential and strong activator for the induction of blood
10 vessel growth. It was therefore an object of the invention to provide NPBs that interfere with the NP-1/VEGF interaction and, thereby, modulate or inhibit NP-1 function.

The NPBs of the invention are preferably polypeptides, antibodies, antibody fragments or bioconjugates, more preferably single chain antibodies (scFv) or
15 corresponding IgGs, which were generated by cloning the scFv-specific DNA sequence into an IgG expressing vector. According to a further embodiment these NPBs were labeled with detectable labels as described above.

The NPBs of the invention preferably bind to an extracellular epitope of the NP-1. Cross-reactivity to NP-2 or other members of the NP family is not excluded.

20 The NPBs of the invention bind to various extracellular epitopes of NP-1. In one embodiment the NPBs bind to the epitope whereto also VEGF binds and which is accordingly involved in the induction of angiogenesis. Such NPBs have the capacity to block and inhibit VEGF/NP-1 interaction. Consequently, they further have the capability to interfere or inhibit the VEGF-dependent induction of angio-
25 genesis. Such NPBs are particularly useful as medicament and for the treatment of angiogenesis.

It is further known that the various splice variants of VEGF also bind to slightly different epitopes of NP-1. The invention also provides NPBs that bind to these different epitopes. Such NPBs have the capacity to block and inhibit the interac-

tion of the splice variants of VEGF and NP-1. Thus, also they have the capability to interfere or inhibit the VEGF-dependent induction of angiogenesis. Such NPBs are particularly useful as medicament and for the treatment of angiogenesis.

Unexpected, surprising and new was the fact that the invention also identified and
5 characterized NPBs that did not bind to any of the known VEGF-binding epitopes, but still modified or inhibited angiogenesis. Such NPBs modulating and inhibiting the NP-1 function, but not interfering with the VEGF/NP-1 interaction are provided in a preferred embodiment. They have the capability to interfere or inhibit the induction of angiogenesis and are particularly useful as medicament
10 and for the treatment of angiogenesis.

For characterization of the NPB's of the invention, said NPBs were tested e.g. in a so-called tube formation assay. In such an assay endothelial cells, which normally express NP-1, are incubated with the various NPBs and than the effect of such binding on tube formation or cell aggregation is analyzed (see Example 16, and
15 Figure 14 and 15).

In parallel these NPBs were tested in a biochemical VEGF/NP-1 interaction assay (see Example 17). For this a competitive ELISA was used where the binding between a VEGF and the various NPBs was qualitatively and quantitatively measured.

20 The NPBs identified in the different assays are provided by further preferred embodiments. Accordingly, one embodiment provides NPBs, particularly scFv and corresponding IgG, which inhibit tube formation. Particularly preferred according to this embodiment are the scFvs 7, 8, 11, 12, 13, 15, 18, 21, 23, 25, 26, 27, 28, 29, 31, 33 and 36 as well as the corresponding IgGs.

25 It is particularly interesting and surprising, that although all NPBs of this embodiment show a strongly inhibiting effect on tube formation, not all bind to or cross-react with the epitopes, which is bound by VEGF. This is explicitly shown in the competitive ELISA of Example 17, wherein the capability of the different

- 42 -

NPBs of the invention is tested to inhibit the interaction and/or binding of NP-1 and VEGF.

Several NPBs clearly interfere and prevent the interaction of NP-1/VEGF. Most of these binders show a strong inhibiting effect on tube formation. A preferred
5 example of this embodiment is scFv8 or the corresponding IgG. According to a further embodiment such NPBs are highly useful for medical treatment, particularly the treatment or prevention of tumor-related and metastasis-related angiogenesis. Consequently, a further embodiment provides compositions and preparations comprising such NPBs as medicaments or for the treatment of NP-1-
10 dependent angiogenesis, most preferably of tumor related angiogenesis.

According to another embodiment the invention provides NPBs that do not interfere or prevent the interaction of NP-1/VEGF, but still inhibit tube formation. A preferred example of this embodiment is scFv13 or the corresponding IgG. Furthermore preferred are the NPBs that bind to the same epitope as scFv13. Preferred
15 are also NPBs that do not bind to the same epitope as VEGF₁₆₅. The assay as described in Example 18 is particularly useful to identify further NPBs, which bind to the same epitope as scFv 13 or another epitope as VEGF₁₆₅.

The following examples, including experiments conducted and results achieved,
20 are provided for illustrative purposes only and are not to be construed as limiting upon the present invention.

DESCRIPTION OF THE DRAWINGS

Figure 1 shows the invasion of stained HT1080 cells through an 8µm Matrigel-coated filter. Fluorescence was quantified after six hours incubation at
25 37°C. Data presented are the mean of n = 3 wells +/- SD.

Figure 2 shows the inhibitory effect of scFv1 on the invasion of HT1080 cells. Invasion was determined in a chemotaxis assay with a Matrigel coated cell migration chamber. The invasion was determined after laser irradiation.

tion (with CALI, gray bars) and without laser irradiation (without CALI, dark gray bars). The invasion of HT1080 cells in the absence of any inhibitory molecule was used as a control (left two bars).

Figure 2a shows the influence of VEGF on the invasiveness of HT1080 cells. Invasion was determined in a chemotaxis assay with a Matrigel coated cell migration chamber. The invasion of cells could only be stimulated with FCS (first and fourth bar from the left). No significant increase of invasion was seen when the cells were pre-incubated with recombinant VEGF (second bar from the left). The addition of anti-human VEGF antibody (aVEGF) had no influence on this result (third bar from the left). BSA as a chemo-attractant did not stimulate invasion (fifth bar from the left). Addition of recombinant VEGF to the chemo-attractant BSA did not stimulate the invasion (sixth bar from the left). The addition of anti-human VEGF antibody (aVEGF) had also no effect on this result (seventh bar from the left).

Figure 3 shows the inhibitory effect of scFv1 and scFv2 on the adhesion of HT1080 cells. Adhesion to collagen S type I was determined after laser irradiation (with CALI, gray bars) and without laser irradiation (without CALI, dark gray bars). The adhesion of HT1080 cells to collagen S type I in the absence of any inhibitory molecule was used as a control (left two bars).

Figure 4 shows the inhibitory effect of scFv1 and scFv2 on the adhesion of HT1080 cells to different matrix proteins. The adhesion of HT1080 cells to the different matrix proteins in the absence of any inhibitory molecule was used as a control (left block of bars).

Figure 5 shows results of FACS analysis of scFv1 and scFv2 with different cell lines (bold line) and HS-27 cells (dotted line) as control.

Figure 6 shows the result of the immunoprecipitation experiments. scFv1 was tested on HT1080 cells and compared to HS-27 cells as a control. The

- 44 -

immuno-complexes were separated by SDS-PAGE and silver stained.
The band at 130 kDa was identified as neuropilin-1.

Figure 7a and 7b show the vector map and sequence of the scFv display vector pXP10.

5 Figure 8a and 8b show the vector map and sequence of the scFv expression vector pXP14.

Figure 9 shows the sequences for the construction primers for a mouse library.

Figure 10 shows the amino acid sequences of scFv1 to scFv36. In each sequence the CDR3 is marked by underlining. The corresponding SEQ ID's are indicated.

Figure 11 shows the nucleotide sequences coding for the polypeptides scFv1 to scFv36.

Figure 12 shows a MALDI-MS spectrum of the peptide mixture obtained from the band with an approximate size of 130 kDa immunoprecipitated with scFv 1. Two trypsin auto digestion peaks, indicated as T, were used for internal calibration. A total of 17 peaks, marked with asterisks, matched neuropilin-1 (SwissProt, O14786), with a mass deviation of less than 10 ppm. The matched peptides cover 22 % (206/923 residues) of the protein.

Figure 13 shows the principle of Chromophore-Assisted Laser Inactivation (CALI).

Figure 14 shows the results of the tube formation assay. The degree of tube formation was determined via light microscopy and was quantified based on the ability of cells to build closed polygons, the number and area of the polygons, the number of branch points and the ability of the cells to form closed tubes e.g. connections between branch points. Inhibitory effects were quantified by comparison with a negative control and were scaled between 0 and 3 (0-1 = no inhibition and 2-3 = strong inhibition effect). 14a) Control experiment without addition of an inhibitory antibody, inhibition of tube formation = 0, closed polygons are formed, high numbers

of branch points, branch points are connected and no significant cell aggregation. 14b) After incubation with 50 μ l/ml of scFv25*, inhibition of tube formation = 3.0, no closed polygons are formed, very low number of branch points and branch points are not connected. The symbol "*" indicates that the respective scFv -as identified by its number as shown in Fig. 10- was cloned into an IgG1 format before performing the assay. 14c) After incubation with 100 μ l/ml of a control antibody (anti- α 2 integrin antibody), inhibition of tube formation = 3.0, no closed polygons are formed, no branch points visible.

Figure 15 shows –presented as a table- all results of the tube formation assay. The degree of tube formation was determined via light microscopy and quantified as described in Figure 14. The symbol "*" indicates that the respective scFv -as identified by its number as shown in Fig. 10- was cloned into an IgG1 format before performing the assay. The commercially available anti-NP-1 antibody did not show any significant inhibition of tube formation. "PBS 10%" indicates a control experiment, without the addition of an antibody.

Figure 16 shows the inhibition of VEGF₁₆₅:NP-1 interaction tested in a competition ELISA. "*" indicates a p-value < 0.01. Twelve scFv's of 28 were found to significantly inhibit the interaction between NP-1 and VEGF₁₆₅.

Figure 17 shows the determination of epitopes for scFv's on cell surface NP-1. HT1080 cells were preincubated with a control scFv, different NP-1-binding scFv or VEGF as indicated in the legend and the binding of fluorescein labeled scFv was tested. The data show that scFv8 and scFv24 and VEGF have mutually overlapping epitopes, whereas scFv13 has an epitope distinct from scFv8 and scFv24 and VEGF.

Figure 18 shows –presented as a table- results of the Transendothelial Invasion assay with HT1080 cells. scFv26, scFv27, scFv34 and scFv35 inhibited the invasion of TH1080 cells. The invasion is determined in % of inhibi-

- 46 -

tion of invaded cells. For inhibition values: "+" represents 1-10% inhibition.

Figure 19 shows results of the migration assay with HUVEC cells. scFv8*, scFv25*, scFv26*, and scFv31* showed an statistically relevant inhibitory effect on the migration of HUVEC cells. The symbol "*" indicates that the respective scFv -as identified by its number as shown in Fig. 10- was cloned into an IgG1 format before performing the assay. The three bars to the left show the dependency of the migration of HUVEC cells on the concentration of VEGF₁₆₅. Concentrations between 0-5 ng/ml were used. It can be seen that the migration of HUVEC cells increases with the increase of VEGF₁₆₅.

EXAMPLES

Example 1: Construction of an immune library

- Two BALB/c mice were each immunized intradermally with 2×10^7 paraformaldehyde fixed HT1080 cells (human fibrosarcoma cell line; ATCC, CCL-121). Following the first immunization, the injections were repeated twice in a period of 39 days, the mice sacrificed and the spleens isolated and frozen in liquid nitrogen. The immunizations were performed by Charles River, Germany GmbH, Kißlegg.
- Total RNA was isolated using the RNeasy Midi Kit (QIAGEN #75142) as described by the manufacturer using half of each spleen preparation. The RNA concentration and purity was determined by a denaturing formaldehyde gel and photometric measurement.
- cDNA was synthesized using 8.9µg of freshly prepared RNA and 10pmol of a primer mix (IgG1-c, IgG2a-c, IgG2b-c, IgG3-c, VLL-c, VLK-c) using the SuperscriptTM II Kit (GibcoBRL Life Technologies #18064-014) These primers anneal to the RNA encoding the IgG heavy-chain genes and the light chain genes of the kappa and lambda family. VH genes were PCR amplified from 1µl of cDNA us-

- 47 -

ing 36 individual combinations of 9 forward primers (MVH1, M+VH2, MVH3, MVH4, MVH5, MVH6, MVH7, MVH8, MVH9) and 4 backward primers (M-JH1, M-JH2, M-JH3, M-JH4) without restriction sites. VL genes were PCR amplified with one primer mix (M-VK1, M-VK2, M-VK3 M-VK4, M-VL1, M-JK1, 5 M-JK2, M-JK3, M-JL1) without restriction sites. PCR products were gel-purified (QIAquick Gel Extraction Kit, #28706) and re-amplified using individual combinations of 9 forward primers (MVH1 *Sfi*I, MVH2 *Sfi*I, MVH3 *Sfi*I, MVH4 *Sfi*I, MVH5 *Sfi*I, MVH6 *Sfi*I, MVH7 *Sfi*I, MVH8 *Sfi*I, MVH9 *Sfi*I) and 4 backward primers (M-JH1 *Sal*I, M-JH2 *Sal*I, M-JH3 *Sal*I, M-JH4 *Sal*I) with restriction sites 10 for VH and one primer mix (M-VK1 *Apa*LI, M-VK2 *Apa*LI, M-VK3 *Apa*LI, M-VK4 *Apa*LI M-VL1 *Apa*LI, M-JK1 *Not*I, M-JK2 *Not*I, M-JK3 *Not*I, M-JL1 *Not*I) with restriction sites for VL. PCR products were gel-purified (QIAquick Gel Extraction Kit, #28706) and cloned into the phage display vector pXP10 using the restriction sites *Sfi*I/*Sal*I for VH and *Apa*LI/*Not*I for VL. The ligation mix was 15 transfected into *E.coli* TG-1 by electroporation resulting in a library size of 10^7 independent clones.

Example 2: Selection and Screening of scFv (Selection on fixed cells)

Single chain Fv were selected from a phage display library generated from mice 20 immunized with fixed HT1080 cells. The library was generated using the phage display vector pXP10.

HT1080 cells were harvested with 0.05% EDTA, fixed with paraformaldehyde, diluted to 1×10^7 cells/ml in PBS and immobilized onto wells of a 96 well UV cross-link plate (Corning Costar). The wells of the UV cross-link plate were 25 blocked with 5% Skim Milk Powder (#70166, Fluka) in PBS (MPBS). 10^{12} cfu (colony forming units) of phage library/ 10^6 cells were pre-blocked for 1 hour at 25°C with MPBS and subsequently incubated for 1.5 hour at room temperature (RT) with the cells. The wells of the UV cross-link plate were washed six times with PBS + 0.05% Tween-20 followed by six washes with PBS. Bound phage 30 were eluted by the addition of 10 mM Glycine pH 2.2, and neutralized with 1M

- 48 -

Tris/HCl pH 7.4. Typically, between 10^3 and 10^6 cfu were eluted in the 1st round of selection, thus the diversity of the enriched repertoire is decreased compared to the original repertoire. The eluate containing the enriched repertoire was amplified by infecting exponentially growing *E. coli* TG1. Phagemid containing *E. coli* were
5 selected and propagated by overnight growth at 30°C on LB agar plates supplemented with 100 µg/ml ampicillin and 1% glucose. Following this step, the enriched repertoire can either be amplified as a polyclonal pool and used for further rounds of selection in an iterative manner until convergence to desired properties is achieved or be spatially separated and screened on a single clone level. Phage
10 particles for the next round of selection were produced by super-infecting exponentially growing cultures of the previous round of selection with helper phage VCS-M13 (Stratagene, La Jolla, CA) and growing the cultures overnight at 20°C in 2xTY supplemented with 100 µg/ml ampicillin and 50 µg/ml kanamycin. Selection ready phage were precipitated with 0.5 M NaCl/4% PEG-6000 from the
15 cleared bacterial supernatant and re-suspended in PBS. One round of selection was performed followed by screening on a single clone level.

Example 2.1: Selection and screening of scFv (Selection on cells in suspension)

Single chain Fv were selected from a large non-immune phage displayed repertoire of human origin containing 10^{11} independent clones, provided by Cambridge
20 Antibody Technology Ltd., Cambridge, UK.

For selection, HT1080 cells (human fibrosarcoma cell line; ATCC, CCL-121) were harvested with 0.05% EDTA and diluted to 1×10^7 cells/ml in DMEM + 10% FCS. Two times 10^{12} cfu of phage library/ 10^7 cells were pre-blocked for 1 hour at 25°C with DMEM + 10% FCS and subsequently incubated with end-over-end
25 rotation for 1.5 hour at 25°C with the cells in Eppendorf tubes pre-blocked with DMEM + 10% FCS. Three times 10^7 cells were used for the first round of selection and 1×10^7 cells were used for the 2nd round of selection, respectively. The cells were washed by centrifugation at 220xg for five minutes, followed by removal of the supernatant and re-suspension in wash buffer. Five washes with

DMEM + 10% FCS + 0.05% Tween-20 as wash buffer and five washes with DMEM + 10% FCS as wash buffer were performed. Bound phages were eluted by the addition of 10 mM glycine pH 2.2, neutralized with 1M Tris/HCl pH 7.4. Typically, between 10^3 and 10^6 cfu were eluted in the 1st round of selection, thus
5 the diversity of the enriched repertoire is decreased compared to the original repertoire. The eluate containing the enriched repertoire was amplified by infecting exponentially growing *E. coli* TG1. Phagemid containing *E. coli* were selected and propagated by overnight growth at 30°C on LB agar plates supplemented with 100µg/ml ampicillin and 1% glucose. Following this step, the enriched repertoire
10 can either be amplified as a polyclonal pool and used for further rounds of selection in an iterative manner even until convergence to desired properties is achieved or be spatially separated and screened for a desired function on a single clone level. Phage particles for the next round of selection were produced by super-infecting exponentially growing cultures of the previous round of selection
15 with helper phage VCS-M13 (Stratagene, La Jolla, CA) and growing the cultures overnight at 20°C in 2xTY supplemented with 100 µg/ml ampicillin and 50 µg/ml kanamycin. Selection ready phage were precipitated with 0.5 M NaCl/4% PEG-6000 from the cleared bacterial supernatant and re-suspended in PBS. In this example two rounds of selection were performed followed by screening on a single
20 clone level.

Example 3: Selection and Screening of scFv (Screening on fixed cells)

For screening, the genes encoding the selected scFv, contained in the phage display vector, were re-cloned to the expression vector pXP14. This vector directs the expression of a scFv in fusion with a Streptag and E-tag and does not contain a
25 filamentous phage gene-3. Expression vector containing *E. coli* TG1 from single colonies were grown in individual wells of a microtiter plate so that each well contains only one scFv clone. The bacteria were grown at 30°C in 2xTY supplemented with 100 µg/ml ampicillin and 0.1% glucose in 96-well microtiter plates (#9297, TPP) until an OD₆₀₀ of 0.7. Expression was induced with IPTG at a final
30 concentration of 0.5 mM and continued at 25°C overnight. Single chain Fv con-

- 50 -

taining cleared lysates were prepared by addition of hen-egg lysozyme (#L-6876, Sigma) to a final concentration of 50 µg/ml for 1 hour at 25°C and centrifugation for 15 minutes at 3000 x g. Prior to the screening ELISA, the cleared lysates were blocked by the addition of an equal volume of DMEM + 10% FCS for 1 hour. For the screening ELISA, HT1080 cells were harvested with 0.05% EDTA, fixed with paraformaldehyde, diluted to 1×10^7 cells/ml in PBS and immobilized onto wells of a 96 well UV cross-link plate (Corning Costar). The wells of the UV cross-link plate were blocked with MPBS and the scFv containing blocked cleared lysates added for 1.5 hours at 25°C. The plates were washed 2x with PBS + 0.1% Tween-20 and 1x with PBS, incubated with HRP conjugated α -E-tag (#27-9413-01, Pharmacia Biotech; diluted 1:5000 in MPBS with 0.1 % Tween-20) for 1 hour, washed 3x with PBS + 0.1% Tween-20 and 3x with PBS, developed with POD (#1 484 281, Roche) and signals read at 370 nm. Positive clones were retested against HT1080 cells and control human fibroblasts Hs-27 (ATCC CRL-1634) using the ELISA screening procedure described above.

In a typical screen, 2760 (30x92) clones were screened for binding to HT1080 cells with 5 % positives defined as clones giving a background subtracted signal > 0.1. 155 positive clones were retested for specific binding to HT1080 cells compared to the Hs-27 control cells with 28 % positives defined as clones giving a background subtracted signal on HT1080 of twice the value of the signal on Hs-27 control cells. scFv1 was identified by applying this selection and screening method.

Example 3.1: Selection and screening of scFv (Screening on adherent cells)

For screening, the genes encoding the selected scFv, contained in the phage display vector, were re-cloned to the expression vector pXP14. This vector directs the expression of a scFv in fusion with a Streptag and E-tag and does not contain a filamentous phage gene-3. Expression vector containing *E. coli* TG1 from single colonies were grown in individual wells of a microtiter plate so that each well contains only one scFv clone. The bacteria were grown at 30°C in 2xTY supple-

mented with 100 µg/ml ampicillin and 0.1% glucose in 96-well microtiter plates (#9297, TPP) until an OD₆₀₀ of 0.7. Expression was induced with IPTG at a final concentration of 0.5 mM and continued at 25°C overnight. Single chain Fv containing cleared lysates were prepared by addition of hen-egg lysozyme (#L-6876, Sigma) to a final concentration of 50 µg/ml for 1 hour at 25°C and centrifugation for 15 minutes at 3000xg. Prior to the screening ELISA, the cleared lysates were blocked by the addition of an equal volume of DMEM + 10% FCS for 1 hour. For the screening ELISA, HT1080 cells were seeded in a 96-well microtiter plate (#9296, TTP) at a density of 3x10⁴ cells/well in DMEM + 10% FCS overnight at 37°C. The wells were blocked with DMEM + 10% FCS for 1 hour at 37°C and the scFv containing blocked cleared lysates added for 1.5 hours at 25°C. The plates were washed 2x with PBS + 0.1% Tween-20 and 1x with PBS, incubated with HRP conjugated α-E-tag (#27-9413-01, Pharmacia Biotech; diluted 1:5000 in 5% Skim Milk Powder (#70166, Fluka) in PBS with 0.1 % Tween-20) for 1 hour, washed 3x with PBS + 0.1% Tween-20 and 3x with PBS, developed with POD (#1 484 281, Roche) and signals read at 370 nm. Positive clones were retested against HT1080 cells and control human fibroblasts Hs-27 (ATCC CRL-1634) using the ELISA screening procedure described above.

In a typical screen, 1472 (16x92) clones were screened for binding to HT1080 cells with 16 % positives defined as clones giving a background subtracted signal > 0.1. 238 positive clones were retested for specific binding to HT1080 cells compared to the Hs-27 control cells with 28 % positives defined as clones giving a background subtracted signal on HT1080 of twice the value of the signal on Hs-27 control cells. scFv2 was identified by applying this selection and screening method.

Example 3.2: Generation of function inhibiting antibodies

Using a large naïve human phage displayed antibody library provided by Cambridge Antibody Technology Ltd., Cambridge, UK, additional NP-1 antibodies were selected on recombinant NP-1. The selection was performed as described in

(Vaughan, T.J et al., 1996 Nat Biotechnol. 14, 309). After two rounds of selection, individual clones were screened for their ability to specifically recognize recombinant NP-1 in ELISA and NP-1 as presented on the cell surface in cell ELISA and FACS.

5

Example 4a: Sequencing and large scale expression

Sequencing of all scFv genes was performed by Sequiserve GmbH, Vaterstetten, Germany using the primer pXP2 Seq2 (5'-CCCCACGCGGTTCCAGC-3') and pXP2 Seq1 (5'TACCTATTGCCTACGGC-3'). The amino acid sequences are shown in Figure 10 and nucleotide sequences are shown in Figure 11.

Unique clones identified by sequencing were streaked out from glycerol stocks onto LB/Amp (100µg/ml)/1% Glucose Agar plates and incubated o/n at 30°C. 10 ml LB/Amp/Glu (1%) media were inoculated with a single colony and grown o/n at 30°C and 200 rpm shaking. The next morning the overnight cultures were placed on ice until inoculation of 1L 2xTY media supplemented with 100µg/ml Ampicillin and 0.1% Glucose in 2L Erlenmeyer-flasks. The cultures were grown at 25°C shaking until an OD₆₀₀ 0.5 – 0.6 was reached and then induced with IPTG 0.1 mM final concentration. Fresh Ampicillin was added to 50 µg/ml and incubation was proceeded at 22°C o/n shaking. In the morning the cultures were centrifuged at 5000 x g for 15 minutes at 4°C, supernatants discarded and the pellets re-suspended carefully on ice with a pipette in 10 ml pre-cooled PBS-0.5 M Na buffer containing protease inhibitors complete (#1697498, Roche). After re-suspension was completed, bacterial suspensions were transferred to 20 ml oakridge centrifuge tubes and hen-egg lysozyme (#L-6876, Sigma) added to a final concentration of 50 µg/ml for 1 hour on ice. The lysed bacteria were centrifuged at 20000 x g for 15 minutes at 4°C and the supernatants (lysate) transferred to a 15 ml plastic tube. For affinity purification the lysates were loaded with 1 ml/min onto 1ml StrepTactin (# 2-1505-010, IBA) columns equilibrated with 10 column volumes (CV) PBS-0.5 M Na buffer via a parallel protein purification system (self-made). After a 10 CV wash with PBS the elution was done with 5

CV PBS/5mM Desthiobiotin (#D-1411, Sigma) and 1 ml fractions collected. The fractions were measured at UV₂₈₀, protein containing fractions were pooled and concentrated with Amicon Ultra Centrifugal Filter Devices 10.000 MWCO (#UFC801024, Millipore) at 4700 x g. The concentrated scFv were checked on
5 12% Bis-Tris SDS-PAGE gels stained with Coomassie Blue for purity and frozen in aliquots with 20 % glycerol at -80°C.

Example 4b: Cloning of scFv into IgG format and expression

The scFvs consist of the sequence of a variable light and heavy chain linked by a
10 linker sequence. The variable light chain and the variable heavy chain were amplified by PCR separately with the usage of primer, which contain restriction sites. Those restriction sites are also present in the vectors, which contain the appropriate constant domains for the heavy and light chain. The amplified variable domains were cut with the restriction enzymes and cloned into the cut vectors. The
15 correct sequence was confirmed via sequencing

Four vectors were used, one contained the constant domain of the heavy chain for IgG1 format. The second contained the constant domain of the heavy chain for IgG4 format and two contained the constant domain of lambda and kappa light chains, respectively. Different restriction sites enabled to cut the vectors and to
20 ligate the variable domains in the vectors.

For expression of the IgGs in mammalian cell lines the vectors contained an Epstein Barr virus origin of replication (oriP sequence) which enhances the level of transcription in 293-EBNA-HEK cells, because the EBNA protein leads to the replication of the episomal vector.
25 A co-transfection was carried out with the vector for the heavy chain and the vector for the light chain leading to the expression of both chains in the cell and the assembly of the IgG in the Endoplasmic Reticulum. The assembled IgG was then secreted to the medium. As transfection method Calcium-phosphate transfection was used, where a precipitate of Calcium-phosphate and the DNA is
30 formed and incorporated into the cell. After the transfection the medium was

changed to serum-free medium. Three harvests per IgG were done every 3 days. The supernatant (media) were sterile-filtrated and stored at 4°C.

For the purification of the IgGs the supernatants were purified via Protein A Sepharose either by gravity flow or by HPLC depending on the volume. For up to 200 ml a gravity flow method was used. For both purification types the supernatant was loaded on the Protein A column, washed with 50 mM Tris pH 7 buffer and eluted with 0.1 M Citrate pH ~2. To the elution fraction 0.25 M Tris pH 9 was added leading to a pH of 5.5-6.0. Depending on the further use of the IgGs they were dialysed against PBS buffer and stored at -20°C.

10

Example 5: FACS analysis for tumor cell specific binding

To test the ability of purified anti HT1080 single chain Fv to bind specifically to target cells, we performed a fluorescence-activated cell sorter (FACS) analysis using HT1080 cells (ATCC CCL-121), KHOS cells (ATCC CRL-1544), PC-3 cells (ATCC CRL-1435), BT-474 cells (ATCC HTB-20), Hela cells (DSMZ ACC-57), HL60 cells (DSMZ ACC-3), Jurkat cells (DSMZ ACC-282), MCF7 cells (DSMZ ACC-115) and chang liver cells (DSMZ ACC-57 contain impurities of Hela cells) (for all 10^6 cells/ml) and Hs-27 cells (10^6 cells/ml) as control cell line (see Figure 5). Cells were incubated with 10 µg/ml of pure scFv in CellWash (BD (Becton, Dickinson and Company) #349524) for 20 min at 4°C, washed, and bound scFvs were detected with a secondary FITC labeled anti E-tag mab (Amersham #27-9412-01). Samples were washed and analyzed on a Becton Dickinson FACScan. Figure 5 shows the log fluorescence intensity (FL1-H; x-axis) versus the relative cell numbers (counts; y-axis) for cells reacting with scFv1. The thin line represents the control cell line (HS-27) and the bold line the tumor cell lines or chang liver cells. scFv1 and scFv2 specifically stain the tumor cell lines with up to 10 fold higher signals compared to the control cell line.

25

Example 6: Competition analysis by FACS

To test the ability of the purified anti neuropilin-1 scFv to block common neuropilin-1 epitopes on the target cells, single cell suspensions of HT1080 are harvested with 0,5mM EDTA/PBS. Approximately 1×10^6 cells are incubated in CellWash “(BD, #349524) with 10 μ g/ml scFv for one hour at 4°C. After washing with Cell Wash 10 μ g/ml FITC labeled scFv is added and incubated for 20 min at 4°C. Signals of bound FITC labeled scFvs with and without pre incubation of other neuropilin-1 binders are analyzed on a Becton Dickinson FACSscan. “

Example 7: Labeling of antibody fragments with FITC

scFv were labeled with fluorescein isothiocyanate (FITC) (Molecular Probes, Eugene, USA #F1906) by the following method: Aliquots of a 10mg/ml solution of FITC in dimethyl sulfoxide were added to 100 μ g of scFv1 dissolved in PBS/0.5M NaHCO₃, pH 9.5 in a ratio of 30:1 (FITC:scFv1). The sample was incubated for two hours at room temperature with agitation, free FITC was separated using desalting columns (2 Micro Spin G-25, Pharmacia 27-5325-01). The ratio of labeling was determined via mass spectrometry and via UV/VIS spectroscopy, whereby the protein concentration was calculated at 280nm and the FITC concentration at 494nm.

Example 8: Invasion assay for identification of inhibitory antibody fragments

The ChemoTx[®] system (Neuro Probe Inc.#106-8, Gaithersburg) is used as a disposable chemotaxis/cell migration chamber in a 96 well format with an 8 μ m filter Track etched Polycarbonate pore size, 5.7 mm diameter/site.

13,3 μ l of 0.3mg/ml Matrigel (Matrigel is a solubilized basement membrane preparation extracted from the Engelbreth-Holm-Swarm (EHS) mouse sarcoma, a tumor rich in extracellular matrix proteins. Its major component is laminin, followed by collagen IV, heparan sulfate proteoglycan, entactin and nidogen. It also contains TGF- β fibroblast growth factor, tissue plasminogen activator, and other growth factors which occur naturally in the EHS tumor) (Becton Dickenson, BD

- 56 -

#356234) diluted in Dulbeccos PBS (Gibco #14040-091) is applied on the membrane filter of the 96-well plate on row B-H and on row A 1,2 µg/site of collagen S type I (Roche #10982929) is diluted in 0,05 M HCl (Sigma #945-50) and is incubated over night at 20°C in a desiccator for gelation. HT1080 cells are grown to

5 70-80% confluence in DMEM supplemented with GlutamaxI (862mg/l (Gibco #31966-021) with 10% FCS (Gibco #10270106). The cells are washed 2x with DMEM/GlutamaxI/0.1 % BSA (Sigma #A-7030) then labeled *in situ* with Bis-benzimide H 33342 (Sigma #B-2261) are diluted 1:100 in DMEM/GlutamaxI/0.1 % BSA for 15 min at 37°C, 7,5% CO₂. Cells are washed 2x with

10 DMEM/GlutamaxI/0.1 % BSA and are loaded with DMEM/GlutamaxI/0.1 % BSA for 15 min at 37°C, 7,5% CO₂ for recovering. After washing 2x with PBS w/o Ca²⁺, Mg²⁺ (Gibco, 10010-015), the cells are detached with 0.5mM EDTA (Sigma #E8008), are collected with Dulbeccos PBS/0.1% BSA/10mM Hepes (Gibco #15630-056), are washed 2x with Dulbeccos PBS/0.1% BSA/10mM

15 Hepes, are suspended in Dulbeccos PBS/0.1% BSA/10mM Hepes and are diluted to 6,7 x 10⁶ cells/ml with Dulbeccos PBS/0.1% BSA/10mM Hepes. 6,7 x 10⁶ cells/ml are incubated 1:1 with 40µg/ml of a control scFv as a negative control for inhibition of invasion and with HT1080 specific scFv for 1h on ice. After dilution to 6,7 x 10⁵ cells/ml with DMEM/GlutamaxI/0.1 % BSA, HT1080 cells and

20 HT1080 cell/scFv dilutions are pipetted in triplicate onto the chemotaxis chamber (row B-H) at a density of 3,4 x 10⁴ cells/well and are incubated for 6 h at 37°C, 7,5% CO₂. DMEM/GlutamaxI with 5% FCS is used as a chemo attractant in the lower chamber. A standard curve from 1x10⁴ to 4x10⁴ cells/site is performed on collagen S type I coated row A of the chemotaxis chamber.

25 DMEM/GlutamaxI/0.1% BSA is used in the lower chamber (cells are not migrating). After scraping the non-migrating cells from the top of the membrane (except the Standard curve on row A) fluorescence of cells, which had migrated through the membrane (not migrated in case of the Standard curve), is measured on the Fluostar Galaxy (bMG) microplate reader using excitation/emission wavelengths

30 of 370/460nm.

Example 8.1: Influence of VEGF on the invasion of HT1080 cells

The invasion assay set-up was identical to the set-up described in Example 8. The invasion membrane (Neuroprobe #106-8, Gaithersburg, MD) was coated overnight with Matrigel (0,3mg/ml; BD #356234, Bedford, MA). 80 % confluent HT1080 cells were stained with Bis-benzimide H33342 and then detached with 0,05% EDTA. Cells (7×10^6 /ml, final 35.000/well) were pre-incubated for 1h at 4°C with:

- a. 0, 25, 50 or 100 ng/ml recombinant human VEGF (R&D Systems #293-VE, Minneapolis) in the presence or absence of 20 µg/ml anti-human VEGF antibody (R&D Systems #AF-293-NA). 5% FCS (not heat-inactivated) in DMEM was used as chemo-attractant in the well below the membrane;
- b. in the presence or absence of 20 µg/ml anti-human VEGF antibody, with 5% FCS and 25, 50 or 100 ng/ml VEGF as chemo-attractant;
- c. 0, 25, 50 or 100 ng/ml VEGF in the presence or absence of 20µg/ml anti-human VEGF antibody, with 1% BSA (Sigma #A7030, ST. Louis, MO) in DMEM in the well below the membrane;
- d. in the presence or absence of 20 µg/ml anti-human VEGF antibody, using 25, 50 or 100 ng/ml VEGF in DMEM containing 1% BSA as chemo-attractant.

50µl of the preincubated cell suspensions (a-d) were pipetted on top of the membrane and the invasion plate was incubated for 6h at 37°C, 7,5% CO₂. The readout of the invasion assay was identical to the readout described in Example 8. No significant increase of invasion was seen when the cells were pre-incubated with different concentrations of recombinant VEGF (a). Also, the addition of anti-human VEGF antibody had no influence on the invasion of HT1080 cells (a), compared to the result of Experiment 8. The addition of recombinant VEGF to the chemo-attractant FCS did not result in an increase of invasion of HT1080 cells (b). A variation of the VEGF concentration did not show an effect either. The ad-

- 58 -

dition of anti-human VEGF antibody had also no effect on this result (b). The pre-incubation with VEGF did not result in an invasion of HT1080 cells when BSA was used as a chemo-attractant (c). The use of VEGF as a chemo-attractant in DMEM and 1% BSA did also not stimulate the invasion of HT1080 cells (d),
5 whereas 5% FCS as a chemo-attractant induced invasion (fourth bar from the left in Figure 2a).

Example 9: Invasion assay for target identification with CALI

This Example is in general identical to Example 8, except for the use of FITC-labeled scFv (see, Example 7 for labeling) and the integration of the CALI process
10 within the invasion assay.

The ChemoTx[®] system (Neuro Probe Inc.#106-8, Gaithersburg) was used as a disposable chemotaxis/cell migration chamber in a 96 well format with an 8µm filter Track etched Polycarbonate pore size, 5.7 mm diameter/site.

15 13,3µl of 0.3mg/ml Matrigel (see Example 8) diluted in Dulbeccos PBS (Gibco #14040-091) was applied on the membrane filter of the 96-well plate on row B-H and on row A 1,2 µg/site. of collagen S type I (Roche #10982929) was diluted in 0,05 M HCl (Sigma #945-50) and was incubated over night at 20°C in a desiccator for gelation. HT1080 cells were grown to 70-80% confluence in DMEM supplemented with GlutamaxI (862mg/l (Gibco #31966-021) with 10% FCS (Gibco
20 #10270106). The cells were washed 2x with DMEM/GlutamaxI/0.1 % BSA (Sigma #A-7030) then labeled *in situ* with Bisbenzimidazole H 33342 (Sigma #B-2261) and were diluted 1:100 in DMEM/GlutamaxI/0.1 % BSA for 15 min at 37°C, 7,5% CO₂. Cells were washed 2x with DMEM/GlutamaxI/0.1 % BSA and
25 loaded with DMEM/GlutamaxI/0.1 % BSA for 15 min at 37°C, 7,5% CO₂ for recovering. After washing 2x with PBS w/o Ca²⁺, Mg²⁺ (Gibco, 10010-015), the cells were detached with 0.5mM EDTA (Sigma #E8008), collected with Dulbeccos PBS/0.1% BSA/10mM Hepes (Gibco #15630-056), washed 2x with Dulbeccos PBS/0.1% BSA/10mM Hepes, suspended in Dulbeccos PBS/0.1%
30 BSA/10mM Hepes and diluted to 6,7 x 10⁶ cells/ml with Dulbeccos PBS/0.1%

- 59 -

BSA/10mM Hepes. $6,7 \times 10^6$ cells/ml were incubated 1:1 with $40\mu\text{g/ml}$ of FITC-labeled anti-beta1 integrin monoclonal antibody (JB1, Chemicon #MAB1963) as a control for inhibition of invasion after CALI and with HT1080 specific FITC labeled scFv for 1h on ice. $1,3 \times 10^5$ HT1080 cells/well or HT1080 cell/scFv or Ab
5 dilution were pipetted in triplicate in two 96-well plate, black, ultra thin clear flat bottom special optics (Costar #3615). One plate was kept on ice in the dark while the other plate was irradiated on an ice block with continuous wave laser at 488nm (0.5W, 30 sec). After dilution to $6,7 \times 10^5$ cells/ml with DMEM/GlutamaxI/0.1 % BSA, HT1080 cells and HT1080 cell/scFv dilutions
10 were pipetted in triplicate (non irradiated triplicate beside irradiated triplicate) onto the chemotaxis chamber (row B-H) at a density of $3,4 \times 10^4$ cells/well and incubated for 6 h at 37°C , 7,5% CO_2 . DMEM/GlutamaxI with 5% FCS was used as a chemo attractant in the lower chamber. A standard curve from 1×10^4 to 4×10^4 cells/site was performed on collagen S type I coated row A of the chemotaxis
15 chamber. DMEM/GlutamaxI/0.1% BSA was used in the lower chamber (cells were not migrating). After scraping the non-migrating cells from the top of the membrane (except the Standard curve on row A) fluorescence of cells, which had migrated through the membrane (not migrated in case of the Standard curve), was measured on the Fluostar Galaxy (bMG) microplate reader using excita-
20 tion/emission wavelengths of 370/460nm. In a general experiment, a value of 45000 corresponded to 100% migrated cells.

The invasion phenotype of HT1080 cells was assessed by comparing their relative ability to invade tumor extracellular matrix (Matrigel) using the Transwell culture system described above. scFv1 showed after CALI an inhibitory effect of 25% on
25 the invasion of the HT1080 cells. The result of the invasion assay with and without CALI (see Example 8) is shown in Figure 2. Figure 2 shows that CALI converts scFv1 in an inhibitory antibody fragment.

Example 10: MTS viability assay

Viable cells were detected by measuring the conversion of the tetrazolium dye MTS (MTS, Celltiter A_{queous} one, Promega #G4000) to formazan. HT1080 cells and HT1080 cell/scFv dilutions (obtained from the dilutions prepared in the Invasion assay) were pipetted in triplicate at a density of $3,4 \times 10^4$ cells/well and were
5 plated in a 96-well plate (black, ultra thin clear flat bottom, special optics, Costar #3615) 10 μ l MTS was added to each well and incubated for 1 hour at 37°C, 7,5% CO₂. Absorbance was measured at 492 nm with the Fluostar Galaxy (bMG) microplate reader. For all tested scFvs, no effect on viability of cells was seen (data
10 not shown).

Example 11: Cell-matrix adhesion assay for identification of inhibitory antibody fragments

21 wells of a 96-well flat bottom plate (Costar #3614) were coated with one matrix protein selected from collagen S type I 1 μ g/well (Roche #10982929), collagen
15 type IV 1 μ g/well (Rockland 009-001-106), fibronectin 1 μ g/well (Sigma F2518) and laminin 1 μ g/well (Roche 1243217) in Dulbeccos PBS (Gibco #14040-091), respectively, at 4° C over night. At the same time 3 wells in row A were coated with 2% BSA (Sigma #A-7030)/Dulbeccos PBS for a blank value. Wells were
20 washed twice with Dulbeccos PBS, and blocked with 2% BSA (Sigma #A-7030)/Dulbeccos PBS for 1h at 37°C and washed with Dulbeccos PBS. HT1080 were harvested, stained with 2,5mM (final concentration) Calcein AM (Molecular Probes C-3099), washed twice with PBS w/o CaCl₂ w/o MgCl₂ (Gibco 10010-015) and diluted to $1,5 \times 10^5$ /ml in buffer (0,5% BSA (Sigma #A-7030) + 10mM
25 Hepes + DMEM (Gibco 31966-02)). HT1080 cells were mixed with 10 μ g/ml scFv and incubated for 30 min on ice. The HT1080 cells alone and HT1080/scFv dilutions were pipetted in triplicate at a density of $1,5 \times 10^4$ cells/well and incubated for one hour at 37°C, 7,5% CO₂. After two additional washing steps with Dulbeccos PBS, where non-adherent cells were washed away, a Standard curve
30 from $3,7 \times 10^3$ to $1,5 \times 10^4$ stained cells/well diluted in Dulbeccos PBS was performed in triplicate in row A. Washed wells were filled with 100 μ l Dulbeccos

- 61 -

PBS and the absorbance of attached cells and of the Standard curve was measured on the Fluostar Galaxy (bMG) microplate reader using excitation/emission wavelengths of 485/520nm. scFv1 showed an inhibitory effect of approximately 20% on the adhesion of HT1080 cells to collagen S type I, collagen type IV, fibronectin and laminin. scFv2 showed an inhibitory effect of 27 % on the adhesion of HT1080 cells to laminin and a relatively low inhibitory effect on the adhesion of HT1080 cells to collagen type IV and fibronectin. No effect was seen on the adhesion of HT1080 cells to collagen S type I. Results for scFv1 and scFv2 are shown in Figure 4.

10

Example 12: Cell-matrix adhesion assay for target identification with CALI

96-well plates (TPP #9296) (cell culture treated) were coated in Row B-H with collagen S type I 1µg/well (Roche #10982929) in Dulbeccos PBS (Gibco #14040-091) and in Row A well 10-12 were coated with 2% BSA (Sigma #A-7030)/Dulbeccos PBS at 4°C over night. The plate was washed with Dulbeccos PBS, blocked Row B-H and Row A well 10-12 with 2% BSA/Dulbeccos PBS for 1h at 37°C and washed again with Dulbeccos PBS. HT1080 cells were grown to 70-80% confluence in DMEM supplemented with GlutamaxI (862mg/l (Gibco #31966-021) with 10% FCS (Gibco #10270106). The cells were washed 2x with DMEM/GlutamaxI/0.1 % BSA (Sigma #A-7030) then labeled *in situ* with Bis-benzimide H 33342 (Sigma #B-2261) were diluted 1:100 in DMEM/GlutamaxI/0.1 % BSA for 15 min at 37°C, 7,5% CO₂. Cells were washed 2x with DMEM/GlutamaxI/0.1 % BSA and loaded with DMEM/GlutamaxI/0.1 % BSA for 15 min at 37°C, 7,5% CO₂ for recovering. After washing 2x with PBS w/o Ca²⁺, Mg²⁺ (Gibco, 10010-015), the cells were detached with 0.5mM EDTA (Sigma #E8008), collected with Dulbeccos PBS/0.1% BSA/10mM Hepes (Gibco #15630-056), washed 2x with Dulbeccos PBS/0.1% BSA/10mM Hepes, suspended in Dulbeccos PBS/0.1% BSA/10mM Hepes and diluted to 6,7 x 10⁶ cells/ml with Dulbeccos PBS/0.1% BSA/10mM Hepes. 6,7 x 10⁶ cells/ml were incubated 1:1 with 40µg/ml of FITC-labeled anti-beta1 integrin monoclonal antibody (JB1, Chemicon #MAB1963) as a control for inhibition of adhesion after

30

- 62 -

CALI and with HT1080 specific FITC labeled scFv for 1h on ice. 1.3×10^5 HT1080 cells/well or HT1080 cell/scfv or Ab dilution were pipetted in triplicate in two 96-well plate, black, ultra thin clear flat bottom special optics (Costar #3615). One plate was kept on ice in the dark while the other plate was irradiated on an ice block with continuous wave laser at 488nm (0.5W, 30 sec). After dilution to 6.7×10^5 cells/ml with DMEM/GlutamaxI/0.1 % BSA, HT1080 cells and HT1080 cell/scFv dilutions were pipetted in triplicate (non irradiated triplicate beside irradiated triplicate) onto the coated and blocked plate. In Row A well 10-12 6.7×10^5 cells/ml with DMEM/GlutamaxI/0.1 % BSA were pipetted as a background control. Plate was incubated for 1h at 37°C, 7.5% CO₂ and washed 2x with Dulbeccos PBS, where non-adherent cells were washed away. In Row A well 1-9 a standard curve from 1×10^4 to 4×10^4 cells/well is performed, in all other wells 50 µl Dulbeccos PBS is pipetted. Fluorescence of cells, which had adhered to the Collagen S type I (not adhered in case of the Standard curve), was measured on the Fluostar Galaxy (bMG) microplate reader using excitation/emission wavelengths of 370/460nm. scFv1 showed after CALI an inhibitory effect of 30% on the adhesion of the HT1080 cells to collagen S type I. scFv2 showed after CALI an inhibitory effect of approximately 10% on the adhesion of HT1080 cells to collagen S type I. In one set of experiments scFv2 showed already an inhibitory effect on the adhesion of HT1080 cells to collagen S type I of 5% without CALI. The results of the adhesion assay with and without CALI are shown in Figure 3.

Example 13: Immunoprecipitation

HT1080 and Hs-27 cells (10^8) were lysed in 3ml 50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1% Triton X-100 (v/v) containing protease inhibitor cocktail (1 pill in 50ml buffer) (Boehringer Mannheim, Cat.-No. 1697498) and 100 µM Pefablock (Roth, Cat.-No. A154.1). Lysates were pre-incubated for 2h at 4°C with Streptactin Sepharose (IBA, # 2-1201-010) and the supernatants used for the immunoprecipitation reactions. HT1080 specific scFv (50 µg/1 mg cell extract) were added to the cleared lysates, samples rotated for 2h at 4°C, gently centrifuged at 700g to pellet the Streptactin Sepharose, the pellet was washed 4 times with 1ml volume

of PBS + 0.1% Tween buffer per wash, before the complexes were isolated by elution from the Streptactin Sepharose pellet with 50 μ l 10 mM D-desthiobiotin in PBS 0.1% Tween 20. The immuno-complexes were separated by SDS-PAGE and silver stained for MS analysis.

- 5 scFv 1 and scFv 2 pulled down a protein, detected as a band on SDS-PAGE by silver staining at a molecular weight of ~130 kDa. This band was only detected in the HT1080 cell extract and not in the Hs-27 cells (control cells), see Figure 6.

Example 14: Protein identification via mass spectroscopy

- 10 The gel bands obtained from immunoprecipitations followed by SDS PAGE were subjected to a tryptic in-gel digest over night at 37 °C. Peptides were extracted using 5% formic acid and the resulting peptide mixture was desalted using ZipTip μ C18 (Millipore) and eluted first with 2 μ l of 30% ACN/0.1% TFA, then with 2 μ l of 70% ACN/0.1% TFA. The two fractions were pooled and one microliter of
15 the obtained peptide mixtures was mixed in a 1:1 ratio with a solution of α -cyano-4-hydroxycinnamic acid (3 mg/ml), co-crystallized on a Teflon-coated stainless steel target and analyzed on a MALDI-TOF instrument yielding peptide mass fingerprints (PMF) in a mass range of m/z 800-3000. The obtained PMF were used to search all entries for the species *Homo sapiens* in the NCBI and SwissProt da-
20 tabases. In all cases, only peptides matching a given protein with a mass deviation of less than 10 ppm were considered for identification.

- The band with an approximate size of 130 kDa, obtained by using scFv1 or scFv2, yielded up to 17 peptide peaks (in different experiments with the same scFv), which matched neuropilin-1, with a maximum protein coverage of 22% (206/923
25 residues). 3 peptides, namely peptide fragments 659-672, 680-702 and 776-787 clearly support the identity of neuropilin-1. Neuropilin-1's splice variant, called soluble neuropilin-1, misses amino acids 645-923 when compared to neuropilin-1 with its 923 amino acids. Therefore, the obtained mass spectrum clearly proves

- 64 -

that the full length version of NP-1 was immunoprecipitated by scFv1 and scFv2. A spectrum is shown in Figure 12.

Example 15: Methods for epitope mapping

- 5 An epitope mapping may be carried out according to one of the following methods:

Example 15.1: "Classical" epitope mapping

Defined fragments of the cDNA for the antigen of interest are expressed as recombinant (fusion)proteins and probed in various assays such as Westernblot or
10 ELISA.

Example 15.2: Phage display technology

The technique of epitope mapping using random peptide phage display libraries was developed to clone small random fragments of the cDNA for the antigen of interest into the phage protein pIII of filamentous phages and display them on the
15 surface of the phage (Fack et al., (1997) J. Immunol. Methods 7, 43-52). Epitope-displaying phages can be captured with antibodies in a procedure called "bio-panning". Sequencing of the inserts of the corresponding phages gives some information on the epitopes. This procedure is in principle capable to identify conformational epitopes.

20 **Example 15.3: Peptide scan technology**

It is based on the synthesis of immobilized peptides on activated membranes using the Fmoc chemistry. Amino acid solutions are applied to the activated membrane leading to a peptide bond between the amino-group on the membrane (the membrane is activated with PEG) and the activated carboxy-group of the applied
25 amino acid. After each cycle a specific washing procedure, acetylation, deprotection and monitoring of free amino-groups is performed. In contrast to the in vivo protein-synthesis membrane bound oligo-peptide chains are stepwise synthesized from C- to the N-terminus. Oligo-peptides containing natural as well as modified

- 65 -

amino acids can be synthesized up to a length of 20 amino acids. Following synthesis the membranes are equilibrated and unspecific binding sites are blocked. After incubation with the antibody of interest and several washing steps the detection is performed using an HRP-conjugated secondary antibody in combination with the ECL-System. Membranes can be stripped, regenerated, and re-used up to 10 times depending on the antibody. Small overlapping oligo-peptides that ideally cover the complete amino acid sequence of the antigen of interest are synthesized on a solid support. This method allows the identification of linear epitopes on the amino acid level. It also allows rapid mutational studies.

10

Example 16: Inhibition of tube formation

HUVEC cells (Cell Line Service, Heidelberg; # 0170 HU) were cultured in gelatine (0.2% gelatine in HBSS w/o Ca^{2+} / Mg^{2+} , 1h at RT) coated 150 cm^2 flasks to 80-90% confluency. Only cells with passage numbers between 2 and 10 were used. An angiogenesis assay kit was used (Chemicon # ECM625) for the assay.

15

Materials:

96 well MTP, half well, tissue culture treated, black with clear bottom, Corning # 3882

Trypsin for HUVEC cells, 0.25 mg/ml, Clonetics # CC-5012

20 Gelatine, 2%, Sigma # G1393

Biospin P6 columns, Biorad # 7326200

Buffers:

PBS Dulbecco's, Invitrogen # 14040-091

HBSS w/o Ca^{2+} / Mg^{2+} , Invitrogen # 14170-088

25 **Media:**

Endothelial cell growth medium for HUVEC cells (CLS Heidelberg), containing: 2% FCS, 0.4% ECGS/H, 0.1 ng/ml EGF, 1.0 ng/ml bFGF, 1.0 $\mu\text{g/ml}$ Hydrocortison, Gentamicin/Amphotericin B.

Purification of scFv's

ScFv's were purified with Biospin P6 columns (Biorad) to remove desthiobiotin, endotoxins and glycerol and were stored in PBS over night on ice. The protein concentration of the purified scFv was determined by measuring absorbance at 280nm. All scFv solutions were adjusted to an identical concentration by addition of PBS.

Preparation of the MTP for the tube formation assay

The required amount of buffer was added to the ECMatrixTM (both included in the angiogenesis kit). 25 µl diluted ECMatrixTM was added to each well of a pre-cooled 96 well MTP (half well plate). The MTP was incubated >1h at 37°C to allow the matrix solution to solidify. Detached endothelial cells were pre-incubated with the scFv's or appropriate IgG's for 30 min at RT.

Cell seeding and antibody incubation

HUVEC cells were detached from the flask by removing cell culture medium, washing the cells 1x with 10 ml HBSS w/o Ca²⁺/Mg²⁺ followed by addition of 5 ml trypsin (Clonetics) and incubation for 2-3 min at 37°C. Trypsin reaction was stopped by adding 5 ml cell culture medium with FCS. Supernatants were combined, centrifuged for 5 min at 240 x g, RT, the supernatant was carefully removed and the cells were resuspended in 5 ml medium and were counted by using a Neubauer cell counting chamber. A cell master mix was prepared by resuspending the required number of cells in the appropriate amount of cell culture medium to obtain a concentration of 10.000 cells in 50 µl per well after addition of the antibody solution. The end concentration in the well was usually 10 µg/ml for scFv's and 50 µg/ml for IgG's. For each binder a 3x premix was prepared. For each binder a 3x premix with 3x 10.000 cells was pre-incubated with the appropriate amount of scFv or IgG in a total volume of 150 µl for 30 min at RT before seeding, to allow binding to NP-1 before contact with matrix proteins. 50 µl of the cell-antibody mixture was transferred to each well of the MTP coated with 25 µl solidified ECMatrix. Appropriate controls were included in each experiment (PBS

- 67 -

in same concentration as for samples with scFv, mouse IgG, commercial anti-NP-1 antibody (R & D Systems, # AF566), anti- α 2 Integrin, as well as an unspecific control scFv's. Cells were incubated for 16h at 37°C. The degree of tube formation was determined via light microscopy and was quantified based on the ability of the cells to form closed polygons, the number and area of the polygons, the number of branch points and the ability of the cells to form closed tubes e.g. connections between branch points. ScFv's were considered as positive if the ability to form closed polygons, the number of branch points and the ability to form closed connections between branch points were reduced. Inhibitory effects were quantified by comparison with the negative control and scaled between 0 and 3 (0-1 = no inhibition and 2-3 = strong inhibition effect). Several scFv were converted into an IgG1 format and were re-tested. Figure 14a-c shows representative pictures of the tube formation assay. Several scFv showed significant inhibition of tube formation (Inhibition of >2.2). Table 1, as shown in Figure 15 summarizes all results of the tube formation assay. Several scFvs inhibited the tube formation significantly, whereas the commercially available anti-NP-1 antibody did not show any significant inhibition of tube formation.

Example 17: Inhibition of NP-1/VEGF interaction in ELISA

In order to test the ability of scFv's to inhibit the interaction between recombinant NP-1 and VEGF, VEGF₁₆₅ (R&Dsystems, #293-VE/CF) was coated at a concentration of 50 nM in PBS on Maxisorp microtiter plates (Nunc, # 430341). Recombinant NP-1-Fc (R&Dsystems, #566-NNS) was preincubated at a concentration of 50 ng/ml with NP-1 scFv (25 μ g/ml) for one hour at RT and was added to the VEGF₁₆₅ coated microtiter plate. Bound NP-1 was detected with anti-Fc-HRP (Jackson Immuno Research, #H909-035-098) followed by reaction with BM blue POD substrate (Roche, # 11484281). The absorption was determined at 370 nM. Twenty-eight scFv's were tested for their ability to inhibit the interaction between recombinant NP-1 and VEGF₁₆₅. Twelve scFv's were found to significantly inhibit the interaction between NP-1 and VEGF₁₆₅. This result is compared to the

- 68 -

results of the tube formation assay described in Example 16. scFv8 inhibits the interaction between NP-1 and VEGF₁₆₅ and inhibits HUVEC tube formation; scFv13 does not inhibit the interaction between NP-1 and VEGF₁₆₅ but inhibits HUVEC tube formation; scFv24 inhibits the interaction between NP-1 and VEGF₁₆₅ but does not inhibit HUVEC tube formation.

Example 18: Determination of NP-1 epitopes

ScFv's were labeled with fluorescein isothiocyanate (Molecular Probes, # F-1906) according to the instructions of the manufacturer. HT1080 cells were preincubated with a control scFv, a NP-1-binding scFv's (e.g. scFv8, scFv13 or scFv22) (both at 25 µg/ml) or VEGF₁₆₅ (R&Dsystems, #293-VE/CF) (5 µg/ml) for 2 hours at 0°C and the fluorescein labeled NP-1-binding scFv (5 µg/ml) was added for 30 min. at 0°C. Bound fluorescein labeled scFv were detected by flow cytometry and the geometric mean fluorescence intensity was recorded. In order to determine if NP-1-binding scFv has overlapping epitopes with VEGF and each other for binding to cell surface NP-1, a competition FACS with directly labeled scFv was performed. In agreement with the VEGF competition ELISA, scFv8 inhibits the interaction between NP-1 and VEGF₁₆₅ and inhibits HUVEC tube formation; scFv13 does not inhibit the interaction between NP-1 and VEGF₁₆₅ but inhibits HUVEC tube formation; scFv24 inhibits the interaction between NP-1 and VEGF₁₆₅ but does not inhibit HUVEC tube formation. Furthermore, scFv8 and scFv24 have mutually overlapping epitopes whereas scFv13 has an epitope distinct from scFv8 and scFv24.

Example 19: Transendothelial Invasion assay with HT1080 cells**Preparation of a monolayer of endothelial cells:**

A Neuroprobe membrane was coated with 50 µl/well 0.2 % Gelatine (Sigma G-1393), was diluted in HBSS w/o Ca⁺/Mg⁺ ions (Gibco 14170-088) and was incubated for 1h at RT under a fume hood. Confluent grown HUVEC cells were har-

vested with Trypsin (Cambrex CC-5012) and ECGM (CLS ready to use Endothelial cell Growth Medium) and were diluted with ECGM to 2×10^5 /ml. Remaining fluid on the coated membrane was removed with a syringe. The lower chamber of the Neuroprobe system was filled with 28.5 μ l/well HBSS and the membrane was placed on top. 50 μ l (1×10^4) of the HUVEC cell suspension was spotted on the membranes in each well and was incubated for 48h at 37° C 5% CO₂.

Preparation of HT1080 cells:

5×10^5 cells were seeded into 6 150 cm² flasks and incubated for 48h at 37° C 5% CO₂.

10 Staining of HT1080 cells:

Calcein AM (Molecular Probes C3099) was diluted 1:1000 in 90 ml DMEM with Glutamax that included 0.1% BSA (Sigma A-7030). The medium was removed from the HT1080 cells and 15 ml/flask of Calcein solution was added to the cells and cells were incubated for 15 min at 37° C 5% CO₂. The solvent was removed and the cells were washed twice with HBSS w/o Ca⁺/Mg⁺ ions. Cells were harvested with EDTA and DMEM with Glutamax that included 0.1% BSA and were diluted to 7×10^5 /ml with DMEM with Glutamax that included 0.1% BSA.

Inhibition of invasion of cells:

All experiments were carried out in triplicates. 170 μ l of the HT1080 cell suspension was pipetted into each well of a 96 well V-bottom plate. 17 μ l scFv (min. 10 μ g/ml), 0.25 mg/ml Cytochalasin D (CCD) (Sigma C-8273) was added and cells were incubated for 15 min. As a negative control a non-specific antibody was used.

Standardcurve:	1x10 ⁴ cells	46.8 μ l cells + 133.2 μ l DMEM with Glutamax 0.1% BSA
	2x10 ⁴ cells	93.6 μ l cells + 86.4 μ l DMEM with Glutamax 0.1% BSA
	4x10 ⁴ cells	57.2 μ l cells directly spotted

Preparation of the membrane system for invasion:

The membrane was disassembled from the lower chamber and the solvent was removed from the lower part of the membrane. The solvent from the wells of the lower chamber was removed as well. The lower chamber was filled with 30 μl /well ECGM/20 % FCS (Invitrogen 10270106) for the test samples (row B-H). For the standard curve and for the background all wells of row A were filled with 30 μl /well ECM and membranes were placed on top.

55 μl (3.5×10^4) of HT1080 samples were pipetted on top of the HUVEC cells layer. The set up was incubated for 12-16h at 37° C and 5% CO₂. Cells from rows B-H were scraped off with a cell scraper and the membranes were rinsed with Dulbeccos PBS. Wells of rows B-H were wiped with a cotton swab (pre wetted in PBS) and membranes were rinsed again with PBS. The membranes were carefully dried and fluorescence at 485/520 nm was measured (Fluostar Galaxy). 4 different single chains inhibited the invasion by values of 6-10%. Table 2 as shown in Figure 18 summarises the results.

Example 20: HUVEC migration assay

The HUVEC migration assay was carried out according to the manufacturer's instructions (BD Biosciences, Bedford/MA, Cat.-Nr. 354143). Briefly, 2×10^4 HUVECs in 250 μl of basal medium (Promocell, Heidelberg, Germany, Cat.-Nr. 22210) containing 1 ng/ml EGF, 1 μg /ml hydrocortisone, 0.4% FCS, 50 ng/ml amphotericin B and gentamicin 50 μg /ml (all from Cambrex, East Rutherford/NJ) were incubated with the antibodies (50 μg /ml) for 30 minutes at room temperature, then seeded into the top chambers of the 24-well insert, which contains a fibronectin-coated, 3- μm -pore FluoroBlok membrane at the bottom of each well. The lower chambers were filled with the same medium additionally containing 5 ng/ml VEGF₁₆₅ (R&D Systems, Minneapolis/MN). The plate was incubated for 22 h at 37°C, 5% CO₂, then the 24-well insert was transferred to a new plate containing 0.5 ml of a 4 μM solution of calcein-AM (Molecular Probes, Eugene/OR) in HBSS (Invitrogen, Carlsbad/CA). After 90 minutes of incubation,

- 71 -

the plate was read out in a BMG FluoStar plate reader (BMG LabTechnologies, Offenburg, Germany) at 485 nm excitation and 520 nm emission wavelength. Statistical analysis was done using a Kruskal-Wallis test, with significance assumed at $p < 0.05$. Some results are shown in Figure 19. As an example, 7 IgG's
5 are shown in Fig. 19 that showed an inhibitory effect on the migration of HUVEC cells between 20-60%. scFv8*, scFv25*, scFv26*, and scFv31* showed a statistically relevant inhibitory effect. The dependency of the migration of HUVEC cells on the concentration of VEGF₁₆₅ is also shown in Figure 19 (three bars on the left). Concentrations of 0-5 ng/ml were used to determine the concentration
10 dependency. The migration of HUVEC cells increased with increasing the VEGF₁₆₅ concentration.

CLAIMS


1. A neuropilin binder (NPB) wherein the NPB is a polypeptide, antibody, scFv, antibody fragment or bioconjugate and is characterized in modulating neuropilin-1 (NP-1) function or having the capability to inhibit NP-1 dependent angiogenesis of endothelial cells and/or invasion of tumor cells, whereby the NPB binds to NP-1 and modulates NP-1 function.
2. The NPB according to claim 1 comprising a sequence selected from the group consisting of SEQ ID No: 1 or SEQ ID No: 2.
3. The NPB according to claim 1 comprising a sequence selected from the group consisting of sequences SEQ ID No: 5 to SEQ ID No: 38.
4. The NPB according to claim 3, whereby the NPB is not binding, interfering or inhibiting the VEGF/neuropilin-1 interaction.
5. The NPB according to claim 1, wherein the NPB is a polypeptide, antibody, scFv, antibody fragment or bioconjugate comprising one CDR3 (Complementary Determining Regions 3) having at least one of the sequences selected from SEQ ID No: 73 to SEQ ID No: 108.
6. The NPB according to any of claims 1 to 5, wherein said NPB is labeled with a detectable label; in particular wherein said detectable label is selected from the group consisting of a radioisotope, an enzyme and a chromophore.
7. Use of the NPB according to any of claims 1 to 6 for the detection of neuropilin-1 expression.
8. Use of the NPB according to any of claims 1 to 6 for the modulation of neuropilin-1 function, particularly modulation or inhibition of neuropilin-dependent invasion or adhesion of cells, preferably tumor cells.

9. A diagnostic kit comprising the NPB according to any of claims 1 to 6 and a container.
10. A composition comprising the NPB according to any of claims 1 to 6 and a pharmaceutical acceptable carrier.
11. An isolated nucleic acid molecule encoding the NPB according to any of claims 1 to 6.
12. A vector comprising a nucleic acid according to claim 11.
13. Use of the NPB according to any of claims 1 to 6 in the manufacture of a medicament for the treatment or prevention of neuropilin-dependent angiogenesis and non-physiological blood vessel growth, particularly correlated with a tumor.
14. Use of the NPB according to any of claims 1 to 6 in the manufacture of a medicament for the treatment or prevention of cancer and/or metastasis of tumor cells, wherein the metastatic potential depends on neuropilin-1-related invasion and/or adhesion, preferably wherein the tumor cells are tumor cells derived from mesodermal cells.
15. The use of claims 13 or 14 wherein the NPB inhibits the function of expressed neuropilin-1, in particular wherein the molecule binds to the extracellular region of neuropilin-1.
16. An *ex vivo* method of determining the dependency of the invasiveness of a naturally occurring invasive cancer cell on the functionality of neuropilin-1, comprising the steps of:
 - b) contacting the cancer cell with a molecule inhibiting neuropilin-1 function;
 - c) contacting said cancer cell with a gel-like matrix under conditions suitable for the growth of said cancer cells; and
 - d) determining the migration of said cancer cells through the gel-like matrix.


17. An *ex vivo* method of determining the dependency of the adhesiveness of a naturally occurring invasive cancer cell on the functionality of neuropilin-1, comprising the steps of:
 - a) contacting the cancer cell with a molecule inhibiting neuropilin-1 function;
 - b) contacting said cancer cell with a layer of extracellular matrix (ECM) proteins under conditions suitable for the growth of said cancer cells; and
 - c) determining the adhesion of said cancer cells to the layer of ECM proteins.
18. The method of claim 17, wherein the layer of ECM proteins comprises one protein selected from the group consisting of collagen S type I, collagen VI, fibronectin, laminin, nidogen, entactin, and vitronectin.
19. A method of identifying a ligand binding specifically to the extracellular region of neuropilin-1, wherein said ligand is capable of inhibiting angiogenesis, tube formation of endothelial cells, and/or invasion or adhesion of tumor cells, comprising the steps of:
 - a) contacting a phage library of ligands with cancer cells or endothelial cells;
 - b) isolating said cells;
 - c) removing phages bound unspecifically and/or not bound to said cells;
 - d) eluting phages bound to said cells; and optionally
 - e) determining the identity of the ligand represented by said binding to neuropilin-1
 - f) testing the ligand in biochemical or biological assays on its capability to interfere with NP-1 function.
20. The method of claim 19, instead of steps e) further comprising the steps of:
 - e) contacting eluted phages with immobilized NP-1;

- 75 -

- f) washing said NP-1 with detergent and/or high salt;
 - g) eluting phages bound to NP-1; and
 - h) determining the identity of the ligand represented by said eluted phages.
21. A method of treating or preventing cancer or metastasis in a patient, said method comprising administering to said patient the NBP according to any of claims 1 to 6, the composition according to claim 10, the nucleic acid sequence according to claim 11 or a ligand identifiable by the method of claims 19 or 20 in an amount effective to inhibit metastasis of neuropilin-1 mediated invasion and/or adhesion.
22. A method of treating or preventing cancer or metastasis in a patient, said method comprising administering to said patient the NBP according to any of the claims 1 to 6, the composition according to claim 10, the nucleic acid sequence according to claim 11 or a ligand identifiable by the method of claims 19 or 20 in an amount effective to inhibit tumor-associated, neuropilin-dependent angiogenesis.



Invasion of Hs-27 control cells



Invasion of HT1080 cells

Fig. 1




Fig. 2




Fig. 2a




Fig. 3




Fig. 4




Fig. 5

~ 130 kDa = Neuropilin




Fig. 6




Fig. 7a

Nucleotide Sequences pXP10

1	GACGAAAGGG	CCTCGTGATA	CGCCTATTTT	TATAGGTTAA	TGTCATGATA
	CTGCTTTCCC	GGAGCACTAT	GCGGATAAAA	ATATCCAATT	ACAGTACTAT
51	ATAATGGTTT	CTTAGACGTC	AGGTGGCACT	TTTCGGGGAA	ATGTGCGCGG
	TATTACCAAA	GAATCTGCAG	TCCACCGTGA	AAAGCCCCTT	TACACGCGCC
101	AACCCCTATT	TGTTTATTTT	TCTAAATACA	TTCAAATATG	TATCCGCTCA
	TTGGGGATAA	ACAAATAAAA	AGATTTATGT	AAGTTTATAC	ATAGGCGAGT
151	TGAGACAATA	ACCCTGATAA	ATGCTTCAAT	AATATTGAAA	AAGGAAGAGT
	ACTCTGTTAT	TGGGACTATT	TACGAAGTTA	TTATAACTTT	TTCCCTTCTCA
201	ATGAGTATTC	AACATTTCCG	TGTCGCCCCT	ATTCCTTTTT	TTGCGGCATT
	TACTCATAAG	TTGTAAAGGC	ACAGCGGGAA	TAAGGGAAAA	AACGCCGTAA
251	TTGCCCTTCT	GTTTTTGCTC	ACCCAGAAAC	GCTGGTGAAA	GTAAAAGATG
	AACGGAAGGA	CAAAAACGAG	TGGGTCTTTG	CGACCACTTT	CATTTTCTAC
301	CTGAAGATCA	GTTGGGTGCT	CGAGTGGGTT	ACATCGAACT	GGATCTCAAC
	GACTTCTAGT	CAACCCACGA	GCTCACCCAA	TGTAGCTTGA	CCTAGAGTTG
351	AGCGGTAGA	TCCTTGAGAG	TTTTCGCCCC	GAAGAACGTT	TTCCAATGAT
	TCGCCATTCT	AGGAACTCTC	AAAAGCGGGG	CTTCTTGCAA	AAGGTTACTA
401	GAGCACTTTT	AAAGTTCTGC	TATGTGGCGC	GGTATTATCC	CGTATTGACG
	CTCGTGAAAA	TTTCAAGACG	ATACACCGCG	CCATAATAGG	GCATAACTGC
451	CCGGGCAAGA	GCAACTCGGT	CGCCGCATAC	ACTATTCTCA	GAATGACTTG
	GGCCCCTTCT	CGTTGAGCCA	GCGGCGTATG	TGATAAGAGT	CTTACTGAAC
501	GTTGAGTACT	CACCAGTCAC	AGAAAAGCAT	CTTACGGATG	GCATGACAGT
	CAACTCATGA	GTGGTCAGTG	TCTTTTCGTA	GAATGCCTAC	CGTACTGTCA
551	AAGAGAATTA	TGCAGTGCTG	CCATAACCAT	GAGTGATAAC	ACTGCGGCCA
	TTCTCTTAAT	ACGTCACGAC	GGTATTGGTA	CTCACTATTG	TGACGCCGGT
601	ACTTACTTCT	GACAACGATC	GGAGGACCGA	AGGAGCTAAC	CGCTTTTTTG
	TGAATGAAGA	CTGTTGCTAG	CCTCCTGGCT	TCCTCGATTG	GCGAAAAAAC
651	CACAACATGG	GGGATCATGT	AACTCGCCTT	GATCGTTGGG	AACCGGAGCT
	GTGTTGTACC	CCCTAGTACA	TTGAGCGGAA	CTAGCAACCC	TTGGCCTCGA
701	GAATGAAGCC	ATACCAAACG	ACGAGCGTGA	CACCACGATG	CCTGTAGCAA
	CTTACTTCGG	TATGGTTTGC	TGCTCGCACT	GTGGTGCTAC	GGACATCGTT
751	TGGCAACAAC	GTTGCGCAAA	CTATTAAGTG	GCGAACTACT	TACTCTAGCT
	ACCGTTGTGG	CAACGCGTTT	GATAATTGAC	CGCTTGATGA	ATGAGATCGA
801	TCCCGGCAAC	AATTAATAGA	CTGGATGGAG	GCGGATAAAG	TTGCAGGACC
	AGGGCCGTTG	TTAATTATCT	GACCTACCTC	CGCCTATTTT	AACGTCCTGG
851	ACTTCTGCGC	TCGGCCCTTC	CGGCTGGCTG	GTTTATTGCT	GATAAATCTG
	TGAAGACGCG	AGCCGGGAAG	GCCGACCGAC	CAAATAACGA	CTATTTAGAC
901	GAGCCGGTGA	GCGTGGGTCT	CGCGGTATCA	TTGCAGCACT	GGGGCCAGAT
	CTCGGCCACT	CGCACCCAGA	GCGCCATAGT	AACGTCTGTA	CCCCGGTCTA
951	GGTAAGCCCT	CCCGTATCGT	AGTTATCTAC	ACGACGGGGA	GTCAGGCAAC
	CCATTGCGGA	GGGCATAGCA	TCAATAGATG	TGCTGCCCCCT	CAGTCCGTTG
1001	TATGGATGAA	CGAAATAGAC	AGATCGCTGA	GATAGGTGCC	TCACTGATTA
	ATACCTACTT	GCTTTATCTG	TCTAGCGACT	CTATCCACGG	AGTGACTAAT
1051	AGCATTGGTA	ACTGTCAGAC	CAAGTTTACT	CATATATACT	TTAGATTGAT
	TCGTAACCAT	TGACAGTCTG	GTTCAAATGA	GTATATATGA	AATCTAACTA
1101	TTAAAAC TTC	ATTTTTAATT	TAAAAGGATC	TAGGTGAAGA	TCCTTTTTGA
	AATTTTGAAG	TAAAAATTAA	ATTTTCCTAG	ATCCACTTCT	AGGAAAAACT
1151	TAATCTCATG	ACCAAAATCC	CTTAACGTGA	GTTTTCGTTT	CACTGAGCGT
	ATTAGAGTAC	TGGTTTTTAGG	GAATTGCACT	CAAAAGCAAG	GTGACTCGCA
1201	CAGACCCCGT	AGAAAAGATC	AAAGGATCTT	CTTGAGATCC	TTTTTTTCTG
	GTCTGGGGCA	TCTTTTCTAG	TTTCCTAGAA	GAACTCTAGG	AAAAAAAGAC
1251	CGCGTAATCT	GCTGCTTGCA	AACAAAAAAA	CCACCGCTAC	CAGCGGTGGT
	GGCATTAGA	CGACGAACGT	TTGTTTTTTT	GGTGGCGATG	GTCGCCACCA
1301	TTGTTTGCCG	GATCAAGAGC	TACCAACTCT	TTTCCGAAG	GTAAGTGGCT
	AACAAACGGC	CTAGTTCTCG	ATGGTTGAGA	AAAAGGCTTC	CATTGACCGA
1351	TCAGCAGAGC	GCAGATACCA	AATACTGTCC	TTCTAGTGTA	GCCGTAGTTA

1401	AGTCGTCTCG	CGTCTATGGT	TTATGACAGG	AAGATCACAT	CGGCATCAAT
	GGCCACCACT	TCAAGAACTC	TGTAGCACCG	CCTACATACC	TCGCTCTGCT
	CCGGTGGTGA	AGTTCTTGAG	ACATCGTGGC	GGATGTATGG	AGCGAGACGA
1451	AATCCTGTTA	CCAGTGGCTG	CTGCCAGTGG	CGATAAGTCG	TGTCTTACCG
	TTAGGACAAT	GGTCACCGAC	GACGGTCACC	GCTATTACAGC	ACAGAATGGC
1501	GGTTGGACTC	AAGACGATAG	TTACCGGATA	AGGCGCAGCG	GTCGGGCTGA
	CCAACCTGAG	TTCTGCTATC	AATGGCCTAT	TCCGCGTCGC	CAGCCCGACT
1551	ACGGGGGGGT	CGTGCATACA	GCCAGCTTG	GAGCGAACGA	CCTACACCGA
	TGCCCCCAA	GCACGTATGT	CGGGTCGAAC	CTCGCTTGCT	GGATGTGGCT
1601	ACTGAGATAC	CTACAGCGTG	AGCTATGAGA	AAGCGCCACG	CTCCCGAAG
	TGACTCTATG	GATGTCGCAC	TCGATACTCT	TTCGCGGTGC	GAAGGGCTTC
1651	GGAGAAAGGC	GGACAGGTAT	CCGGTAAGCG	GCAGGGTCGG	AACAGGAGAG
	CCTCTTTCCG	CCTGTCCATA	GGCCATTTCG	CGTCCCAGCC	TTGTCTCTC
1701	CGCACGAGGG	AGCTTCCAGG	GGGAAACGCC	TGGTATCTTT	ATAGTCCTGT
	GCGTGCTCCC	TCGAAGGTCC	CCCTTTGCGG	ACCATAGAAA	TATCAGGACA
1751	CGGGTTTCGC	CACCTCTGAC	TTGAGCGTCG	ATTTTTGTGA	TGCTCGTCAG
	GCCCAAAGCG	GTGGAGACTG	AACCTCGCAG	TAAAAACACT	ACGAGCAGTC
1801	GGGGGCGGAG	CCTATGGAAA	AACGCCAGCA	ACGCGGCCTT	TTACGGTTT
	CCCCCGCCTC	GGATACCTTT	TTGCGGTCGT	TGCGCCGAA	AAATGCCAAG
1851	CTGGCCTTTT	GCTGGCCTTT	TGCTCACATG	TTCTTTCCTG	CGTTATCCCC
	GACCGGAAAA	CGACCGGAAA	ACGAGTGTAC	AAGAAAGGAC	GCAATAGGGG
1901	TGATTCCTGT	GATAACCGTA	TTACCGCCTT	TGAGTGAGCT	GATACCGCTC
	ACTAAGACAC	CTATTGGCAT	AATGGCGGAA	ACTCACTCGA	CTATGGCGAG
1951	GCCGCAGCCG	AACGACCGAG	CGCAGCGAGT	CAGTGAGCGA	GGAAGCGGAA
	CGGCGTCGCG	TTGCTGGCTC	GCGTCGCTCA	GTCACCTCGT	CCTTCGCCTT
2001	GAGCGCCCAA	TACGCAAACC	GCCTCTCCCC	GCGCGTTGGC	CGATTCAATTA
	CTCGCGGGTT	ATGCGTTTGG	CGGAGAGGGG	CGCGCAACCG	GCTAAGTAAT
2051	ATGCAGCTGG	CACGACAGGT	TTCCCGACTG	GAAAGCGGGC	AGTGAGCGCA
	TACGTCGACC	GTGCTGTCCA	AAGGGCTGAC	CTTTCGCCCC	TCACTCGCGT
2101	ACGCAATTAA	TGTGAGTTAG	CTCACTCATT	AGGCACCCCA	GGCTTTACAC
	TGCGTTAATT	ACACTCAATC	GAGTGAGTAA	TCCGTGGGGT	CCGAAATGTG
2151	TTTATGCTTC	CGGCTCGTAT	GTTGTGTGGA	ATTGTGAGCG	GATAACAATT
	AAATACGAAG	GCCGAGCATA	CAACACACCT	TAACACTCGC	CTATTGTTAA
2201	TCACACAGGA	AACAGCTATG	ACCATGATTA	CGCCAAGCTT	TGGAGCCTTT
	AGTGTGTCTT	TTGTGATAC	TGGTACTAAT	GCGGTTGCAA	ACCTCGGAAA
2251	TTTTTGGAGA	TTTTCAACGT	GAAAAAATTA	TTATTTCGAA	TTCTTTTAGT
	AAAAACCTCT	AAAAGTTGCA	CTTTTTTAAT	AATAAGCGTT	AAGGAAATCA
2301	TGTTCCCTTC	TATGCGGCC	AGCCGGCCAT	GGCCAGGTC	CAGTCGACAG
	ACAAGGAAAG	ATACGCCGGG	TCGGCCGGTA	CCGGGTCCAG	GTCAGCTGTC
2351	GTGGAGGCGG	TTCAGGCGGA	GGTGGCTCTG	GCGGTGGCGG	AAGTGCACTC
	CACCTCCGCC	AAGTCCGCCT	CCACCGAGAC	CGCCACCGCC	TTCACGTGAG
2401	ATCAAACGGC	GGCCGCAGGT	GCGCCGGTGC	CGTATCCGGA	TCCGCTGGAA
	TAGTTTGCCG	CCGGCGTCCA	CGCGGCCACG	GCATAGGCCT	AGGCGACCTT
2451	CCGCGTGCCG	CATAGGCTGG	CGGCGGCTCT	GGTGGTGGTT	CTGGTGGCGG
	GGCGCACGGC	GTATCCGACC	GCCGCCGAGA	CCACCACCAA	GACCACCGCC
2501	CTCTGAGGGT	GGCGGCTCTG	AGGGTGGCGG	TTCTGAGGGT	GGCGGCTCTG
	GAGACTCCCA	CCGCCGAGAC	TCCCACCGCC	AAGACTCCCA	CCGCCGAGAC
2551	AGGGTGGCGG	TTCCGGTGGC	GGCTCCGGTT	CCGGTGATTT	TGATTATGAA
	TCCCACCGCC	AAGGCCACCG	CCGAGGCCAA	GGCCACTAAA	ACTAATACTT
2601	AAAATGGCAA	ACGCTAATAA	GGGGGCTATG	ACCGAAAATG	CCGATGAAAA
	TTTTACCGTT	TGCGATTATT	CCCCCGATAC	TGGCTTTTAC	GGCTACTTTT
2651	CGCGCTACAG	TCTGACGCTA	AAGGCAAAC	TGATTCTGTC	GCTACTGATT
	GCGCGATGTC	AGACTGCGAT	TTCCGTTTGA	ACTAAGACAG	CGATGACTAA
2701	ACGGTGCTGC	TATCGATGGT	TTCATTGGTG	ACGTTTTCCG	CCTTGCTAAT
	TGCCACGACG	ATAGCTACCA	AAGTAACCAC	TGCAAAGGCC	GGAACGATTA
2751	GGTAATGGTG	CTACTGGTGA	TTTTGCTGGC	TCTAATTCCC	AAATGGCTCA
	CCATTACCAC	GATGACCACT	AAAACGACCG	AGATTAAGGG	TTTACCGAGT

2801 AGTCGGTGAC GGTGATAATT CACCTTTAAT GAATAATTTT CGTCAATATT
TCAGCCACTG CCACTATTAA GTGGAAATTA CTTATTAAAG GCAGTTATAA
2851 TACCTTCTTT GCCTCAGTCG GTTGAATGTC GCCCTTATGT CTTTGGCGCT
ATGGAAGAAA CGGAGTCAGC CAACTTACAG CGGGAATACA GAAACCGCGA
2901 GGTAACCAT ATGAATTTTC TATTGATTGT GACAAAATAA ACTTATTCCG
CCATTTGGTA TACTTAAAAG ATAATAACA CTGTTTTATT TGAATAAGGC
2951 TGGTGTCTTT GCGTTTCTTT TATATGTTGC CACCTTTATG TATGTATTTT
ACCACAGAAA CGCAAAGAAA ATATACAACG GTGGAAATAC ATACATAAAA
3001 CGACGTTTGC TAACATACTG CGTAATAAGG AGTCTTAATA AGAATTCAC
GCTGCAAACG ATTGTATGAC GCATTATTCC TCAGAATTAT TCTTAAGTGA
3051 GGCCGTCGTT TTACAACGTC GTGACTGGGA AAACCCCTGGC GTTACCCAAC
CCGGCAGCAA AATGTTGCAG CACTGACCCT TTTGGGACCG CAATGGGTTG
3101 TTAATCGCCT TGCAGCACAT CCCCCTTTTCG CCAGCTGGCG TAATAGCGAA
AATTAGCGGA ACGTCGTGTA GGGGAAAGC GGTCGACCGC ATTATCGCTT
3151 GAGGCCCGCA CCGATCGCCC TTCCCAACAG TTGCGCAGCC TGAATGGCGA
CTCCGGGCGT GGCTAGCGGG AAGGGTTGTC AACCGTCGG ACTTACCCT
3201 ATGGCGCCTG ATGCGGTATT TTCTCCTTAC GCATCTGTGC GGTATTTTCA
TACCGCGGAC TACGCCATAA AAGAGGAATG CGTAGACACG CCATAAAGTG
3251 ACCGCATACG TCAAAGCAAC CATAGTACGC GCCCTGTAGC GCGCGATTAA
TGGCGTATGC AGTTTCGTTG GTATCATGCG CGGGACATCG CCGCGTAATT
3301 GCGCGGCGGG TGTGGTGGTT ACGCGCAGCG TGACCGCTAC ACTTGCCAGC
GCGGCCGCCC ACACCACCA TGC GCGTCGCG ACTGGCGATG TGAACGGTCG
3351 GCCCTAGCCC CCGCTCCTTT CGCTTTCTTC CCTTCTTTTC TCGCCACGTT
CGGGATCGGG GCGGAGGAAA GCGAAAGAAG GGAAGGAAAG AGCGGTGCAA
3401 CGCCGGCTTT CCCCCTCAAG CTCTAAATCG GGGGCTCCCT TTAGGGTTCC
GCGGCCGAAA GGGGCAGTTC GAGATTTAGC CCCCAGGGGA AATCCCAGG
3451 GATTTAGTGC TTACGGCAC CTCGACCCCA AAAAATTGA TTTGGGTGAT
CTAAATCACG AAATGCCGTG GAGCTGGGGT TTTTGAAC AAACCCACTA
3501 GGTTACGTA GTGGGCCATC GCCCTGATAG ACGGTTTTTC GTCCTTTGAC
CCAAGTGCAT CACCCGGTAG CGGGACTATC TGCCAAAAG CAGGAACTG
3551 GTTCGAGTCC ACGTTCTTTA ATAGTGGACT CTTGTTCCAA ACTGGAACAA
CAAGCTCAGG TGCAAGAAAT TATCACCTGA GAACAAGGTT TGACCTTGT
3601 TACTCAACC TATCTCGGGC TATCTTTTGG ATTTATAAGG GATTTTGCCG
ATGAGTTGGG ATAGAGCCCG ATAAGAAAAC TAAATATTCC CTAAAACGGC
3651 ATTTCCGGCT ATTGGTTAAA AAATGAGCTG ATTTAACAAA AATTTAACGC
TAAAGCCGGA TAACCAATTT TTTACTCGAC TAAATGTTT TTAAATTGCG
3701 GAATTTTAAC AAAATATTAA CGTTTACAAT TTTATGGTGC AGTCTCAGTA
CTTAAATTTG TTTTATAATT GCAAATGTTA AAATACCACG TCAGAGTCAT
3751 CAATCTGCTC TGATGCCGCA TAGTTAAGCC AGCCCCGACA CCGCCAACA
GTAGACGAG ACTACGGCGT ATCAATTCGG TCGGGGCTGT GGGCGGTTGT
3801 CCCGCTGACG CGCCCTGACG GGCTTGCTG CTCCCGGCAT CCGCTTACAG
GGGCGACTGC GCGGGACTGC CCGAACAGAC GAGGGCCGTA GCGAATGTC
3851 ACAAGCTGTG ACCGTCTCCG GGAGCTGCAT GTGTCAGAGG TTTTCACCGT
TGTTGACAC TGGCAGAGGC CCTCGACGTA CACAGTCTCC AAAAGTGGCA
3901 CATCACCGAA ACGCGCGA
GTAGTGGCTT TGCGCGCT

Fig. 7b




Fig. 8a

Nucleotide Sequences pXP14

```
1   GACGAAAGGG CCTCGTGATA CGCCTATTTT TATAGGTAA TGTCATGATA
   CTGCTTCCG GGAGCACTAT GCGGATAAAA ATATCCAATT ACAGTACTAT
51  ATAATGGTTT CTTAGACGTC AGGTGGCACT TTTCGGGGAA ATGTGCGCGG
   TATTACCAAA GAATCTGCAG TCCACCGTGA AAAGCCCCTT TACACGCGCC
101 AACCCCTATT TGTTTATTTT TCTAAATACA TTCAAATATG TATCCGCTCA
   TTGGGGGATAA ACAAATAAAA AGATTTATGT AAGTTTATAC ATAGGCGAGT
151 TGAGACAATA ACCCTGATAA ATGCTTCAAT AATATTGAAA AAGGAAGAGT
   ACTCTGTTAT TGGGACTATT TACGAAGTTA TTATAACTTT TTCCTTCTCA
201 ATGAGTATTC AACATTCCG TGTCGCCCTT ATTCCTTTT TTGCGGCATT
   TACTCATAAG TTGTAAAGGC ACAGCGGGAA TAAGGGAAAA AACCGCGTAA
251 TTGCCCTCCT GTTTTTGCTC ACCCAGAAAC GCTGGTGAAA GTAAAAGATG
   AACGGAAGGA CAAAAACGAG TGGGTCTTTG CGACCACTTT CATTTTCTAC
301 CTGAAGATCA GTTGGGTGCT CGAGTGGGTT ACATCGAACT GGATCTCAAC
   GACTTCTAGT CAACCCACGA GCTCACCCAA TGTAGCTTGA CCTAGAGTTG
351 AGCGGTAAGA TCCTTGAGAG TTTTCGCCCC GAAGAACGTT TTCCAATGAT
   TCGCCATTCT AGGAACTCTC AAAAGCGGGG CTTCTTGCAA AAGGTTACTA
401 GAGCACTTTT AAAGTTCTGC TATGTGGCGC GGTATTATCC CGTATTGACG
   CTCGTGAAAA TTTCAAGACG ATACACCGCG CCATAATAGG GCATAACTGC
451 CCGGGCAAGA GCAACTCGGT CGCCGCATAC ACTATTCTCA GAATGACTTG
   GGCCCGTTCT CGTTGAGCCA GCGGCGTATG TGATAAGAGT CTTACTGAAC
501 GTTGAGTACT CACCACTCAC AGAAAAGCAT CTTACGGATG GCATGACAGT
   CAACTCATGA GTGGTCAGTG TCTTTTCGTA GAATGCCTAC CGTATGCTCA
551 AAGAGAATTA TGCAGTGCTG CCATAACCAT GAGTGATAAC ACTGCGGCCA
   TTCTCTTAAT ACGTCACGAC GGTATTGGTA CTCACTATTG TGACGCCGGT
601 ACTTACTTCT GACAACGATC GGAGGACCGA AGGAGCTAAC CGCTTTTTTG
   TGAATGAAGA CTGTTGCTAG CCTCCTGGCT TCCTCGATTG GCGAAAAAAC
651 CACAACATGG GGGATCATGT AACTCGCCTT GATCGTTGGG AACCGGAGCT
   GTGTTGTACC CCCTAGTACA TTGAGCGGAA CTAGCAACCC TTGGCCTCGA
701 GAATGAAGCC ATACCAAACG ACGAGCGTGA CACCACGATG CCTGTAGCAA
   CTTACTTCGG TATGGTTTGC TGCTCGCACT GTGGTGCTAC GGACATCGTT
751 TGGCAACAAC GTTGCGCAAA CTATTAAGTG GCGAACTACT TACTCTAGCT
   ACCGTTGTTG CAACGCGTTT GATAATTGAC CGCTTGATGA ATGAGATCGA
801 TCCCGGCAAC AATTAATAGA CTGGATGGAG GCGGATAAAG TTGCAGGACC
   AGGGCCGTTG TTAATTATCT GACCTACCTC CGCCTATTTT AACGTCCTGG
851 ACTTCTGCGC TCGGCCCTTC CGGCTGGCTG GTTTATTGCT GATAAATCTG
   TGAAGACGCG AGCCGGGAAG GCCGACCGAC CAAATAACGA CTATTTAGAC
901 GAGCCGGTGA GCGTGGGTCT CGCGGTATCA TTGCAGCACT GGGGCCAGAT
   CTCGGCCACT CGCACCCAGA GCGCCATAGT AACGTCGTGA CCCCAGTCTA
951 GGTAAGCCCT CCCGTATCGT AGTTATCTAC ACGACGGGGA GTCAGGCAAC
   CCATTCGGGA GGGCATAGCA TCAATAGATG TGCTGCCCTT CAGTCCGTTG
1001 TATGGATGAA CGAAATAGAC AGATCGCTGA GATAGGTGCC TCACTGATTA
   ATACCTACTT GCTTTATCTG TCTAGCGACT CTATCCACGG AGTGACTAAT
1051 AGCATTGGTA ACTGTCAGAC CAAGTTTACT CATATATACT TTAGATTGAT
   TCGTAACCAT TGACAGTCTG GTTCAAATGA GTATATATGA AATCTAACTA
1101 TTAAAACTTC ATTTTTAATT TAAAAGGATC TAGGTGAAGA TCCTTTTTGA
   AATTTTGAAG TAAAAATTAA ATTTTCCTAG ATCCACTTCT AGGAAAAACT
1151 TAATCTCATG ACCAAAATCC CTTAACGTGA GTTTTCGTTT CACTGAGCGT
   ATTAGAGTAC TGGTTTTAGG GAATTGCACT CAAAAGCAAG GTGACTCGCA
1201 CAGACCCCGT AGAAAAGATC AAAGGATCTT CTTGAGATCC TTTTTTCTG
   GTCTGGGGCA TCTTTTCTAG TTTCTAGAA GAACTCTAGG AAAAAAAGAC
```

1251 CGCGTAATCT GCTGCTTGCA AACAAAAAAA CCACCGCTAC CAGCGGTGGT
GCGCATTAGA CGACGAACGT TTGTTTTTTT GGTGGCGATG GTCGCCACCA
1301 TTGTTTGCCG GATCAAGAGC TACCAACTCT TTTTCCGAAG GTAACGGCT
AACAAACGGC CTAGTTCTCG ATGGTTGAGA AAAAGGCTTC CATTGACCGA
1351 TCAGCAGAGC GCAGATACCA AATACTGTCC TTCTAGTGTA GCCGTAGTTA
AGTCGTCTCG CGTCTATGGT TTATGACAGG AAGATCACAT CGGCATCAAT
1401 GGCCACCACT TCAAGAACTC TGTAGCACCG CCTACATACC TCGCTCTGCT
CCGGTGGTGA AGTTCTTGAG ACATCGTGGC GGATGTATGG AGCGAGACGA
1451 AATCCTGTTA CCAGTGCGTG CTGCCAGTGG CGATAAGTCG TGTCTTACCG
TTAGGACAAAT GGTCACCGAC GACGGTCACC GCTATTCAGC ACAGAATGGC
1501 GGTGCGACTC AAGACGATAG TTACCGGATA AGGCGCAGCG GTCGGGCTGA
CCAACCTGAG TTCTGCTATC AATGGCCTAT TCCGCGTCGC CAGCCCGACT
1551 ACGGGGGGTT CGTGCATACA GCCCAGCTTG GAGCGAACGA CCTACACCGA
TGCCCCCAAA GCACGTATGT CGGGTCAAC CTCGCTTGCT GGATGTGGCT
1601 ACTGAGATAC CTACAGCGTG AGCTATGAGA AAGCGCCACG CTTCCCGAAG
TGACTCTATG GATGTCGCAC TCGATACTCT TTCGCGGTGC GAAGGGCTTC
1651 GGAGAAAAGC GGACAGGTAT CCGGTAAGCG GCAGGGTCGG AACAGGAGAG
CCTCTTTCCG CCTGTCCATA GGCCATTGCG CGTCCCAGCC TTGTCTCTC
1701 CGCACGAGGG AGCTTCCAGG GGGAAACGCC TGGTATCTTT ATAGTCCTGT
CGGTGCTCCC TCGAAGGTCC CCTTTGCGG ACCATAGAAA TATCAGGACA
1751 CGGGTTTCGC CACCTCTGAC TTGAGCGTCG ATTTTTGTGA TGCTCGTCAG
GCCCAAAGCG GTGGAGACTG AACTCGCAGC TAAAAACACT ACGAGCAGTC
1801 GGGGGCGGAG CCTATGGAAA AACGCCAGCA ACGCGGCCTT TTTACGGTTC
CCCCGCCTC GGATACCTTT TTGCGGTGCGT TGCGCCGGAA AAATGCCAAG
1851 CTGGCCTTTT GCTGGCCTTT TGCTCACATG TTCTTTCTCT CGTTATCCCC
GACCGGAAAA CGACCGGAAA ACGAGTGTAC AAGAAAGGAC GCAATAGGGG
1901 TGATTCTGTG GATAACCGTA TTACCGCCTT TGAGTGAGCT GATACCGCTC
ACTAAGACAC CTATTGGCAT AATGGCGGAA ACTCACTCGA CTATGGCGAG
1951 GCCGCAGCCG AACGACCGAG CGCAGCGAGT CAGTGAGCGA GGAAGCGGAA
CGGCGTCGGC TTGCTGGCTC GCGTCGCTCA GTCACTCGCT CCTTCGCCTT
2001 GAGCGCCCAA TACGCAAACC GCCTCTCCCC GCGCGTTGGC CGATTCAATTA
CTCGCGGGTT ATGCGTTTGG CGGAGAGGGG CGCGCAACCG GCTAAGTAAT
2051 ATGCAGCTGG CACGACAGGT TTCCCGACTG GAAAGCGGGC AGTGAGCGCA
TACGTCGACC GTGCTGTCCA AAGGGCTGAC CTTTCGCCCC TCACTCGCGT
2101 ACGCAATTAA TGTGAGTTAG CTCACTCATT AGGCACCCCA GGCTTTACAC
TGCCTTAATT AACTCAATC GAGTGAGTAA TCCGTGGGGT CCGAAATGTG
2151 TTTATGCTTC CGGCTCGTAT GTTGTGTGGA ATTGTGAGCG GATAACAATT
AAATACGAAG GCCGAGCATA CAACACACCT TAACACTCGC CTATTGTAA
2201 TCACACAGGA AACAGCTATG ACCATGATTA CGCCAAGCTT GCATGCAAAAT
AGTGTGTCCT TTGTCGATAC TGGTACTAAT GCGGTTGAA CGTACGTTTA
2251 TCTATTTCAA GGAGACAGTC ATAATGAAAT ACCTATTGCC TACGGCAGCC
AGATAAAGTT CCTCTGTCAG TATTACTTTA TGGATAACGG ATGCCGTCGG
2301 GCTGGATTGT TATTACTCGC GGCCAGCCG GCCATGGCCC AGGTGCAGCT
CGACCTAACA ATAATGAGCG CCGGGTCGGC CGGTACCGGG TCCACGTGCA
2351 GCAGGTCGGC CTCGAGATCA AACGGGCGGC CGCAGGTGCG CCGGTGCCGT
CGTCCAGCCG GAGCTCTAGT TTGCCCGCCG GCGTCCACGC GGCCACGGCA
2401 ATCCGATCC GCTGGAACCG CGTGGGGCCG CAAGCGCTTG GAGCCACCCG
TAGGTCTAGG CGACCTTGGC GCACCCCGGC GTTCGCGAAC CTCGGTGGGC
2451 CAGTTCGAAA AATAATAAGG ATCCGAATTC ACTGGCCGTC GTTTTACAAC
GTCAAGCTTT TTATTATTCC TAGGCTTAAG TGACCGGCAG CAAAATGTTG

2501 GTCGTGACTG GGAAAACCTT GCGGTTACCC AACTTAATCG CCTTGCAGCA
CAGCACTGAC CCTTTTGGGA CCGCAATGGG TTGAATTAGC GGAACGTCGT
2551 CATCCCCCTT TCGCCAGCTG GCGTAATAGC GAAGAGGCCG GCACCGATCG
GTAGGGGGAA AGCGGTGCGA CGCATTATCG CTTCTCCGGG CGTGGCTAGC
2601 CCCTTCCCAA CAGTTGCGCA GCCTGAATGG CGAATGGCGC CTGATGCGGT
GGGAAGGGTT GTCAACGCGT CGGACTTACC GCTTACC GCG GACTACGCCA
2651 ATTTTCTCCT TACGCATCTG TCGGGTATTT CACACCGCAT ACGTCAAAGC
TAAAAGAGGA ATGCGTAGAC ACGCCATAAA GTGTGGCGTA TGCAGTTTCG
2701 AACCATAGTA CGCGCCCTGT AGCGGCGCAT TAAGCCCGGC GGGTGTGGTG
TTGGTATCAT GCGCGGGACA TCGCCGCGTA ATTGCGGGCCG CCCACACCAC
2751 GTTACGCGCA GCGTGACCGC TACACTTGCC AGCGCCCTAG CCCCCGCTCC
CAATGCGCGT CGCACTGGCG ATGTGAACGG TCGCGGGATC GGGGGCGAGG
2801 TTTTCGCTTT TCCCTTCCT TTCTCGCCAC GTTCGCGGC TTTCCCGTC
AAAAGCGAAA AAGGGAAGGA AAGAGCGGTG CAAGCGGCCG AAAGGGGCAG
2851 AAGCTCTAAA TCGGGGGCTC CCTTTAGGGT TCCGATTTAG TGCTTTACGG
TTCGAGATTT AGCCCCGAG GGAAATCCCA AGGCTAAATC ACGAAATGCC
2901 CACCTCGACC CAAAAAACT TGATTTGGGT GATGGTTCAC GTAGTGGGCC
GTGGAGCTGG GGTTTTTTGA ACTAAACCCA CTACCAAGTG CATCACCCGG
2951 ATCGCCCTGA TAGACGGTTT TTCGTCCTTT GACGTTTCGAG TCCACGTTCT
TAGCGGGACT ATCTGCCAAA AAGCAGGAAA CTGCAAGCTC AGGTGCAAGA
3001 TTAATAGTGG ACTCTGTTC CAAACTGGAA CAATACTCAA CCCTATCTCG
AATTATCACC TGAGAACAAG GTTTGACCTT GTTATGAGTT GGGATAGAGC
3051 GGCTATTCTT TTGATTTATA AGGGATTTTG CCGATTTTCGG CCTATTGGTT
CCGATAAGAA AACTAAATAT TCCCTAAAAC GGCTAAAGCC GGATAACCAA
3101 AAAAAATGAG CTGATTTAAC AAAAATTTAA CGCGAATTTT AACAAAATAT
TTTTTTACTC GACTAAATTG TTTTAAATT GCGCTTAAAA TTGTTTTATA
3151 TAACGTTTAC AATTTTATGG TGCAGTCTCA GTACAATCTG CTCTGATGCC
ATTGCAAATG TTAAAATACC ACGTCAGAGT CATGTTAGAC GAGACTACGG
3201 GCATAGTTAA GCCAGCCCCG ACACCCGCCA ACACCCGCTG ACGCGCCCTG
CGTATCAATT CGGTCGGGGC TGTGGGCGGT TGTGGGCGAC TCGCGGGGAC
3251 ACGGGCTTGT CTGCTCCCGG CATCCGCTTA CAGACAAGCT GTGACCGTCT
TGCCCGAACA GACGAGGGCC GTAGGCGAAT GTCTGTTTCA CACTGGCAGA
3301 CCGGGAGCTG CATGTGTCAG AGGTTTTTAC CGTCATCACC GAAACGCGCG
GGCCCTCGAC GTACACAGTC TCCAAAAGTG GCAGTAGTGG CTTTGCGCGC
3351 A
T

Fig. 8b

cDNA primers

VLK-c	CTGGATGGTGGGAAGATGGA
VLL-c	TCAGAGGAAGGAAACAGGGT
IgG1-c	CTTACAACCACAATCCCTGGGCACAATTTT
IgG2a-c	CTTTGTGGGCCCTCTGGGCTCAAT
IgG2b	TGAAATGGGCCCCTGGGCTCAAG
IgG3-c	GGGCTTGGGTATTCTAGGCTCGAT

VH forward primers without restriction sites

M-VH1	GAGGTGCAGCTTCAGGAGTCAGG
M-VH2	CAGGTGCAGCTGAAGGAGTCAGG
M-VH3	GAGGTCCAGCTGCAACAGTCTGG
M-VH4	GAGGTTTCAGCTGCAGCAGTCTGG
M-VH5	CAGGTCCAACCTGCAGCAGCCTGG
M-VH6	CAGGTTTCAGCTGCAGCAGTCTGG
M-VH7	GAGGTGAAGCTGGTGGAGTCTGG
M-VH8	GAGGTGAAGCTGGTGAATCTGG
M-VH9	GAGGTTTCAGCTTCAGCAGTCTGG

VH backward primers without restriction sites

M-JH1	TGAGGAGACGGTGACCGTGGTCCC
M-JH2	TGAGGAGACTGTGAGAGTGGTGCC
M-JH3	TGCAGAGACAGTGACCAGAGTCCC
M-JH4	TGAGGAGACGGTGACTGAGGTTCC

VL forward primer without restriction sites

M-VK1	GACATTGTGATGACACAGTCTCC
M-VK2	GATGTTGTGATGACCCAACTCC
M-VK3	GATATCCAGATGACACAGACTCC
M-VK4	CAAATTGTTCTCACCCAGTCTCC
M-VL1	CAGGCTGTTGTGACTCAGGAATC

VL backward primers without restriction sites

M-JK1	TTTGATTTCCAGCTTGGTGCCTCC
M-JK2	TTTTATTTCCAGCTTGGTCCCCC
M-JK3	TTTCAGCTCCAGCTTGGTCCCAGC
M-JL1	ACCTAGGACAGTGACCTTGGTTCC

Fig 9

VH forward primers with restriction sites

MVH1 Sfil	GTCCTCGCAACTGCGGCCAGCCGGCCATGGCCGAGGTGCAGCTTCAGGAGTCAGG
MVH2 Sfil	GTCCTCGCAACTGCGGCCAGCCGGCCATGGCCGAGGTGCAGCTGAAGGAGTCAGG
MVH3 Sfil	GTCCTCGCAACTGCGGCCAGCCGGCCATGGCCGAGGTCCAGCTGCAACAGTCTGG
MVH4 Sfil	GTCCTCGCAACTGCGGCCAGCCGGCCATGGCCGAGGTTCAGCTGCAGCAGTCTGG
MVH5 Sfil	GTCCTCGCAACTGCGGCCAGCCGGCCATGGCCGAGGTCCAAGTGCAGCAGCCTGG
MVH6 Sfil	GTCCTCGCAACTGCGGCCAGCCGGCCATGGCCGAGGTTCAGCTGCAGCAGTCTGG
MVH7 Sfil	GTCCTCGCAACTGCGGCCAGCCGGCCATGGCCGAGGTGAAGCTGGTGGAGTCTGG
MVH8 Sfil	GTCCTCGCAACTGCGGCCAGCCGGCCATGGCCGAGGTGAAGCTGGTGGAACTCTGG
MVH9 Sfil	GTCCTCGCAACTGCGGCCAGCCGGCCATGGCCGAGGTTCAGCTTCAGCAGTCTGG

VH backward primers with restriction sites

MJH1 Sall	GAGTCATTCTCGTGTGACACGGTGACCGTGGTCCC
MJH2 Sall	GAGTCATTCTCGTGTGACACTGTGAGAGTGGTGCC
MJH3 Sall	GAGTCATTCTCGTGTGACACAGTGACCAGAGTCCC
MJH4 Sall	GAGTCATTCTCGTGTGACACGGTGACTGAGGTTCC

VL forward primers with restriction sites

MVK1 ApaL1	TGAGCACACAGTGCACTCGACATTGTGATGACACAGTCTCC
MVK2 ApaL1	TGAGCACACAGTGCACTCGATGTTGTGATGACCCAACTCC
MVK3 ApaL1	TGAGCACACAGTGCACTCGATATCCAGATGACACAGACTCC
MVK4 ApaL1	TGAGCACACAGTGCACTCCAAATTGTTCTCACCAGTCTCC
MVL1 ApaL1	TGAGCACACAGTGCACTCCAGGCTGTTGTGACTCAGGAATC

VL backward primers with restriction sites

M-JK1 Not1	GAGTCATTCTCGACTTGCGGCCGCTTTGATTTCCAGCTTGGTGCCTCC
M-JK2 Not1	GAGTCATTCTCGACTTGCGGCCGCTTTTATTTCCAGCTTGGTCCCCCC
M-JK3 Not1	GAGTCATTCTCGACTTGCGGCCGCTTTCCAGCTCCAGCTTGGTCCCAGC
M-JL1 Not1	GAGTCATTCTCGACTTGCGGCCGCACCTAGGACAGTGACCTTGGTTCC

Fig. 9

Polypeptide or NPB	SEQ ID No.	Protein Sequence	SEQ ID No. of the CDR 3 as underlined
scFv1	1	1 EVQLQSGSE LVPKALVKI SCKASGYTIV SYDINWVKQR PGQGLEWIGW 51 IYPGDGSKY NEKFKGKATL TVDKSSTTV MQLSSLTSEN SAVYFCARGG 101 KYFDYWGQGT TLTVSTGGG SGGGGSGGG SALDIVMTQS PKFMSTSVGD 151 RSVVTCKASQ NVATNVAWYQ QKPGQSPKPL TYSASFRSSG VPDRFTGSGS 201 GTDFTLTISN VQSEDLAEYF CQQYNSYPYT EGGGTKLEIK AAAGAPVPYP 251 DPLEPRGAAS AWSHPQFEK*	73
scFv2	2	1 EVQLLESGG LVOPGGSLRL SCAASGFTFS SYAMSWVRQA PGKGLEWVSA 51 ISGGGGSTYY ADSVKGRFTI SRDNSKNTLY LQMSLRAED TAVYYCARD 101 GLQQGPRRRG ARVNFYYGL DWGGRGTTVT VSSGGGGSGG GSGGGGSAQ 151 AVLTQPSSAS GTPGQRTVIS CSGSNSNIGR NYVFWYQQFP GTAPKILYR 201 NNQRPSPGPD RFGSKSGTS ASLAISGLRS EDEADYYCAS WDDSLTWVEG 251 GGTKVTVLGA AAGAPVPYPD PLEPRGAASA WSHPPQFEK*	74
scFv3	5	1 ASVKVSKTIS GYTFIAYYIH WVRQAPGQGL EWMGRINPNT GGINLAQKFQ 51 GRVTIVTRDTS ISTAHMELSR LSSDDTAVYY CARERIVPAG LRNRGMVTAV 101 GMDVWGRGTL VTVSSGGGGS GGGGGGGGGS AQSIVTQPPS MSGTPGQRTV 151 ISCSGSRNI GRNYVYWYQQ FPGTAPKLLI YRNNRPSGV PDRFSASKSG 201 TSASLAISGL RSEDEADYYC ATWDDSLSGT WVFGGGTKLT VLGA	75
scFv4	6	1 LLESGGGLVQ PGSLRLSCA ASGFTESSYA MSWVRQAPGK GLEWVSAISG 51 SGGSTYYADS VKGRFTISR DSKNTLYLQM NSLRAEDTAV YYCARGGGRY 101 DSSHGFDSWG RGTMTVTSSG GGGGGGGGGS GGSALSLEYL TQPPSVSVAP 151 GETATITCGG RSLGSKVHVH YQKPGQAPT LVIIYDSVRP SGVPERFESAS 201 NSRLSATLTV SRVEAGDEAD YYCQVWDRSS DHYVFGTGTK LTVLGA	76
scFv5	7	1 QLLESGGGLV QPGSLRLSC AASGFTESSY AMSWVRQAPG KGLEWVSAIS 51 GSGGSTYYAD SVKGRFTISR DSKNTLYLQ MNSLRAEDTA VYCARDWRW 101 QQFGGWEDPW GRGTLVTSS GGGGGGGGGS GGGSALETT LTQSPATLSL 151 SPGETATLFC RASQSVRNLL VVYQQKLGQA PRLLIFGAST RASGIPDRFT 201 GSGSGTDFSL TITKLEPEDE AVYQCQRYGG FPITFGQGR LEIKRAA	77
scFv6	8	1 QLVSQGGGLV QPGSLRLAC EASGERFESSY GMSWVRQAPG KGLEWVSSMS 51 DSGANTYYAD SVKGRFTISR DNAKKMLYLQ MSSLRGEDTA VYCATLFRG 101 SGYVRHWGRG TLTVTSSGGG GSGGGGGGGS GSAQAVLTQP SSASGTPGQR	78

Fig. 10

			151 201	VIISCSGSSS NIASNYVYVY QQLPGTAPKL LISKNRRPS GVPDRFSGSK SGTSASLAIS ELRSEDEADY YCAAWDDRLS GPAFGGGTKL TVLGAAA	
scFv7	9		1 51 101 151 201	KKPGSSVKVS CKASGGTFSS YAIWVRQAP GQGLEWMGGI IPMSGTPNYA QKFQDRVIT ADKSTSTAYM ELSSLRSED AVYICARGGR YVDFGRGPSY HYYYMDVWGR GTLTVSSGG GSGGGGGSGG GSAQSVLTQ PPSASGTPGQ RVTISCSGAT SNIGRNYVYV YHQLPGTAPK LLIYRNDQRP SGVPDRFSGS KSGTSASLAI SGLRSDDEAD YYCAAWDDNL SGLFFGGGTK LTVLGAAA	79
scFv8	10		1 51 101 151 201	AQVQLQWGP GLVKASELLS LNCTVSGSSL SSGGYWWSWI RQHPGKGLEW IGYIHYSGST YYNPSLKS RV TISVDTSKNQ FSLKLSVTA ADTAVYYCAR VPLREDGFDV WGGTGLTVTS SGGGGGGGG SGGGSDIQM TQSPSTLSAS IGDRVITICR ASEGIVHWLA WYQKPGKAP KLLIYKASSL ASGAPSRFSG SGSGTDFTLT ISSLQPDDEA TYCQQYSNY PLTEGGGTKL EIKRAAA	80
scFv9	11		1 51 101 151 201	ELKKPGSSVK VSCAPRGTF NSYALNVRQ APQGLEWMG GIPIFGSAN YAPKFGQRTV ITADESTTA YLESLRSE DTAVYYCARA LHLDYVWRTY NYIEDNWGKG TMVTVSSGG GSGGGGGGG GSALSSLTQ DPAVSVALGQ TVRITCQDGS LRSYASWYQ QKPGQAPLV IYKNSRPSG IPDRFSGSDS GNTASLTITG AQAEDEADY CNSRDRSGNR VVEGGGTKL TVLGAAA	81
scFv10	12		1 51 101 151 201	SLRSCAASG FTFSSYAMSW VRQAPGKLE WVS AISGSGG STYYADSVKG RFTISDRNSK NTLYLQMSL RAEDTAVYC ARGVTYHYDH DRRGVTAQIY NHGLDVWGRG TTVTVSSGG GSGGGGGGG GSAQAVLTQ SSASGTPGQR VTISCSGSSS NIGKNYVYVY QQLPGTAPKL LIYRNNRPS GVPDRFSGSK SGTSASLAIS GLRSEDEADY YCAARDNGLS AYVIFGGGTK LTVLGAAA	82
scFv11	13		1 51 101 151 201	VKKPGESLKI SCKSGSYFPP NYWIAWVRQ PGKGLEWMGI IYPGDSDTIY SPSFRGQVTI SADKSI STAY LQWSSLKASD TAMYICARQ CSGGKCYEKM YASDIWGRGT LVTVSSGGG SGGGGGGGG SALSVELTQ PSASGTPGQR VTISCSGSTS NIGRNSVFWH QQLPGTAPKV LISSDNQPS GVSDRFSGSD SGTSASLVIS RLRFEDEGY YCAAWDDSLS AYVEGSGTKL TVLGAAA	83
scFv12	14		1 51 101 151 201	AEVKKPGSSV RVSCKASGDT FSYNAINWVR QAPQGLEWM GGIIPMEGTA KQAQKFGQRV TFTADESTST AYMELTRLS EDTAMYICAR RGSYSNYERG YYYHMDVWQ GTLTVSSGG GSGGGGGGG GGSALPVLQ PPSASGAPGQ RITISCSGST ENIGRNYVDW YKQLPGTAPK LFIYKNDQRP SGVPDRFSGS KSGTSASLVV SGLRSEDEAD YYCLTWDDSL SGPFEGGGTK LTVLGAAA	84
scFv13	15		1 51 101 151 201	LQESGPGLVK PSGLTSLTCA VSGGSINNN WWSWVRQPPG KGLEWIGEYI QSGSTNYNPS LKSRVTISVD KSNQFSLKM SSVTAADTAV YYCARLNNH GPYYGMDVWG RGTTLTVSSG GSGGGGGGG GGSQAQSVLT QPPSASGTPG QRTISCSGS SNNIGSNEVY WYQQLPGTAP KLLIYRNNQR PSVPDRFSA SKSGTSASLA ISGLRSEDEA DYYCAAWDDR RVVEGGGTKL TVLGAAA	85

Fig. 10

scFv14	16	1 51 101 151 201	VQLQESGPG SIYDGGYTY GSLSAFWGQ DRVTITCRT SGTDFLTIS	VKPSETLSL SPSLKSRATI TLVTVSSGG QRISSYLNW SLOPEDEFAT	CTVSGGPV SFDTSKNQV GSGGGSGG QKPGKAPKL YCOQSYSTPI	SSYWGFI LNLTSVTAAD GSAIDQLTQ LIYAASSLQ TFGQTRLEI	PPGKLEWIG TAVYCAKDP SPSSLSASVG GVPSRFSGG KRAAA	86
scFv15	17	1 51 101 151 201	LLESGGLVQ SGGSTYYAD QEGGWEDPW PGERVTLSR SGSGTEFTL	PGSLRLSCA VKGRFTISR RGTLVTVSS ASQSVGSKLA ISSLQSEDEF	ASGTFESSY NSKNTLYLQ GGSGGGGGG WYQKPGQAP VYCCQYNNW	MSWVRQAPG NSLRAEDTAV GGGALDVM RLLIFFTSTR PPYTFGQGT	GLEWVSAISG YYCARDWRWQ TQSPATLSVS ASGIPAREFS VEIKRAAA	87
scFv16	18	1 51 101 151 201	AEVKKPGDS NYAQKFQGR HYFSDYWGR VTISCSGSS SGTSASLAIS	VKSCASGYR TMTDTSTST TTVTVSSGG NIGSNYVYV GLRSEDEADY	FETYGFESW DDTAVYFCR GSAQSVLTQ LIHKNRRPS HCAWDDSL	QAPGQGLEW AEDSRGYWN PSASGTPGQ GVPDFSGSK AVVFGGKT	GWINTYNGK GVPDFSGSK TVLGAAA	88
scFv17	19	1 51 101 151 201	LESGLLVQ GGSTYYADSV EGGWEDPWGR GDRATLSRA SGSGTDFTL	GGSLRLSCA KGRFTISRDN GTMTVSSGG SHSVSHNHLA ISRLEPEDEF	SGTFESSYAM SKNTLYLQMN GGSGGGGGG WYQNPQAP SYCCQYQY	SWVRQAPGKE SLRAEDTAVY GSALETTLT RLLIFFGASSR RTTFGQGT	LEWVSAISGS YCARDWRWQ QSPGTLSP AAGIPDRFS EIKRAAA	89
scFv18	20	1 51 101 151 201	KKPGSSVRV KQFQGRVTIT SYIMEVWGK VTISCSGSS SGPSASLAIS	CKAPGGTFGN ADKSTTTAHM TLVTVSSGG NIGSNYVYV GLRSEDEADY	SAISWVRQTP ELSLRSEDT GSGGGGGGG QOLPGAAPKL YCAWDDSL	GQGLEWMGGI AVYICARGGL GSAQSVLTQ LIYRNNQRP GPAFGGKT	IPMFTTANYA GREFDGPSE PAASGTPGQ GVPDFSGSK TVLGAAA	90
scFv19	21	1 51 101 151 201	VQLVQSGAEV IPLINIPNYA WNAFDQWGR TVRITCQGD GNIASLTITG	KKPGSSVKVS KQFQGRVTIT TLVTVSSGG LTSYAAWYQ QAEDEGDFY	CKASGGTFSS ADKSTTTAYM GSGGGGGGG QKPGQAPLLV CSSRDSGGY	DAISWVRQAP ELTSLRFEDA GSAQSVLTQ FYGKDKRPS FVEGAGTKL	GQGLEWMGRI AVYICARVNN DPAVSVALGQ IPERFSGSS VLGAAA	91
scFv20	22	1 51 101 151 201	KKPGSSVKVS KQFQGRVTIT YMDVWQGT TISCSGSSN GTSASLAISG	CKASGGTFSS ADDSMTTVYM MVTVSSGGG IGVNYVYWR LRSEDEADY	YAIWVRQAP ELSLTSEDT GSGGGGGGG QFPGAAPHV CSTWDDTLG	QQGLEWMGGE GVYICARDLM SAQSVLTQPP IYNNDQRP YIFGVGKT	IPVFGTANYA RLARRDEYYY AASGTGQKI VPDFSGSKS VLGAAA	92
scFv21	23	1 51	QPGSLRLSC SVKGRFTISR	AASGTFESSY DNSKNTLYLQ	AMSWVRQAPG MNSLRAEDTA	KGLEWVSAIS VYICARDWRW	GSGGSTYYAD QQFGGWEDPW	

Fig. 10

			101 151 201	GQGLTVTVSS GDNLRFSAS ITGALAEDEA	GGGGGGGGG WYQLKPGQAP DYCNSTRDSS	GGGGSALSSE VLVIYGNR GNPVVEGTGT	LTQDPAVSVA PSGIPDRFSA KVTVLGAAA	LGQTVRITCQ SSSGNTASLA	93
scFv22	24		1 51 101 151 201	SSVKVSKIS LKITSSTSTR VTVSSGGGS GRNYVYVYQ RSEDEADYYC	GGNLRLLTVT TAYLELRSLK GGGGGGGGG VPGTAPQLLV STWDDSLSSP	WVROAPGQGL SEDFAVYCA AQSVVTQPPS YNNQRPSGV VFGGTKLTV	EWVGRILPDS ASSKIGFQVG ASATPGQRVT PDRFSGSKSG LGAAA	VNQVVKFQRR ELDYWGRGTL ISCSGSSNI TSASLGISGL	94
scFv23	25		1 51 101 151 201	TFSSYAMSW TYLQMNLSR TLVTVSSGG SNIGSNYVY SGLRSEDEAD	YQAPGKGLEW AEDFAVYCA GGGGGGGGG YQQLPGTAPK YYCAAWDDTL	VSAISGGSGS RGRRRERSIN GSALSIVLTQ LLIYRNNQRP SGVLFEGGTK	TYYADSVKGR MIRGVRPQYD PPSASGTPGH SGVPDRFSGS LTVLGA	FTISRDNKSN DSGMDVWGRG RVTISCSGSS KSGTSASLAI	95
scFv24	26		1 51 101 151 201	YAMSWVRQAP QMNLSRAEDT VTVSSGGGS GRNYVDWYQ RSEDEADYYC	GKLEWVSAI AVYICARNTG GGGGGGGGG LPGTAPKLLI AAWDDSLSGW	SGSGGSTYYA KGITLVRGVY AQAVLTQPS YRNNKRPSGV VFGGTKLTV	DSVKGRETIS CQDCDRSSTS ASGTPGQRVT PDRFSGSKSG LGAAA	RDNSKNTLYL RMDVWQGTTL ISCSGTSNI TSASLISGL	96
scFv25	27		1 51 101 151 201	GLVQPGGSPR YADSVKGRFT GLFDYWGRGT TISCSGSTFN GTSASLVVSG	LSCAASGTFE ISRDNSKNTL MVTVSSGGG IGRNYVDWYK LRSEDEADYY	SSYAMSWVRQ YLQMNLSRAE SGGGGGGGG QLPGTAPKLE CLTWDDSLSG	APGRGLEWVS DTAVYVCAKD SAQSVVTQPP IYKNDQRPSG PVFGGTKVT	AISGGSGSTY MGYSYGYGTR SASGAPGQRI VPDRFSGSKS VLGAAA	97
scFv26	28		1 51 101 151 201	ESGGGLVQPG GSTYADSVK GGWFDPMWGRG DRATLSRAS SGTEFTLTIS	GSRLSCAAS GRFTISRDN TIVTVSSGGG QSIGGNLAWY SLQSEDFAVY	GFTFSSYAMS KNTLYLQMN SGGGGGGGG QKPGQPPRL YCOQYNNWPP	WVROAPRKGL LRAEDTAVY GSALETTLTQ LIFGASTRAS WTFGQGTRE	EWVSAISGGG CARDWRWQOE SPATLSVSPG GTPAREFSGG IKRAAA	98
scFv27	29		1 51 101 151 201	QPGGSLRLSC SVKGRFTISR MDVWGRGTTV SCSGSTFNIG SASLVVSGLR	AASGTFSSY DNSKNTLYLQ TVSSGGGGG RNYVDWYKQL SEDEADYYCL	AMSWVRQAPG MNSLRAEDTA GGGGGGGSA PGTAPKLEFY TWDDSLSGPV	KGLEWVSAIS VYICAKGDGV QSVLTQPPSA KNDORPSGV FEGGTKLTVL	SGSGSTYYAD VAGITYYYYG SGAPGQRITI DRFSGSKSGT GAAA	99
scFv28	30		1 51 101 151	ASGFGNGYE MSANTVYMEM TVSSGGGGSG YSASWYRQKE	MHWVRQAPGQ SRLRFEDTAV GGGGGGGSA GQAPVIVMYG	RLEWLGRINA YYCVRFHDWR LSELTDQDPA NTRRPSGIPD	AIGDTRYSRE HCNSATCOPP VSVALGQTVR RISGSSSGNT	FQDRVSI TRD FDHWGKGTLV ITCQGDLSRY ASLTISGAQA	100

Fig. 10

scFv29	31	201	EDEADYYCNS RDSSGNHLVF GGTGKLTVLG AAA	101
		1	VQPGSLRLS CAASGFTFSS YAMSWVRQAP GKGLEWVSAI SGSGGSTYYA	
		51	DSVKGRFTIS RDNSKNTLYL QMNSLRAEDT AVYYCARDHR SGRGGSYLL	
		101	RPLDYWGQGT MVTVSSGGG SGGGGSGGG SALPVLTPPP SASGTPGQRV	
		151	TISCSGSSSN IGRNYYVWYQ QLPGTAPKLL IYRNNLRPSG VPDREFSGSKS	
scFv30	32	201	GTSASLAISG LRSEDEADYY CAAWDDTLTG VVEGGTKLT VLGAAA	102
		1	EVRKPGASVK ISCKASGFTF TSYLFHWVRQ APQORLEWMG WINAGNGNTK	
		51	YSPKFQGRVT LTGDTSTSTT YMELSSLTSE DPAVYYCARD QVFESGSYY	
		101	IRPSDFWGR GTLVTVSSGG GSGGGSGGG GGSIDIQMTQS PSTLSASIGD	
		151	RVTITCRASE GIYHMLAWYQ QKPGKAPKLL IYKASSLASG APSRFSGSGS	
scFv31	33	201	GTDFTLTISS LQPDDEFATYY CQOYSNYPLT FGGGKLEIK RAAA	103
		1	VRPGSLRLS CAASGETFDD YGMSWVRQAP GKGLEWVSGI NWSGGSTGYA	
		51	DSVKGRFTIS RDNAKNSLYL QINSLRAEDT AVYYCARRRY ALDWGRGTM	
		101	VTVSSGGGGS GGGGGSGGGS ALSSELTQDP ATVSVALGQT VRTICQGDLS	
		151	DKYYATWYQQ KPGQAPLLVF FSENRPPSGI PDRFSGNSG NTASLTITGA	
scFv32	34	201	QAEDEADYYC NSREIGTNRI LFGGKLTIV LGAAA	104
		1	LVQPGSLRLS SCAAAGFTFS TFEWNWVRQA PGKLEWVSY ISGSGHAIYY	
		51	ADSVKGRFTI SRDNANNSLY LQMNSLTAED TAVYYCAREK YQLLLGKYDY	
		101	GMDVWGRGTT VTVSSGGGGS GGGGGSGGGS ALPVLTPPP ASCTPGQRTV	
		151	ISCSGSSSNI GSNTLNWYQQ LPTAPKLLI YSNDQRPSPG PDRFSGSKSG	
scFv33	35	201	TSASLAISGL QSEDEADYYC AAWDDSLNGW VFGGKTKTV LGAAA	105
		1	RASGGTSSSS AFSWVRQAPG QGLQWMGGII PLFGAANYAQ KVRAGLTITA	
		51	DESGTSSYMK LENLQSDDTA VYFCATNGQT RSPPGYYIGM DVWGRGTLVT	
		101	VSSGGGGSGG GSGGGGSAQ SVLTQLPSAS GAPGQRITIS CSGSTENIGR	
		151	NYVDWYKQLP GTAPKLFYK NDQRPSPGPG RPSGSKSGTS ASLVVSGLRS	
scFv34	36	201	EDEADYYCLT WDDSLSGPVE GGTGKLTVLG AAA	106
		1	ACKGFGYTFV DHGISWVRQA PQGLEWMGW INTHDGHTNY AQKTQARLTM	
		51	TTDASINTSY MELRSLTSDD TAVYYCARGG ETRTAHRSRR ATNDNGYFYI	
		101	SSGLDVWGQG TLVTVSSGGG GSGGGSGGGG GSAQAVLTQP SSASGTPGQR	
		151	VTISCSGSSS NIGSNYYVWY QQLPGTAPKL LIYRNNQRPS GVPDRFSGSK	
scFv35	37	201	SGTSASLAIS GLRSEDEADY YCAAWDDSLG GWVFGGKTKL TVLGAAA	107
		1	PGASVKVSCK ASGYTFTSY MHWVRQAPGQ GLEWMGIINP SGGSTSYAQK	
		51	FQGRVTMTRD TSTSTVYMEI SSLRSEDYAV YYCARGSGAR MVRGVIIIDPY	
		101	GMDVWGRGTL VTVSSGGGGS GGGGGSGGGS AQSVLTQPPS ASCTPGQRTV	
		151	ISCSGSSSNV GSNIYVSWYQQ FPGTAPKLLI YRNNQRPSG PDRFSGSKSG	
		201	ISASLAISGL RSEDEADFYC VAWDDSLREY VFGTGKTKTV LGAAA	

Fig. 10

scFv36	38	1 51 101 151 201	ESGGGLVQPG GSLRLSCAAS GFTESSYAMS WVRQAPGKGL EMVSAISGSG GSTYYADSVK GRETISRDN KNTLYLQMNS LRAEDTAVYY CAKGGTRVTH RGGFDIWGRG TMVTVSSGG GSGGGSGGG GSALPVLTOP PSASGAPGQR ITISCSGSTF NIGRNYVDWY KQLPGTAPKL FIYKNDQRPS GVPDRFSGSK SGTSASLVVS GLRSEDEADY YCLTWDDSLG GPVFGGGTKL TVLGAAA	108
--------	----	------------------------------	--	-----

Fig. 10

Ref.:	SEQ ID No.	Nucleotide Sequence
scFv1	3	<p>1 GAGGTCCAGTGCACACAGTCTGGACCTGAGCTGGTGAAGCCTGGGGTTTAGTGAAGATATCCTGTCAAGG 71 CCTCGGATACACCGTCAAGCTACGATATAAATAGGTGGTGAAGCAGGCGCTGGACAGGACTTGAGTG 141 GATTGGATGGATTATCCTGGAGATGGTAGTAACTAAGTACAATGAGAAATCAAGGGCAGGCCACACTG 211 ACTGTAGACAAATCCTCCACACAGTCTACATGAGCTCAGCAGCCCTGACTTCTGAGAACTCTGCAGTCT 281 ATTCTGTGCAAGAGGTGGTAAATACTTTGACTACTGTGGGCCAAGGACCACCTCTCACAGTGTGACAGG 351 TGGAGGCGTTCAGGCGGAGGTGGCTCTGGCGGTGGCGGAAGTGCACTCGACATTTGTGATGACACAGTCT 421 CCAAAATTCATGTCCACATCAGTAGGAGACAGGGTCAGGTCACCTGCAAGGCCAGTCAGAATGTGGCTA 491 CTAAATGAGCCTGGTATCAACAGAAACAGGGCAATCTCTAAACCACTGACTTACTCGGCATCCTTCCG 561 GTCCAGTGGAGTCCCTGATCGCTTCACAGGCACTGGATCTGGGACAGATTCACCTCTACCATCAGCAAT 631 GTGCAGTCTGAAGACTTGGCAGAGTATTTCTGTACGAATATAACAGTATCCGTACACGTTCCGAGGGG 701 GGACCAAGCTGGAATAAAAGCGCGCAGGTGCGCGGTGCCGTATCCAGATCCGCTGGAACCGCGTGG 771 GGCCGCAAGCGCTTGAGGCCACCCGAGTTCGAAAAATAA</p>
scFv2	4	<p>1 GAGGTGCAGCTGTGGAGTCTGGGGGAGGCTTGTACAGCCTGGGGTCCCTGAGACTCTCCTGTGCAG 71 CCTCTGGATTACACCTTTAGCAGCTATGCCATGAGTGGGTCCGCCAGGTCCAGGAAAGGGCTGGAGTG 141 GGTCTCAGCTATTAGTGGTAGTGGTAGCATACTACGAGACTCCGTGAAAGGCCGTTTACCATC 211 TCCAGAGACAAATCCAAGAACACGCTGTATCTGCAATGAACAGCTGAGAGCCGAGGACACGGCCGTGT 281 ATTACTGTGCGGAGACTCGGGCTACAGAGGACCCCGGAAGAGGGGCCGAGTAAATTTCTCCTA 351 CTACGGTCTGGACGTCTGGGGCGGGGACACCGTACCGTCTCGAGTGGAGCGCGGTTTCAGGCGGA 421 GGTGGCTCTGGCGGTGGCGGAAGTGCACAGGCTGTGCTGACTCAGCCGCTCTCAGCGTCTGGGACCCCG 491 GGCAGAGGTCACCATCTCTTGTCTGGAAGCACTCCAACATCGGACGCAATTAATGTATCTGTGTAACA 561 GCAGTCCAGGAACGGCCCCCAAAATCCTCATACAGGAACAATCAGCGGCCCTCAGGGTCCCTGAC 631 CGATTCTTGGCTCCAAGTCTGGCACATCAGCCCTCCCTGGCCATCAGTGGGCTCCGTCGAGGATGAGG 701 CTGATTATTACTGTGCATCATGGGATGACAGCCTGACTTGGGTGTTCCGCGGAGGACCAAGGTCAACGT 771 CCTAGGTGCGCGCGAGGTGCGCGGTGCCGTATCCAGATCCGCTGGAACCGCGTGGGCGCGCAAGCGCT 841 TGGAGCCACCCGAGTTCGAAAAATAA</p>
scFv3	39	<p>1 GGGCCTCAGTGAAGGTCTCCTGCAAGACCTCTGGATACACCTTCATCGCCTATTATATTCATTGGGTGG 71 ACAGGCCCCTGGAACAAGGCTTGAGTGGATGGGACGGATCAACCCTAACACTGGTGGCATAAACCTTGCA 141 CAGAAGTTTCAGGGCAGGGTCAACCGTACAGGAGACAGTCCATCAGACAGCCACATGGAGCTGAGTA 211 GGCTGAGCTCTGACGACACGGCCGTATACTACTGCGAGAGAGAGGATCGTACCAGTGGTCTGAGGAA 281 CCGTGGATGGTGAATGGAATGACGCTGCGGCGCGGGAACCCCTGGTCAACGCTCTCGAGTGA 351 GGCGGCGGTTCAGGCGGAGGTGGCTCTGGCGGTGGCGGAAGTGCAGTCTGTCTGGAGGAGGTCCACATTTGGAAGAA 421 CAATGTCTGGACCCCCGGCAGAGGTCACCATCTCTTGTCTGGAGGAGGTCCACATTTAGGAATATGAACGG 491 TTATGTATACTGGTACCAGCAGTCCAGGAACGGCCCCCAAACTCTCATTTATAGGAATATGAACGG 561 CCTCAGGGGTCCCTGACCGGATCTCTGCCTCCAGTCTGGCAACCTCAGCCTCCCTGGCCATCAGTGGAC</p>

Fig. 11

scFv4	40	631	TCCGGTCCGAGGATGAGGCTGATTATTACTGCGCAACGTGGGATGACAGTCTGAGTGGGACTTGGGTGTT
		701	CGCGGAGGGACCAAGCTGACCGTCTAGGTGCGGGCGG
scFv5	41	1	CTGTTGAGTCTGGGGAGGCTTGGTACAGCCTGGGGGTCCCTGAGACTCTCCTGTGAGCCTCTGGAT
		71	TCACCTTTAGCAGCTATGCCATGAGCTGGTCCGACAGGCTCCAGGAAGGGCTGGAGTGGTCTCAGC
		141	TATTAGTGGTACTGGTAGCATACTACGACAGTCCGTGAAGGCCGGTTCAACATCTCCAGAGAC
		211	AATTCCAAGAACACGCTGTATCTGCAATGAACAGCTGAGAGCCGAGACACGGCCGTATTACTGTG
		281	CGAGAGTGGGGGCGATATGATAGTAGTACGCGTTGACTCTCTGGGCCGGGGACAATGGTCACCGT
		351	CTCGAGTGGAGGCGCGGTTACGGCGAGGTGGTCTTGGCGGTGGCGGAAGTGCATTTCTTATGAGCTG
		421	ACTCAGCCACCTCAGTGTCTGGTGGCCCCAGGAGAGACGGCCACAATACCTGTGGGGAGCGACGCTTG
		491	GCTCCAAAGTTGTGCATTGGTATCAGCAGAAGCCAGGCCAGCCCCATACATTGGTCATTTATTATGATTC
		561	CGTCCGGCCCTCGGGGGTCCCTGAGCGATTCTCTGGCTCCAACCTCTCGGTGTCTGGCCACCTGACCGTC
		631	AGCAGGTGCAAGCCGGGATGAGGCCGACTATTATTGTCAAGTGTGGGATAGAAGTAGTGACCAATTATG
		701	TCTTCGGAACCTGGGACCAAGCTGACCGTCTTAGTTCGGGGCCG
		1	CAGCTGTTGAGTCTGGGGAGGCTTGGTACAGCTTGGGGGTCCCTGAGACTCTCCTGTGACGCTCTG
scFv6	42	71	GATTCACTTTAGCAGCTATGCCATGAGCTGGTCCGCCAGGCTCCAGGAAGGGCTTGAGTGGTCTC
		141	AGCTATTAGTGGTAGGTAGCATACTACGACAGTCCGTGAAGGCCGGTTCAACATCTCCAGA
		211	GACAAATCCAAGAACACGCTGTATCTGCAATGAACAGCTGAGAGCCGAGACACGGCCGTGATTACT
		281	GTGCGACTCTTTTAGGGAAAGTGGTACGTTCTGCTCACTGGGGCAGGGGAACCTGGTCACTCGAG
		351	TGGAGGCGCGGTTACGGCGAGGTGGTCTGGCGGTGGCGGAAGTGCACAGGCTGTGCTGACTCAGCCG
		421	TCCTCAGCGTCTGGGACCCCGGGCAGAGGTTCATCTCTTGTGTTGGAAGCAGCTCCAACATCGCAA
		491	GTAATTATGTATACTGGTACCAACCACTCCAGGAACGGCCCCCACTCCTCATCTCTAAGAATAGTCG
		561	GCGGCCCTCAGGGTCCCTGACCGATTCTCTGGTCCCAAGTCTGGCACCTCAGCCTCCCTGGCCATCAGT
		631	GAACTCCGTCGAGGATGAGGTGATTATTACTGTGCAGCATGGGATGACAGGCTGAGTGGTCCGGCAT
		701	TCGGCGGAGGACCAAGCTGACCGTCTTAGTTCGGGGCCG
		1	CAGCTGGTGCAGTCTGGGGAGGCTTGGTGCAGCCGGGGGTCCCTGAGACTCGCCTGTGAAGCCTCTG
		71	GATTCAAGGTTAGCAGCTATGGCATGAGCTGGTCCGCCAGGCTCCAGGAAGGGCTTGAGTGGTCTC
		141	TTCCATGAGCGATAGTGGTGCATAACATACTACGACAGTCCGTGAAGGCCGGTTCAACATCTCCAGA
scFv7	43	1	AAGAAGCCTGGTCTCTCGTGAAGTCTCTCTGCAAGGCTTCTGGAGGCACCTTCAGCAGTTATGCTATTA
		71	GTTGGTCCGACAGGCCCTGGACAAGGCTTGAGTGGATGGAGGGATCATTCCTATGTCTGGTACACC

Fig. 41

		<p>141 AAACACGACAGAAAGTTCAGGACAGAGTCACGATTACCGCGGACAAATCCACGAGCACAGCCTACATG</p> <p>211 GAGCTGAGCAGCCTGAGATCTGAGGACACGGCGGTGTATTACTGTGCGAGGGGGGGCGCTACGTTGACT</p> <p>281 TCGGTCTGGTGGCCCTTCGTACCACTACTACTAGTGGACGTCTGGGCGAGGGAACCTGGTCAACCGTCTC</p> <p>351 GAGTGGAGCGCGGTTCAGCGGAGGTGGCTCTGGCGGTGGCGAAGTGCACAGTGTGTGGACGAG</p> <p>421 CCGCCCTCAGCGTCTGGGACCCCGGACAGAGGGTCACCATCTCTGTCTTCTGGGCGACCTCCAACATCG</p> <p>491 GAAGGAATATGTTTACTGTGTACCAACCTCCAGGAGCGGCCCAAGCTCCTCATCTATAGGAATGA</p> <p>561 TCAGCGTCCCTCAGGGTCCCTGACCGATTCTCTGGGTCCAAGTGGCACCTCAGCCTCCCTGGCCATC</p> <p>631 AGTGGCCTCCGTCGACGATGAGGTGATTATTACTGTGTGCTGGTGGGACGACAACTGAGTGGTCTAT</p> <p>701 TTTTCGGCGGAGGACCAAGCTGACCGTCTCTAGGTGCGGCGCG</p>
scFv8	44	<p>1 GCCCAGGTGCAGCTACAGAGTGGGCGCCAGCACTGGTGAAGGTCGGAGATCCTGTCCCTCAACTGCA</p> <p>71 CTGTCTCTGGTAGCTCCCTCAGCAGTGGTGTACTACTGGAGCTGGATCCGCCAGCACCCAGGGAAGG</p> <p>141 CCTGGAGTGGATTGGGTACATCCATTACAGTGGGAGCACGTACTAACCCTCCCTCAAGAGTCGAGTT</p> <p>211 ACCATATCAGTAGACACGCTAAGAACCAAGTCTCCCTGAAGCTGAGCTCTGTGACTGCCGCGGACACGG</p> <p>281 CTGTGTATTATTGTGCGAGAGTCCGTGAGATTGATGGTGTGATGTCTGGGCGCAAGGCACCCCTGGT</p> <p>351 CACCGTCTCAGTGGTGGAGCGGTTCAGCGGAGGTGGCAGCGCGGTGGGATCGGATCGGACATCCAGATG</p> <p>421 ACCAGTCTCTCCACCTGTCTGCATCTATTTGGAGACAGAGTACCATCACCTGCCGGGCCAGTGAGG</p> <p>491 GTATTATCAGTGGTGGCTGGTATCAGAGAAGCCAGGGAAGCCCCCTAACTCCTGATCTATAAGGC</p> <p>561 CTCTAGTTAGCCAGTGGGCGCCCTCAAGGTCAGCGGAGTGGATCTGGACAGATTCACTCTCACC</p> <p>631 ATCAGCAGCCTGCAGCCTGATGATTTTGCACTTATTACTGCCAACATAATAGTAATTATCCGCTCACTT</p> <p>701 TCGGCGGAGGGACCAAGCTGGAGATCAACCTGCGGCGCG</p>
scFv9	45	<p>1 CTGAGCTGAAGAACCTGGTCTCGTAAAGTCTCCTGCAAGGCTCTAGAGGCACCTTCAACAGTTA</p> <p>71 TGCTCTCAACTGGGTGGGACAGGCCCCCTGGACAGGCTTGAGTGGATGGGAGGATCATCCCTATTTT</p> <p>141 GGTAGTGCAAAATTACGCACCGAAGTTCAGGCGAGAGTCAACCAFTACCGCGGACGAATCCACGACACAG</p> <p>211 CCTACTGGAGCTGAGCAGCTGAGATCTGAGGACACGCGCGGTATATTACTGTGCGGAGCTCTCCATTT</p> <p>281 GGATTACGTTTGGAGGACTTATAATTACTACTTTGACAACTGGGCAAGGAGCAATGGTCAACCGTCTCG</p> <p>351 AGTGGAGCGCGGTTTCAGCGGAGGTGGTCTCTGGCGTGGCGAAGTGCATTTCTTCTGAGCTGACTC</p> <p>421 AGGACCTGCTGTGTCTGTGGCTTGGACAGACAGTCAGGATCACATGCCAGGAGACAGCCTCAGAG</p> <p>491 TTATTATGCAAGCTGGTACAGCAGAAGCCAGGACAGGCCCTGTCTTGTCTATCTATGGTAAAAATAGT</p> <p>561 CGGCCCTCAGGGATCCCAGACCGATTCTCTGGCTCCGACTCAGAAACACAGCTTCTTGAACCATCTG</p> <p>631 GGGCTCAGGCGGAAGATGAGGCTGACTATTACTGTAACTCCCGGACAGAACTGGTAACCGCGTGGTCTT</p> <p>701 CGGCGGAGGGACCAAGCTGACCGTCTCTAGTGGCGCGCG</p>
scFv10	46	<p>1 TCCCTGAGACTCTCCTGTGGGCGCTCTGGATCACCTTTAGCAGCTATGCCATGAGTGGTCCGCCAGG</p> <p>71 CTCCAGGAAGGGGCTGGAGTGGGTCTCAGTATTAGTGGTAGTGGTAGCATACTACGCAGACTC</p> <p>141 CGTGAAGGCGCGGTTCCATCTCCAGAGACAAATCCAGAACACCGTGTATCTGCAAAATGAACAGCCTG</p> <p>211 AGAGCCAGGACACGCGCGTGTATTACTGTGGAGAGGGTTACGTATCACTATGACCATGACAGGCGTG</p> <p>281 GTGTGACCGCGCAAAATATATAACCAAGGTTGGACGTCTGGGGAGGGGACCCAGGTCAACCGTCTCGAG</p>

Fig. 11

scFv11	47	<p>351 TGGAGGCGGGTTT CAGGCGGAGGTGGCTCTGGCGGTGGCGGAAGTGCACAGGTGCTGCTGACTCAGCCG</p> <p>421 TCCTCAGCGTCTGGACCCCGGGCAGAGGTCAACATCTCTGTGTTCTGGAAGAGTCCAACATCGGAA</p> <p>491 AGAATATGTATCTGTTATCAGCAGCTCCAGGAACGGCCCCAAACTCTCATCTATAGGAATATCA</p> <p>561 GCGGCCCTCAGGAGTCCCTGACCGATTCTCTGGCTCCAAGTCTGGACCTCAGGCTCCCTGGCCATCAGT</p> <p>631 GGGCTCGGTCCGAGGATGAGGCTGATTATATTGTGCGGACGGGATAACGGCCTGAGTGCTTATGTGA</p> <p>701 TATTCGGCGGAGGACCAAGCTGACCGTCTAGGTGCGGCCG</p>
scFv12	48	<p>1 AGGTGAAAAGCCCGGAGTCTCTGAAGTCTCTGCAAGGTTCTGGATACAGCTTTCCCAACTACTG</p> <p>71 GATCGCTGGTGGCCAGATGCCCGGGAAGCCCTGGAGTGGATGGGATCATCTATCCTGGTGACTCT</p> <p>141 GATACTATATACAGCCGCTCTCCGAGGCCAGTCAACATCTCAGCCGACAGTCCATCAGCACCCGCT</p> <p>211 ACCTGAGTGGAGCAGCTGAAGCCTCGACACCCGCTATCTACTGTGCGAGACAGGGTTGTAGTGG</p> <p>281 TGGTAATGCTACGAGAAATGTATGCTTCTGATATCTGGGSCAGGGAAACCTTCCATGAGCTGACTCAGC</p> <p>351 GGAGCGCGGTTCAGCGGAGGTGGCTCTGGCGGTGGCGAAGTGCATTTCCATGAGCTGACTCAGC</p> <p>421 CACCTCAGCGTCTGGACCCCGGGCAGAGGTCAACATCTCTTCTTCTGGAAGCACGTCACACATCGG</p> <p>491 AAGGAATCTGTATTTTGGCACCAAGCAGTACCAGGAACGGCCCCCAAGTCTCATCTCTTCTGATAAT</p> <p>561 CAGGACCCCTCAGGGGTCTGTACAGATTCTCTGGCTCCGACTCTGGCACCTCAGCCTCCCTGGTCATCA</p> <p>631 GTCGCTCCGTTTGAAGATGAGGTGATTACTACTGTGACGATGGGATGACAGTCTGAGTGCTTATGT</p> <p>701 CTTCCGAAGTGGACCAAGCTGACCGTCTAGGTGCGGCCG</p>
scFv13	49	<p>1 GGGTGAAGTGAAGAAGCTGGTCTCTCGTGAGGTCTCTGCAAGGTTCTGGAGACACCTTCAGCTA</p> <p>71 CAATGCTATCAACTGGTGGCGACAGGCCCTGGACAAGGTTGAGTGGATGGAGGGATCATCCCTATG</p> <p>141 TTTGTACAGCAAGCAGGCACAGAAAGTCCAGGGCAGAGTACAGTTTACCGGGACGAATCCACGAGCA</p> <p>211 CAGCCTACATGGAGTTGACTAGGTGAGATCCGAGGACACGCCCATGTATTACTGTGCGGACGGGCTC</p> <p>281 GTACAGTAATTACGAGAGGGGTATTACTATACATGGAGTCTGGGCGCAGGAACCTTGGTCAACGTC</p> <p>351 TCGAGTGGAGGCGCGGTTCAGCGGAGGTGGCTCTGGCGTGGCGGAAGTGCATGCCGTGCTGACTC</p> <p>421 AGCCACCTCAGCGTCTGGGCCCCCGGCGAGAGTACCATCTCTTGTTCGGAAGCACCTTCAACAT</p> <p>491 CGGAGAAATTAATTGACTGGTATAACAACCTCCCCGGAACGGCCCCCTAACTCTTCACTATAAGAAAT</p> <p>561 GATCAGCACCTCAGGGTCCCTGACCGATTCTCTGGTCCAAGTCTGGCACCTCAGCCTCCCTGCTCG</p> <p>631 TAAGTGGACTCCGCTCCGAGGATGAGGTGATTATTACTGTGACTTGGGATGACAGCCTGAGTGGTCC</p> <p>701 GGTGTCCGCGGGGGACCAAGCTGACCCCTCTAGGTGCGGCCG</p>
scFv13	49	<p>1 GCTCAGGAGTCCGGCCAGGACTGGTGAAGCCTTCGGGACCTTGTCCCTCACCTGGCTGTCTCTGGT</p> <p>71 GGCTCATCAACAATAATAATTGGTGGAGTTGGTCCGCCACGCCCGGAGGGCTGGAGTGGATTG</p> <p>141 GGGAAATCTATCAGAGTGGAGCACCATAACAACCTCCCTCAAGAGTCGAGTCACCATATCAGTGA</p> <p>211 CAAGTCCAAACACCAGTTCTCCCTGAAGTGAAGTCTGTGACCGCCGCGGACAGCCGCTGTATTACTGT</p> <p>281 GCGAGGCTTAAGTGAACACCGGCCCTACTACGGTATGGATGGAGTCTGGGCGAGGGCACCTTGGTCAACG</p> <p>351 TCTCAGTGGAGGCGCGGTTCAGGGGAGGTGGCTCTGGCGTGGCGGAAGTGCACAGTCTGTGCTGAC</p> <p>421 GCAGCGCCCTCAGCGTCTGGACCCCGGACAGAGTCAACATCTCTTGTCTGGAAAGCAGTCCAAC</p> <p>491 ATCGGAAGTAATTTGTATATCTGTAACAGAGTCCAGGAACGGCCCCCAACTCTCATCTATAGGA</p> <p>561 ATAATCAGCGGCCCTCAGGGGTCCCTGACGATTCTCTGCTCCAAGTCTGGCACCTCAGCCTCCCTGGC</p>

Fig. 11

scFv14	50		631 CATCAGTGGGCTCCGGTCCGAGGATGAGGCTGATTATTACTGTGGGCGATGGGATGACAGGCGTGTGGTA 701 TTCGGCGGAGGACCAAGCTGACCGTCTTAGTGGGCGCG
			1 GGTGCAGCTGCAGAGTCCGGGCCAGGACTGGTGAAGCCTTCGGAGACCCCTGTCCCTCACCTGCACCTGTC 71 TCTGGCGGCCCGTCCGACAGTAGTATTACTACTGGGCTTCATCGCCAGCCCCAGGAAAGGGCTGG 141 AGTGGATTGGAGTATTTATGATGGTGGCTACACTACTACAGCCGTCCTAAAGAGTCGAGCTACCAT 211 ATCCTTCGACACGTCGAAGAACAGGCTCCCTGAACCTGACCTCTGTACCAGCGGACACAGGCGCTC 281 TATTACTGTGGAAAGACCCGGGCGAGTTTGGCGCTTCTGGGCGAGGAAACCCCTGTCACCGTCTCGA 351 GTGAGGCGGCGGTTTCCAGGCGAGGTGGCTCTGGCGGTGGCGAAGTGCACTTGACATCCAGTTGACCCA 421 GTCTCCATCCTCCTGTCTGGTCTGTAGGAGACAGAGTCAACATCACTTGCCGGACAGTCAGCGCAT 491 AGCAGCTATTTAAATTGGTATCAGCAGAAGCCAGGGAAAGCCCCCTAAGCTCCTGATCTATGCTGCATCCA 561 GTTTGCAAGTGGGGTCCCATCAAGGTTTCACTGGCAGTGGTCTGGGACAGATTTTCACTCTCACCATCAG 631 CAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCACAGAGTTACAGTACCCCGATCACCTTCGGC 701 CAAGGACACGACTGGAGATTAAACGTGGCGCGC
scFv15	51		1 CTGTTGGAGTCTGGGGAGGTTGGTACAGCTTGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGAT 71 TCACCTTTAGCAGCTATGCCATGAGCTGGTCCGCCAGGCTCCAGGGAAGGGCTGGAGTGGTCTCAGC 141 TATTAGTGGTAGTGGTAGCACATATACTACGACAGCTCCGTGAAGGCCGGTTCACCATCTCCAGAGAC 211 AATCCAGAAACACGCTGTATCTGCAATGACAGCCTGAGAGCCGAGGACACGCGCTGTATTACTGTG 281 CGAGAGTTGGAGATGGACAAATTTGGGGGTGGTTCGACCCCTGGGCGAGGACCCCTGGTCAACCGT 351 CTCGAGTGGAGCGCGGTTCAAGCGGAGGTGGTCTGGCGGTGGCGAAGTGCACTTGATGTTGTGATG 421 ACTCAGTCTCCAGCCACCTGTCTGTGTCTCCAGGGGAAGAGTCACTCCTCCTGACGGGCCAGTCAGA 491 GTGTTGGCAGCAAGTTGGCCTGGTACCAGCAGAAACCTGGCAGGCTCCAGGCTCCTCATCTTTGGTAC 561 ATCGACCGGCGCAGTGGTATCCAGCCAGGTTCACTGGCAGTGGTCTGGGACAGATTCACCTCTCACC 631 ATCAGCAGCTGCAGTCTGAAGATTTTGCAGTTTATTAATGTCAGAGTATAATACTGGCCTCCGTACA 701 CTTTTGGCCAGGGGACCAAGGTGGAATCAACGTGCGGCGC
			1 GCTGAGTGAAGAAGCCTGGGACTCAGTGAAGTCTCCTGCAAGCCTCTGTTACAGGTTTGAAACCT 71 ATGGTTTCAGCTGGGTGCGACAGGCCCTTGGACAAGGCTTGAGTGGATGGATGGATGAACACTTACAA 141 TGGTAAGACAAATATGCAAGAAAGTTCCAGGCAGAGTCAACATGACACAGACAGTCCACGAGCACA 211 GCCTACATGGAGTTGAGGAGCTGAGATCGGACGACACGCGCTGTATTTTGTTCGAGAGCTGAGGATG 281 ATAGCAGAGGTTATTGGAACCATTAATCTCCGACTACTGGGAGGGGACCCAGTCCCGTCTCGAG 351 TGGAGGCGGCGGTTTCAAGCGAGGTTGGTCTGGCGGTGGCGGAGTGCACAGTCTGTGCTGACTCAGCCA 421 CCCTCAGGCTCTGGACCCCGGGCAGAGGTTACCATCTCTTTGTTCTGGAAGCAGTCCACATCGGAA 491 GTAATTATGATATACTGGTACCAGAGCTCCAGGAACGCGCCCAAACTCCTCATCCATAAGATAATCG 561 CGGCGCTCAGGGGTCCCTGACCGATTCTCTGGCTCCAGTCTGGCACCTCAGCCTCCCTGGCCATCAGT 631 GGGCTCCGGTCCGAGGATGAGGCTGATTATCACTGTGACGCTGGGATGACAGCCTGAGTGTGTGTTT 701 TCGGCGGAGGGACCAAGTACCGTCTTAGTGGCGCGC
scFv17	53		1 TTGGAGTCTGGGGAGGCTTGGTACAGCCTGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCA 71 CCTTTAGCAGCTATGCCATGAGTGGTCCGCCAGGCTCCAGGGAAGGAGCTGGAGTGGTCTCAGCTAT

Fig. 11

scFv18	54	<p>141 TAGTGGTAGTGGTGTAGCACATACGCAGACTCCGTGAAGGGCCGGTTACCATCTCCAGAGACAAT</p> <p>211 TCCAAGAACACGCTGTATCTGCAAAATGAACAGCCCTGAGAGCCGAGGACACGGCCCGTGTATTAATCTGTGCGA</p> <p>281 GAGATTGGAGATGGCAACAATTTGGGGCTGGTTCCAGCCCTGGGCGGAGGACAATGGTCACCGTCTC</p> <p>351 GAGTGGAGGCGGGGTTTCCAGGCGAGGTGGCTCTGGCGGTGGCGAAGTGCACTTGAACGACACTCACG</p> <p>421 CAGTCTCCAGGACCCCTGTCTTTGTCTCCAGGTGATAGAGCCACCCCTCTCTGAGGGCCAGTACAGTG</p> <p>491 TTAGTCACAAACACTTAGCCTGTGATACAGCAAAATCCCTGGCCAGGCTCCAGGCTCCCTCATTTTGGTGC</p> <p>561 ATCCAGCAGGCGCGCTGGCATCCCTGACAGGTTCACTGGCAGTGGGTCTGGGACAGACTCACTCTCACC</p> <p>631 ATCAGCAGACTGGAGCCTGAAGATTTTGCATCATATTACTGTACAGATATGGTAGCCCCCGGGGACGT</p> <p>701 TCGGCCAAGGACCAAGGTGGAAATCAAACGTGGGCGCGC</p>
scFv18	54	<p>1 GAAGAACCTGGGTCTCGGTGAGGGTCTCTGCAAGGCTCTCTGGAGGCACCTTCGGCAACTCTGTATC</p> <p>71 AGCTGGGTGCACAGACCCCTGGACAAGGGCTTGAAGTGGATGGGAGGAATCATTCCTATGTTTACTACAG</p> <p>141 CAAACTACGCACAGAAATTCAGGGCAGAGTACCATTACCGCGGACAAATCCACGACACAGCCACAT</p> <p>211 GGAGCTGAGCAGCCTGAGATCTGAGGACACGGCCCTCTATTACTGTGAGAGGGGAGTGGGACGATTT</p> <p>281 TTTGACGGCCCTCCCACTTCTCTACTACATGGAAGTCTGGGCAAGAAACCCCTGCTCACCGTCTCGA</p> <p>351 GTGAGGCGGGGTTTCAAGCGGAGGTGGCTCTGGCGGTGGCGAAGTGCACAGTCTGTGTGACGCAGCC</p> <p>421 GCGGCAGCGTCTGGACCCCGGCGAGAGGTACCATTCTTTGTTCTGGAAGCAACTCCAAACATCGGA</p> <p>491 AGAAATTATGTCTACTGGTATCAGCAGCTCCAGAGCGGCCCCAAACTCCTCATATAGGAATAATC</p> <p>561 AGCGCCCTCAGGGGTCCTGACCGATTCTCTGGCTCCAAGTCCGGCCCTCAGCCTCCCTGGCCATCAG</p> <p>631 TGGGCTCCGCTCCGAGGATGAGGCTGATTATTACTGTGAGCATGGGATGACAGCCTGAGTGGCCCTGCA</p> <p>701 TTGCGGCGAGGACCAAGCTGACCGTCTCTAGGTGCGGCGCGC</p>
scFv19	55	<p>1 AGGTCCAGCTGGTACAGTCTGGGCTGAGGTGAAGACCTGGGTGCTCGGTGAAGTCTCTGCAAGGC</p> <p>71 TTCTGGAGGCACCTTCAGCAGCGATGCTATCAGTGGGTGCGACAGGCCCTGGACAAGGACTTGAGTGG</p> <p>141 ATGGGAAGGATCATCCCTCTAATTAATAATACCAACTACGCACAGAAGTCCAGGGCAGAGTCAAGATTA</p> <p>211 CCGCGGACAAATCCACGACACAGCCTACATGGAGCTGACCAAGCCTAAGATTGAGGACGCGGCCGTGA</p> <p>281 TTAATGTGCGAGAGTGAATACTGGAACGCTTTGACCAAGTGGGCGGGGAAACCCCTGCTCACCGTCTCG</p> <p>351 AGTGGAGGCGGGTTCAGGCGGAGGTGGCTCTGGCGGTGGCGAAGTGCACCTTCTCTGAGCTGACTC</p> <p>421 AGAACCTGCTGTGTCTGTGGCTTGGACAGAGTCAAGATTACATGCCAAGGAGACACCCCTCACAAAG</p> <p>491 TTATTATGGGCTGGTACCAAGAGAGCCAGGACAGGCCCTCTGCTGTCTTCTATGGTAAAGACAAG</p> <p>561 CGGCCCTCAGGGATCCAGAGCGATTCTCTGGCTCCAGCTCAGGAATAATTTGCTTCTTGAACCATCAGT</p> <p>631 GGGCTCAGGCGGAGGATGAGGCTGACTTTTACTGTAGTTCCCGGACAGCAGTGGGTACCGTTTGTCTT</p> <p>701 CCGGCTGGGACCAAGCTGACCGTCTTAGTGGGCGCGC</p>
scFv20	56	<p>1 GAAGAACCTGGTCTCTCGGTGAAGTCTCTCTGCAAGGCTTCTGAGGCAACCTTCACAGCTATGCAATC</p> <p>71 AGTTGGGTGACAGGCCCTTGACAAAGGCTTGAAGTGGATGGGAGGTTTATCCCTGTATTTGGCACAG</p> <p>141 CAACTACGCACAGAAATGAGGCGAGAGTACGATCAGCCGCGAGGATTCATGACACAGTGTACAT</p> <p>211 GGAGCTGAGTACCTGACCTCTGAAGACACGGGCTGATTACTGTGCGAGAGATCTCATGCGGCTGGCC</p> <p>281 CGTCGCGATGAATACTACTATTACTACATGACCTCTGGGCGCAAGGAGCAATGGTCAACCGTCTCGAGTG</p>

Fig. 11

scFv21	57	351 421 491 561 631 701	GAGCGGGGGTTGAGCGGAGGTGGCTCTGGCGGTGGCGGAAGTGCACAGTCTGTGCTGACTCAGCCACC CGCAGCGTCTGGGACCTACGGGCAGAGAAGATCACCATCTCTTGTCTGGAAGCAGTTCACAAATATCGGAGTT AATTATGTTTACTGGTACCGGCAATTCCAGGAGCGGCCCCACGCTGTCATCTATAATAATGATCAGC GGCCCTCAGGGGTCCCTGACCGATTCTCTGGTCCAAAGTCTGGACCTCCGCCCTCCCTGGCCCATCAGTGG GCTCCGGTCCGAGGATGAGGCTGATTATTTGTTCCACATGGGATGACACCCCTGAGTGGTTATATCTTC GGAGTTGGGACCAAGGTACCGTCTAGGTGGGCGCG
scFv21	57	1 71 141 211 281 351 421 491 561 631 701	CAGCCTGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACTTTAGCAGCTATGCCATGAGCT GGTCCCGCAGGCTCCAGGGAAGGGCTGGAGTGGTCTCAGCTATTAGTGGTGGTAGCACATA CTACGCAGACTCCGTGAAGGCGGTTACCATCTCCAGAGACAATCCAAGAACACGCTGTATCTGCAA ATGAACAGCCTGAGAGCCGAGGACACGGCCGTATTACTGTGCAGAGATTGGAGATGGCAACAATTG GGGCTGGTTCGACCCCTGGGCCAGGGCACCTGGTCACTCTGAGTGAAGTGGAGCGCGGTTCAAGCGG AGGTGGTCTGGCGGTGGGGAAGTGCACTTCTTCTGAGTGAAGTGGAGCCCTGTGTCTGTGGCC TTGGGACAGACAGTCAAGATCACATGCCAAGGAGACAACCTCAGAAGTTTCTGCAAGCTGGTACCAGC TGAAGCCAGGACAGGCCCTGTACTTGTCTATGTTAGAACACCGGCCCTCAGGGATCCCAGACCG ATTCTTGCCTCCAGTCAAGAAACACAGCTTCTTGGCCATCACTGGGCTCTGGCGGAAGATGAGGCT GACTACTGTAACTCCCGGGACAGCAGTGGTAACTTATGTCTTCGAACTGGGACCAAGGTCAACCG TCCTAGGTGGGCGCG
scFv22	58	1 71 141 211 281 351 421 491 561 631 701	GGTCTTCGTTGAAGTCTCCTGCAGAAATTTCCGGAGGCAATCTCAATAGGCTTACTGTCACTGGTGGCG ACAGGCCCTGGACAAGGCTTGAGTGGTGGCGAGGATTCTCCGACTCAGTAAATCAAGTCTGTGAAG TTCCAGCGCAGACTCAACTGACCTCTGACACTCCACGCGCAGACCTATTTAGAACTGAGGAGCCTGA AATCTGAAGACACGGCCGTATTATTGTGGCGTCACTCTAAATAGGCTTCCAGTTGGGAGCTCGA CTACTGGGCGGGGCACTGGTCACTCGAGTGGAGGGCGGTTCAAGCGGAGGTGGCTCTGGC GGTGGCGAAGTGCACAGTGTCTGAGCAGCGCCCTCAGCGTCTGCTACCCCGGGCAGAGGTCA CCATCTTGTCTGGAAGCAGCTCCAAATCGGAAGAAATTATGTCTACTGGTACCAGCAGGTCCCAGG AACGGCCCCCAACTCCTCTCTATAACAATAATCAGCGGCCCTCAGGGTCCCTGACCGATTCTCTGGC TCCAGTCTGGCACCTCAGCCTCCCTGGGCAATCAGTGGCTCCGCTCCGAGTGAAGTGAATTAATTA GTTCAACATGGGATGACAGCCTGAGTAGTCCGGTATTCCGGCGGGGGACCAAGCTGACCCGTCTAGGTGC GGCCGC
scFv23	59	1 71 141 211 281 351 421 491	CACCTTAGCAGCTATGCCATGAGTGGTCCGCCAGGCTCCAGGAAGGGCTGAGTGGTCTCAGCT ATTAGTGGTAGTGGTAGCACATACTACGAGACTCCGTGAAGGCCGTTCCACATCTCCAGAGACA ATTCGAAGAACACGCTGTATCTGCAATGAACAGCCTGAGAGCGGAGGACACGGCCGTGTATTACTGTC GAGAGTAGACGGCGGAGAGGAGTATTATATGATTCCGGGAGTTAGCCACATACGACGACTCTGGC ATGGACGTCTGGGCGGGGACCCCTGGTCACTGCTCGAGTGAAGCGGGGTTCAAGCGGAGGTGGCT CTGGCGGTGGCGGAAGTGCACTTCTATGTGTGCTGACTCAGCCACCTCAGCGTCTGGACCCCGGGCA TAGGTCACCATCTCTTGTCTGGAAGCAGTCCAACATCGGAAGTAATTATGTATACTGGTACCAGCAG CTCCAGGAACGGCCCCCAACTCTCTATATAGGAATAATCAGCGGCCCTCAGGGGTCCCTGACCGAT

Fig. 11

scFv24	60	<p>561 TCTCTGGCTCAAAGTCTGGCACTCAGCCTCCCTGGCCATCAGTGGGTCCGGTCCGAGGATGAGGCTGA</p> <p>631 TTATTACTGTGAGCATGGGATGACACCTTAAGTGTCTCCTATTTCGGGGAGGGACCAAGCTGACCGTC</p> <p>701 CTAGGTGCGGCGCGC</p>
scFv25	61	<p>1 GCTATGCCATGAGCTGGTCCGCCAGGCTCCAGGAAGGGCTGGAGTGGTCTCAGCTATTAGTGGTAG</p> <p>71 TGGTGGTAGACATACTACGACACTCCGTGAGGGCCGGTTCACCATCTCCAGAGACAAATCCAAGAAC</p> <p>141 ACGTGTATCTGCAAAATGAACAGCTGAGAGCCGACACGGCCGTATTACTGTGCGAGAAATACAG</p> <p>211 GAAAGGCATTAATTGGTTCGGGAGTATATTTGTCAGGACTGTGACCGCAGTCTACATCCCGCATGGA</p> <p>281 CGTCTGGGCGAGGGCACCCCTGGTCAACCTCTCAGTGGAGGGCGGGTTCAGGGGAGGTGGCTCTGGC</p> <p>351 GGTGGCGGAAGTGCACAGGCTGTCTGACTCAGCCGTCTCAGCGTCTGGGACCCCGGCGAGAGGTCA</p> <p>421 CCATCTCTTGTCTGGAAGCACTCCAACTCGAAGGAATATATGATGATTGGTACCAAGCAGCTCCAGG</p> <p>491 AACGGCCCCAACTCCTCATCTATAGGAATAATAAGCGGCCCTCAGGGTCCCTGACCGATTCTCTGGC</p> <p>561 TCCAAGTCTGGCACCTCAGCCTCCCTGGCCATCAGTGGGTCCGGTCCGAGGATGAGGCTGATTATTACT</p> <p>631 GTGCAGCTTGGGATGACAGCCTGAGTGGTGGGTATTCGGCGGAGGACCAAGCTGACCGTCTTAGGTGC</p> <p>701 GGCGGC</p>
scFv26	62	<p>1 TGGAGTCTGGGGAGGCTTGGTACAGCCTGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCA</p> <p>71 CTTTAGCAGCTATGCCATGAGCTGGTCCGCCAGGCTCCACGGAAGGGCTGGAGTGGTCTCAGCTATT</p> <p>141 AGTGGTAGTGGTAGCACATACAGCAGACTCCGTGAAGGGCGGTTCACCATCTCCAGAGACAATT</p> <p>211 CCAAGAACAGCTGTATCTGCAAAATGAACAGCCTGAGAGCCGAGACACGGCCGTGTATTACTGTGCGAG</p> <p>281 AGATTGGAGATGGCAACAATTTGGGGCTGGTTCGACCCCTGGGGCGAGGGACCACTGACCGTCTCG</p> <p>351 AGTGGAGGGCGGGTTCAGGGGAGGTGGTCTGGCGGTGGCGGAAGTGCATTTGAACGACACTCACGC</p> <p>421 AGTCTCCAGCACCTGTCTGTCTCCGGGGACAGAGCCACCTCTCCTGCAGGGCAGTCAAAGTAT</p> <p>491 TGGTGGCAACTTAGCCTGGTACCAAGCAAACTGGCCAGCCTCCAGGCTCCTCATCTTTGGTGCATCC</p> <p>561 ACTAGGGCCTCTGGTACCCAGCCAGGTTTCACTGGCAGTGGGTCTGGGACAGAGTTCATCTCACCATCA</p>

Fig. 11

			631 701	GCAGCCTGCAGTCTGAAGATTTTGCAGTTTATTACTGTACGACGATATAATAAAGTGGCCTCCATGGACTTT CGGCCAAGGGACACGACTGGAGATTAAAGCTGCGGCGCG
scFv27	63	1 71 141 211 281 351 421 491 561 631 701	ACAGCCTGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCAACCTTAGCAGCTATGCCATGAGC TGGGTCCGCCAGGCTCCAGGGAAGGGCTGGAGTGGGTCTCAGCTATTAGTGGTAGTGGTGGTAGCAGCAT ACTACGAGACTCCGTGAAGGCCGGTTCACCATCTCCAGAGACAATTCAGAGACACGCTGTATCTGCA AATGAACAGCCTGAGAGCCGAGGACACGGCCGTGTATTACTGTGCGAAAGGGGACGGGTAGTGGCTGGA ACTACGTACTACTACGTATGAGCTGTGGGCTGGGCGAGGACACCGTCAACGCTCTCGAGTGGAGGCG GCGGTCAGGCGGAGTGGCTCTGGCGTGGCGGAAGTGCACAGTCTGTGCTGACGACGCGCCCTCAGC GTCTGGGGCCCCGGGAGAGATCACCATCTCTTTGCCGAAGCACTTCAACATCGGAGAGAAATAT GTTGACTGGTATAAACAACCTCCCGGAAGGGCCCCCAACTCTTATCTATAAGAAATGATCAGCGACCT CAGGGTCCCTGACCGATTCTCTGGCTCCAAGTCTGGCACTCAGCCTCCCTGGTCTGTAAGTGGACTCCG CTCCAGGATGAGGCTGATTATTACTGTCTGACTTGGGATGACAGCCTGAGTGGTCCGGTCTTCGGCGGG GGGACCAAGCTGACCTGCTAGTGGCGGCGCG	
scFv28	64	1 71 141 211 281 351 421 491 561 631 701	GGCCTCTGGATTTCGGCTCAATGGCTATGAATGCATTGGGTGCGCCAGGCCCCCGGACAAAGGCTTGAG TGGTTCGGCCCGGATCAACGCTGCCATTGGCGACACACGGTATTCAAGGAGTTCAGAGTAGAGTCTCCA TTACAGAGACATGTCGGCGAACACAGCTCTACATGGAGATGAGCAGGCTGAGATTGAAGACACAGGCTGT TTATTATTGTGTGAGATTCCAGATTGGCGACATTGTAATAGTGCACCTGTACGCCCCCTTTTGACCCAC TGGGCAAGGGAACCTGGTCAACGCTCGAGTGGAGGGCGGTTACGGCGGAGGTGGCTCTGGCGGTG GCGAAGTGCATTCTTCTGAGTGAATCAGGACCTGCTGTGTCTGTGGCTTGGGACAGACAGTCAAG GATCAGATGCCAAGGAGACAGCTCAGATACTATTCTCAAGTTGGTACCGGACGAGCAAGCAGGCGCAGGCC CCTGTATTGTCTATGTATGGTAACACCGCCGCGGCTCAGGGATCCAGACCGAATCTCTGGCTCCAGCT CAGGAACACAGCTTCCTTGACCATCAGTGGGCTCAGGCGGAAGATGAGGCTGACTATTATTGTAACTC CCGAGACAGTAGTGGTAACCATCTGGTCTTCGGCGGAGGACCAAGCTGACCGTCTAGGTGCGGCGCG	
scFv29	65	1 71 141 211 281 351 421 491 561 631 701	GTACAGCCTGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACTTTAGCAGCTATGCCATGA GCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGCTATTAGTGGTAGTGGTGGCAGCAC ATVACTACGAGACTCCGTGAAGGCCGGTTCACCATCTCCAGAGACAATTCAGAGACAGCTGTATCTG CAATGAACAGCCTGAGAGCCGAGGACACGGCCGTGTATTACTGTGGAGAGATCATCGGTGCGGACGGG GAGTGGGAGCTACTACTACGCCCTTTGACTGTGGGCGGCAAGGACAAATGGTCAACCTCTCGAGTGG AGGCGGCTTCAGCGGAGGTGGCTCTGGCGTGGGGAAGTCACTGCCTGCCTGTGCTGACTCAGCCACCC TCAGGCTCTGGACCCCGGAGAGGTCACCATCTCTTGTCTGGAAGCAGCTCCAACTCAGGAGGA ATTATGTATACTGTGTACAGCAGTCCCGAGGACCGCCCCCAACTACTCATCTATAGAAAATACTGCG GCCCTCAGGGTCCCTGACCGATTCTCTGGCTCCAGTCTGGCACCTCAGCCTCCCTGGCCATCAGTGGG CTCCGTCGAGGATGAGGCTGATTATTACTGTGAGCATGGGATGACACCCCTGAGTGGTGGTATTTCG GCGGAGGACAAAGCTGACCTCTAGTGGCGGCGCG	
scFv30	66	1 71 141	CGGAGGTGAGGAAGCTGGGGCTTCAGTGAAGATTCTCTGCAAGGCTTCTGGATTCACTTCACTAGTTA TCTATTCCATTGGTGGCCAGGCCCCCGGACAAAGGCTTGAAGTGGGTGGATCAACGCTGGCAAT GGAACACAAATATTCTACCGGACTCTCAGGGCAGAGTTACCTTACCGGGGACACATCCACGAGCAAA	

Fig. 11

scFv31	67	<p>211 CCTACATGGAGCTGAGCAGCCTGACATCTGAGGACACGGCTGTTTATTACTGTGCGAGAGATCAGGTGTT</p> <p>281 CTATGAGAGTGGTCTTACTACATACGCCCTTCTTTTGACTTCTGGGCGAGGGCACCCTGGTCAACCGTC</p> <p>351 TCTTCAGGTGGAGCGGTTTCAGGCGAGGTTGCGAGCGGGTGGCGGATCGGACATCCAGATGACCCAGT</p> <p>421 CTCCTTCCACCCCTGCTGCATCTATTGGAGACAGAGTCAACCATCACCTGCCGGGCCAGTGAGGCTATTTA</p> <p>491 TCACTGGTTGGCCTGGTATCAGCAGAAGCCAGGGAAAGCCCCATAACTCTCTGATCTATAAGGCTCTAGT</p> <p>561 TTAGCCAGTGGGCGCCCATCAAGGTTGAGCGGCGAGTGGATCTGGACAGATTCTACTCTCACCATCAGCA</p> <p>631 GCCTGCAGCCTGATGATTTTGCAACTTATTACTGCCAACAAATATAGTAATTATCCGCTCACTTTCGGCGG</p> <p>701 AGGGACCAAGCTGGAGATCAACCGTGGCGCGCG</p>
scFv31	67	<p>1 TGGTACGGCCTGGGGGTCCCTGAGACTCTCTGTGAGCCTCTGGATTACCTTTGATGATATGGCAT</p> <p>71 GAGCTGGTCCGCCAAGCTCCAGGGAAGGGCTGGAGTGGTCTCTGGTATTAAATGGAATGGTGGTAGC</p> <p>141 ACAGGTTATGCAGACTCTGTGAAGGCCGATTCACCATCTCCAGAGACACGCCAAGAACTCCCTGTATC</p> <p>211 TGCAAAATAACAGTCTGAGAGCCGAGGACACAGCCGTGTATTACTGTGCAAGAAGCGGTATGCGTTGGA</p> <p>281 TTATTGGGCGAGGGACAATGGTCAACCGTCTCGAGTGGAGCGGCGGTTCAGGCGGAGGTGGCTCTGGC</p> <p>351 GGTGGCGGAAGTGCACTTCTTCTGAGCTGACTCAGGACCCCTGCTACTGTCTGTGGCCTTGGGACAGA</p> <p>421 CAGTCAGGATAACTTGTGAGGCGGACAGCCTCGACAAATATTATGCAACCTGGTATCAACAGAAGCCTGG</p> <p>491 ACAGGCCCTCTACTTGTCTTCTGAAACAGGCGGCCCTCAGGGATCCAGACCGTTCTCTTGGC</p> <p>561 TCCAACTCGGAAACACAGCTTCTTGACCATCACTGGGCTCAGGCGGAGGATGAGGCTGACTATTACT</p> <p>631 GCAACTCCCGGAAATCGGTACTAATCGAATCCTATTTCGGCGGAGGGACCAAGCTGACCCGTCTAGGTGC</p> <p>701 GGCCGC</p>
scFv32	68	<p>1 TTGGTTCAGCTGGAGGGTCCCTGAGACTCTCTGTGAGCCTGGATTACCTTCAGTACTTTTGAAA</p> <p>71 TGAATTGGTCCGCCAGGCCCAAGGAAAGGGCTGGAGTGGTTCATATATTAGTGGTAGTGGTCATGC</p> <p>141 CATATACTACGAGACTCTGTGAAGGCCGATTCACCATCTCCAGAGACACGCCAACAACACTACTGTAT</p> <p>211 CTGCAAAATGAACAGTCTGACAGCCGAGGACACGGCTGTATTACTGTGGAGAGAAAAGTACCAGCTAC</p> <p>281 TACTTGGCAAGTACGACTACGGTATGGACGTCTGGGGCGGGGACACGGTCAACCGTCTCGAGTGGAGG</p> <p>351 CGGCGTTACGGCGGAGTGGCTCTGGCGGTGGCGAAGTGCATGCTGTGTGCTGACTCAGCCACCCCTCA</p> <p>421 GCGTCTGGGACCCCGGCGAGGGTCAACATCTTCTTGTCTGGAAGCAGCTCCAACATCGGAAGTAATA</p> <p>491 CTTTAACTGGTACCAGAGCTCCAGGAACGGCCCCCAAACTCCTCATCTATAGTAATGATCAGCGGCC</p> <p>561 CTCAGGGTCCCTGACCGATTCTGTGGTCCAAGTGGCACCTCAGCCTCCCTGGCCATCAGTGGGCTC</p> <p>631 CAGTCTGAGGATGAGGCTGATTATTACTGTGCAGCATGGGATGACAGCTGAATGGCTGSGTGTTCGGCG</p> <p>701 GAGGGACCAAGTCAACCGTCCCTAGGTGCGGCGCG</p>
scFv33	69	<p>1 AGGGCCTCTGGGGGACCTCCAGCAGTCTCTGCTTTCAGCTGGGTGCGACAGGCCCTTGGACAGGGGCTTC</p> <p>71 AGTGGATGGAGGGATCATCCCTCTCTTTGGTGCAGCAAACTACGCCAAGGTCGGGCGGACTCAC</p> <p>141 GATTACCGCGGACGAGTCCACGGGACGCTTACATGAACCTGGAATTTGCAGTCTGACGACACGGCC</p> <p>211 GTTTATTCTGTGGACTAACGGACAGACGAGGTGCGCCACCGGCTACTACTACGGCATGGACGCTCTGGG</p>

Fig. 11

scFv34	70	<p>281 GCCAGGCAACCTGGTCACCGTCTCAGTGGAGGGCGGTTTCTAGGGGAGGTGGCTCTGGCGGTGGCGG 351 AAGTGACAGTCTGTGTTGACGAGCTGCCCTCAGGCTCTGGGCCCCGGGACAGGATCACCATCTCT 421 TGTTCCGGAAACACCTTCAACATCGGGAGAAATATGTTGACTGGTATAAACAACTCCCGGAAACGGCCC 491 CCAAACTCTTCATCTATAAGAAATGATCAGGACCTCAGGGTCCCTGGCCGATTCTCTGGCTCCAATC 561 TGGCACCTCAGCCTCCCTGGTCTGTAAGTGGATCCGCTCCGAGTAGAGGTGATTATTACTGTCTGACT 631 TGGATGACAGCCTGAGTGGTCCGGTGTTCGGCGGGGGACCAAGTAGCCCTCTAGTGGCGGGC</p>
scFv35	71	<p>1 GCCTGCAAGGTTTGGTTACACCTTCGTGATCATGGAATTAGTTGGGTGGACAGGCCCTGGACAAG 71 GGCTTGGTGGATGGATGGATGATCAACACTCAGCAGCTCACACAAATATGCACAAAGACACAGGCCAG 141 ACTCACATGACACAGATGCCTCCATTATATCTTACATGGAGCTGGAGCCTGACATCTGACGAC 211 ACGCCGTCTATTATTGTGCCCGGGGGAGAGACTCGGACCGACATAGATCTCGCAGGGCCACGAACG 281 ACAAATGGATATCCCTATTACTCTCTGCTGACGCTCTGGGGCCAGGAACCTGGTCAACGCTCTGAG 351 TGGAGCGCGGGTTCAGGCGGAGGTGGCTCTGGCGGTGGCGGAAGTGCACAGGCTGTGCTGACTCAGCCG 421 TCCTCAGCGTCTGGGACCCCGGGCAGAGGTCAACATCTCTTGTCTGGAAGCAGCTCCAACATCGGAA 491 GTAAATTATGATATCTGTTACACAGCTCCAGGAACGGCCCCCAACTCCTCATCTATAGGAATAATCA 561 GCGGCCCTCAGGGGTCCCTGACCGATTCTCTGGTCCAAAGTCTGGCACCTCAGCCTCCCTGGCCCATCAGT 631 GGGCTCCGTCGAGGATGAGGCTGATTATTACTGTGACGATGGGATGACAGCCTGAGTGGTTGGTGT 701 TCGGCGGAGGACCAAGCTGACCGTCTCTAGGTGGCGGGC</p>
scFv36	72	<p>1 AGCCTGGGCTCAGTGAAGTTTCTGCAAGGATCTGGATACACTTACCAGCTACTATATATGCACTG 71 GGTGCGACAGGCCCTTGACAGGGCTTGAGTGATGGAAATATCAACCTTAGTGGTAGCACAAGC 141 TACGCACAGAAAGTTCCAGGCAGAGTCAACATGACAGGACACGTCACAGACAGTCTACATGGAGC 211 TGAGCAGCTGAGATCTGAGACACGGCGGTATTAATGTGCGAGAGGTTCGGGCGCCAGAAATGGTTCG 281 GGGAGTTATTATAGACCTACGGTATGGACGCTGGGGCCGAGGACCCCTGGTCAACGCTCTCGAGTGA 351 GGCGCGGTTACGGCGGAGGTGGCTCTGGCGGTGGCGGAAGTGCACAGTCTGTGCTGACTCAGCCACCT 421 CAGGCTCTGGGACCCCGGGCAGAGGTCAACATCTCTTGTCTGGAAGCAGCTCCACAGTCTGGAAGTAA 491 TTATGTATCCTGGTATCAGCAGTCCAGGAACGGCCCCCAACTCTATATAGGAATAATCAGCGG 561 CCCTCAGGGTCCCTGACCGGTCTCTGGTCCAAAGTCTGGCAITTCAGCCTCCCTGGCCATCAGTGGGC 631 TCCGTCGAGGATGAGGCTGATTTTACTGTGTAGCATGGGATGACAGCCTGAGGGAATATGTCTTCGG 701 AACTGGGACCAAGTCAACCTCTCTAGGTGGCGGGC</p>
scFv36	72	<p>1 GGAGTCTGGGGAGGCTTGTGTACAGCCTGGGGGTCCCTGAGACTCTCTGTGACGCTCTGGATTACCC 71 TTTAGCAGCTATGCCATGAGCTGGTCCGCCAGGCTCCAGGGAAGGGCTGGAGTGGTCTCAGCTATTAT 141 GTGGTAGTGGTGTAGCACATACTACGAGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAGACAATC 211 CAAGAACACGCTGTATCTGCAAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTGTATCTGTGCGAAA 281 GGTGGACTAGGGTGACCCACCGGGTGGTGTGATATATATGGGCGGAGGACAAATGGTCAACGCTCTCGA 351 GTGGAGCGCGGTTTTCAGGCGGAGGTGGCTCTGGCGGTGGCGGAAGTGCATGCTGCTGTGCTGACTCAGCC 421 CCGCTCAGCGTCTGGGGCCCCCGGCGAGAGTCAACATCTCTTGTTCGGAAGCAGCTTCAACATCGGG 491 AGAAATTATGTTGACTGGTATAAACAACTCCCGGAACGGCCCCCAAACTCTTCACTATAAGAAATGATC 561 AGCGACCTCAGGGGTCCCTGACCGATTCTCTGGCTCCAAGTCTGGCACCTCAGCCTCCCTGGTCTGTAAG</p>

Fig. 11

		631	TGGACTCCGCTCCGAGGATGAGGCTGATTATTACTGTCTGACTTGGGATGACAGCCTGAGTGGTCCGGTG
		701	TTGGCGGGGGGACCAAGCTGACCGTCTAGGTGCGGCGGC

Fig. 11




Fig. 12




Fig. 13



Fig. 14c



Fig. 14b



Fig. 14a

Tab. 1: Inhibition of tube formation

scFv	Average inhibitory effect
control (10% PBS)	0.8
scFv4	1.7
scFv5	1.6
scFv7	2.4
scFv8	2.4
scFv9	1.5
scFv11	2.2
scFv12	1.9
scFv13	2.1
scFv15	1.9
scFv16	1.6
scFv18	2.0
scFv19	1.6
scFv20	1.3
scFv21	2.0
scFv22	1.5
scFv23	2.1
scFv24	1.7
scFv25	2.3
scFv26	2.1
scFv27	2.3
scFv28	2.2
scFv29	2.1
scFv30	1.8
scFv31	2.4
scFv32	1.7
scFv33	2.1
scFv34	1.5
scFv35	1.4
scFv36	1.9
scFv7*	2.3
scFv8*	2.5
scFv13*	2.5
scFv25*	2.6
scFv26*	2.4
scFv28*	2.1
scFv31*	2.3
scFv33*	2.1
anti-alpha-2-integrin	2.3
anti-NP-1	1.1

Fig. 15




Fig. 16




Fig. 17

Tab.2 Transendothelial Invasion assay

scFv	Inhibition of Invasion
scFv26	+
scFv27	+
scFv34	+
ScFv35	+

Fig. 18




Fig. 19

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
8 July 2004 (08.07.2004)

PCT

(10) International Publication Number
WO 2004/056874 A3

(51) International Patent Classification⁷: **C07K 16/30**,
16/28, A61K 39/395, A61P 35/00

Kristian, Hobold [DK/DE]; Daiserstrasse 50, 81371
München (DE).

(21) International Application Number:
PCT/EP2003/014756

(74) Agents: FLEUCHAUS, Andrea et al.; Melchiorstr.42,
81479 München (DE).

(22) International Filing Date:
22 December 2003 (22.12.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/435,893 20 December 2002 (20.12.2002) US
03000615.9 15 January 2003 (15.01.2003) EP

(71) Applicant (for all designated States except US): XERION
PHARMACEUTICALS AG [DE/DE]; Sauerbruchstr.
50, 81377 München (DE).

(71) Applicant (for US only): TUFTS UNIVERSITY
[US/US]; 136 Harrison Avenue, Boston, MA 02111 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): UNGER, Christine,
Margarete [DE/DE]; Arndt Strasse 11, 80469 München
(DE). BESTE, Gerald [DE/DE]; Helmpertstr. 2, 80687
München (DE). ZEHETMEIER, Carolin [DE/DE]; St.
Martin Strasse 3, 81541 München (DE). LAIN, Blanca
[ES/US]; 100 Washington St. Apt. 7, Brighton, MA
02135 (US). TORELLA, Claudia [IT/DE]; Brodstr. 6A,
81829 München (DE). NIEWÖHNER, Jens [DE/DE];
Wengleinstrasse 3, 81477 München (DE). JAY, Daniel, G.
[US/US]; 45 Bigelow Street, Brighton, MA 02135 (US).
EUSTACE, Brenda, K. [US/US]; 95 Coolidge Street #2,
Brookline, MA 02446 (US). KNAUER, Roland [DE/DE];
Gabelsberger Strasse 63, 80333 München (DE). JENSEN,

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,
SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv)) for US only

Published:

— with international search report
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(88) Date of publication of the international search report:
9 December 2004

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: NEUROPILIN-1 INHIBITORS

(57) Abstract: The present invention relates to molecules interfering with the function of neuropilin-1 in the context of angiogenesis and the treatment of cancer. Molecules, polypeptides, antibodies, compositions and methods are provided that are useful for reducing, inhibiting or treating angiogenesis, the invasion of blood vessels into tumors, and/or the invasion or the metastatic potential of specific tumor cells. Additionally, a method is provided that allows identifying molecules, which interfere with the functionality of neuropilin-1. Furthermore, a method is provided that allows determining whether a naturally occurring tumor cell depends on functional neuropilin-1 for its invasiveness and/or metastatic potential.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 03/14756

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K16/30 C07K16/28 A61K39/395 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, Sequence Search, MEDLINE, BIOSIS, EMBASE, WPI Data, PAJ, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 99/55855 A (LEE YOON S ;WRIGHT JIM A (CA); YOUNG AIPING H (CA); GENESENSE TECH) 4 November 1999 (1999-11-04) examples page 2, lines 10-12 page 6, lines 13-22</p> <p style="text-align: center;">----- -/-</p>	1-22

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * & * document member of the same patent family

Date of the actual completion of the international search

8 October 2004

Date of mailing of the international search report

20/10/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

COVONE-VAN HEES, M

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 03/14756

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>ROCHE JOELLE ET AL: "Semaphorin SEMA3F inhibits cell attachment and spreading in human mammary tumor cells"</p> <p>PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 43, March 2002 (2002-03), pages 22-23, XP001182920</p> <p>& 93RD ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; SAN FRANCISCO, CALIFORNIA, USA; APRIL 06-10; 2002</p> <p>ISSN: 0197-016X</p> <p>abstract</p>	1,8,10, 14,15, 21,22
X	<p>TAKAHASHI TAKUYA ET AL: "Semaphorins A and E act as antagonists of neuropilin-1 and agonists of neuropilin-2 receptors"</p> <p>NATURE NEUROSCIENCE, vol. 1, no. 6, October 1998 (1998-10), pages 487-493, XP002295428</p> <p>ISSN: 1097-6256</p> <p>abstract</p> <p>page 487, left-hand column, lines 16-19</p> <p>page 492, left-hand column, paragraph 1</p> <p>figure 1</p>	1,6-8, 10-12
X	<p>MATTHIES ANNETTE M ET AL: "Neuropilin-1 participates in wound angiogenesis"</p> <p>AMERICAN JOURNAL OF PATHOLOGY, vol. 160, no. 1, January 2002 (2002-01), pages 289-296, XP002295429</p> <p>ISSN: 0002-9440</p> <p>page 290, left-hand column, paragraph 2</p> <p>page 291, left-hand column, paragraph 3 - right-hand column, paragraph 1</p> <p>page 292, left-hand column</p> <p>figure 3</p> <p>page 295, left-hand column, last paragraph</p>	1,7-10
X	<p>HIDEYASU OH ET AL: "Selective induction of neuropilin-1 by vascular endothelial growth factor (VEGF): a mechanism contributing to VEGF-induced angiogenesis"</p> <p>PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 99, no. 1, 8 January 2002 (2002-01-08), pages 383-388, XP002255027</p> <p>ISSN: 0027-8424</p> <p>page 387, left-hand column, paragraph 2 - right-hand column, paragraph 1</p> <p>figure 3</p> <p>Discussion</p>	1,7,8, 10,13
	----- -/-	

INTERNATIONAL SEARCH REPORT

International Application No

NO 7/EP 03/14756

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 02/086157 A (ALGARTE-GENIN MICHELE ;LATIL ALAIN (FR); UROGENE SA (FR); CUSSENOT) 31 October 2002 (2002-10-31) page 5, lines 18-31 page 11, lines 17-34 page 21, line 1 - page 22, line 26	1,8, 10-12, 14-16, 21,22
A		4
A	JAY D G: "SELECTIVE DESTRUCTION OF PROTEIN FUNCTION BY CHROMOPHORE-ASSISTED LASER INACTIVATION" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 85, no. 15, August 1988 (1988-08), pages 5454-5458, XP000857275 ISSN: 0027-8424 the whole document	6

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 03/14756

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 7, 8, 21, 22 (partially)
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 8, 21, 22 are directed to a method of treatment of the human/animal body, and claim 7 is directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

EP 03/14756

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9955855	A	04-11-1999	AU 749802 B2	04-07-2002
			AU 3402199 A	16-11-1999
			AU 747639 B2	16-05-2002
			AU 3402299 A	16-11-1999
			BR 9909809 A	19-12-2000
			BR 9909859 A	19-12-2000
			CA 2326824 A1	04-11-1999
			CA 2326825 A1	04-11-1999
			WO 9955854 A2	04-11-1999
			WO 9955855 A2	04-11-1999
			CN 1298444 T	06-06-2001
			CN 1298445 T	06-06-2001
			EP 1073728 A2	07-02-2001
			EP 1073729 A2	07-02-2001
			JP 2002512792 T	08-05-2002
			JP 2002512793 T	08-05-2002
			US 2002187954 A1	12-12-2002
			US 6417169 B1	09-07-2002
			US 2003083274 A1	01-05-2003
WO 02086157	A	31-10-2002	EP 1402060 A2	31-03-2004
			WO 02086157 A2	31-10-2002
			US 2004152110 A1	05-08-2004

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.